<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003160.pub3" GROUP_ID="DEMENTIA" ID="899501052509240020" MERGED_FROM="" MODIFIED="2015-12-29 20:47:52 +0000" MODIFIED_BY="Sue Marcus" REVIEW_NO="126" REVMAN_SUB_VERSION="5.3.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2015-12-29 20:46:38 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-12-02 11:50:46 +0000" MODIFIED_BY="Helen Collins">Statins for the prevention of dementia</TITLE>
<CONTACT>
<PERSON ID="13051" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Bernadette</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>McGuinness</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION>Consultant Geriatrician</POSITION>
<EMAIL_1>B.McGuinness@qub.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>07803004182</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Centre for Public Health</DEPARTMENT>
<ORGANISATION>Queen's University Belfast</ORGANISATION>
<ADDRESS_1>Institute of Clinical Sciences, Block B</ADDRESS_1>
<ADDRESS_2>Grosvenor Road</ADDRESS_2>
<CITY>Belfast</CITY>
<ZIP>BT12 6BA</ZIP>
<REGION>Co Antrim</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>02895048231</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2015-12-29 20:44:46 +0000" MODIFIED_BY="Sue Marcus">
<PERSON ID="13051" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Bernadette</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>McGuinness</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION>Consultant Geriatrician</POSITION>
<EMAIL_1>B.McGuinness@qub.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>07803004182</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Centre for Public Health</DEPARTMENT>
<ORGANISATION>Queen's University Belfast</ORGANISATION>
<ADDRESS_1>Institute of Clinical Sciences, Block B</ADDRESS_1>
<ADDRESS_2>Grosvenor Road</ADDRESS_2>
<CITY>Belfast</CITY>
<ZIP>BT12 6BA</ZIP>
<REGION>Co Antrim</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>02895048231</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17000" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>David</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Craig</LAST_NAME>
<SUFFIX>BSc MPhil MD FRCP</SUFFIX>
<POSITION>Consultant Physician</POSITION>
<EMAIL_1>david.craig@southerntrust.hscni.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Geriatric Medicine</DEPARTMENT>
<ORGANISATION>Craigavon Area Hospital</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Craigavon</CITY>
<ZIP/>
<REGION>Northern Ireland</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13004" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Roger</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Bullock</LAST_NAME>
<SUFFIX/>
<POSITION>Consultant in Old Age Psychiatry</POSITION>
<EMAIL_1>rogerbullock1@me.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Kingshill Research Centre, Victoria Hospital</ORGANISATION>
<ADDRESS_1>Okus Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Swindon</CITY>
<ZIP>SN4 4HZ</ZIP>
<REGION/>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>01793 437501</PHONE_1>
<PHONE_2/>
<FAX_1>01793 437521</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13060" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Passmore</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Ageing and Geriatric Medicine</POSITION>
<EMAIL_1>p.passmore@qub.ac.uk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+ 44 771 161 3739</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Centre for Public Health</DEPARTMENT>
<ORGANISATION>Queen's University Belfast</ORGANISATION>
<ADDRESS_1>Block B, ICSB, Grosvenor Road</ADDRESS_1>
<ADDRESS_2/>
<CITY>Belfast</CITY>
<ZIP>BT12</ZIP>
<REGION>Northern Ireland</REGION>
<COUNTRY CODE="GB">UK</COUNTRY>
<PHONE_1>+ 44 28 9063 2672</PHONE_1>
<PHONE_2/>
<FAX_1>+44 28 9032 5839</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2015-12-03 13:25:18 +0000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="11" MONTH="11" YEAR="2015"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="11" MONTH="11" YEAR="2015"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="26" MONTH="7" YEAR="2017"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2001"/>
<LAST_CITATION_ISSUE ISSUE="12" YEAR="2015"/>
</DATES>
<WHATS_NEW MODIFIED="2015-12-29 20:46:38 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2015-12-29 20:46:38 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="29" MONTH="12" YEAR="2015"/>
<DESCRIPTION>
<P>Search updated, no new studies found. Conlcusions unchanged</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-11-11 15:40:07 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="11" MONTH="11" YEAR="2015"/>
<DESCRIPTION>
<P>The search was updated, no new studies found and conclusions not changed.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2015-12-03 13:24:15 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2015-12-03 13:24:15 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>The conclusions to this review have changed as studies are now included in this review, compared to the previous review in which there were no included studies. The conclusions are that there is no evidence from RCTs that statins prevent AD or dementia.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2015-12-03 13:24:12 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>The search of October 2007 retrieved new studies for consideration by the authors. Two studies have been included in this update (with a total of 26,340 participants), and several studies have been excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2008-11-07 16:13:16 +0000" MODIFIED_BY="Helen Collins">
<DATE DAY="10" MONTH="10" YEAR="2007"/>
<DESCRIPTION>
<P>A new author team has taken over the updating of this review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-03-27 10:50:45 +0000" MODIFIED_BY="Helen Collins">
<DATE DAY="4" MONTH="10" YEAR="2006"/>
<DESCRIPTION>
<P>minor update of review</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="30" MONTH="5" YEAR="2001"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2015-12-15 13:37:09 +0000" MODIFIED_BY="Anne Lawson">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2015-12-15 13:37:09 +0000" MODIFIED_BY="Anne Lawson">
<SOURCE MODIFIED="2015-12-15 13:37:09 +0000" MODIFIED_BY="Anne Lawson">
<NAME>NIHR</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>This protocol/review was supported by the National Institute for Health Research, via a Cochrane Programme Grant to the Cochrane Dementia and Cognitive Improvement group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service or the Department of Health</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2015-12-29 20:21:50 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2015-12-15 13:52:09 +0000" MODIFIED_BY="Anne Lawson">
<TITLE MODIFIED="2015-11-02 12:09:37 +0000" MODIFIED_BY="[Empty name]">Statins for the prevention of dementia</TITLE>
<SUMMARY_BODY MODIFIED="2015-12-15 13:52:09 +0000" MODIFIED_BY="Anne Lawson">
<P>
<B>Background</B>
</P>
<P>Dementia (including Alzheimer's disease) is a global healthcare concern; the number of people affected worldwide is predicted to double every 20 years, reaching 74.7 million in 2010 and 131.5 million in 2050. Therefore, it is important to find means of preventing dementia. It has been suggested that high levels of cholesterol in the serum (part of the blood) may increase the risk of dementia and that treatment with cholesterol-lowering medicines such as statins may reduce the risk of dementia.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We searched medical databases for clinical trials comparing giving a statin to giving a placebo (pretend medicine) to people with normal cognitive function (which is brain activities that allow us to gain and use knowledge) and of sufficient age to be at risk of Alzheimer's disease.</P>
<P>
<B>Key results</B>
</P>
<P>We found two suitable randomised trials for inclusion in this review with 26,340 participants; neither showed any reduction in occurrence of Alzheimer's disease or dementia in people treated with statins compared to people given placebo. Side effects were low in both statin and placebo groups with no difference between groups in the risk of dropping out of the trial due to side effects.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>There were limitations in the included studies involving the methods of assessment of cognition and the inclusion only of participants deemed to be of moderate to high risk of a problem with their blood (vascular) system. Nevertheless, there was good evidence that statins given in late life to people at risk of vascular disease do not prevent cognitive decline or dementia.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2015-12-15 13:52:09 +0000" MODIFIED_BY="Anne Lawson">
<ABS_BACKGROUND MODIFIED="2015-10-23 16:09:35 +0100" MODIFIED_BY="[Empty name]">
<P>This is an update of a Cochrane review first published in 2001 and then updated in 2009. Vascular risk factors including high cholesterol levels increase the risk of dementia due to Alzheimer's disease and of vascular dementia. Some observational studies have suggested an association between statin use and lowered incidence of dementia. </P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2015-12-14 20:28:22 +0000" MODIFIED_BY="Anne Lawson">
<P>To evaluate the efficacy and safety of statins for the prevention of dementia in people at risk of dementia due to their age and to determine whether the efficacy and safety of statins for this purpose depends on cholesterol level, apolipoprotein E (ApoE) genotype or cognitive level.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2015-12-15 13:52:09 +0000" MODIFIED_BY="Anne Lawson">
<P>We searched ALOIS (the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group), <I>The Cochrane Library</I>, MEDLINE, EMBASE, PsycINFO, CINAHL, LILACS, ClinicalTrials.gov and the World Health Organization (WHO) Portal on 11 November 2015.<BR/>
</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2015-10-23 16:14:25 +0100" MODIFIED_BY="[Empty name]">
<P>We included double-blind, randomised, placebo-controlled trials in which statins were administered for at least 12 months to people at risk of dementia.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2015-12-15 13:52:09 +0000" MODIFIED_BY="Anne Lawson">
<P>We used standard methodological procedures expected by Cochrane.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2015-12-15 13:52:09 +0000" MODIFIED_BY="Anne Lawson">
<P>We included two trials with 26,340 participants aged 40 to 82 years of whom 11,610 were aged 70 or older. All participants had a history of, or risk factors for, vascular disease. The studies used different statins (simvastatin and pravastatin). Mean follow-up was 3.2 years in one study and five years in one study. The risk of bias was low. Only one study reported on the incidence of dementia (20,536 participants, 31 cases in each group; odds ratio (OR) 1.00, 95% confidence interval (CI) 0.61 to 1.65, moderate quality evidence, downgraded due to imprecision). Both studies assessed cognitive function, but at different times using different scales, so we judged the results unsuitable for a meta-analysis. There were no differences between statin and placebo groups on five different cognitive tests (high quality evidence). Rates of treatment discontinuation due to non-fatal adverse events were less than 5% in both studies and there was no difference between statin and placebo groups in the risk of withdrawal due to adverse events (26,340 participants, 2 studies, OR 0.94, 95% CI 0.83 to 1.05).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2015-12-15 13:52:09 +0000" MODIFIED_BY="Anne Lawson">
<P>There is good evidence that statins given in late life to people at risk of vascular disease do not prevent cognitive decline or dementia. Biologically, it seems feasible that statins could prevent dementia due to their role in cholesterol reduction and initial evidence from observational studies was very promising. However, indication bias may have been a factor in these studies and the evidence from subsequent RCTs has been negative. There were limitations in the included studies involving the cognitive assessments used and the inclusion of participants at moderate to high vascular risk only.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2015-12-29 20:21:50 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2015-12-22 10:06:50 +0000" MODIFIED_BY="[Empty name]">
<P>This is an update of the review published in 2009 (<LINK TAG="OTHER_VERSIONS_REFERENCES" TYPE="SECTION">Other published versions of this review</LINK>), which concluded that statins given in late life to people at risk of vascular disease have no effect in preventing Alzheimer's disease (AD) or dementia. Biologically, it seemed feasible that statins could prevent dementia by lowering cholesterol and initial evidence from observational studies was very promising. However, indication bias may have been a factor in these studies and the evidence from the two included randomised controlled trials (RCTs) was negative. This updated review aimed to re-assess the evidence.</P>
<CONDITION MODIFIED="2015-12-22 10:05:22 +0000" MODIFIED_BY="[Empty name]">
<P>Dementia is defined as "a progressive and largely irreversible clinical syndrome that is characterised by a widespread impairment of mental function" (<LINK REF="REF-NICE-2006" TYPE="REFERENCE">NICE 2006</LINK>). It is characterised by a cluster of symptoms and signs including difficulties in memory, disturbances in language, psychosocial and psychiatric changes, and impairments in activities of daily living (ADL) (<LINK REF="REF-Burns-2009" TYPE="REFERENCE">Burns 2009</LINK>). The intellectual decline is usually progressive and spares the level of consciousness until the very late stages of the illness. Alzheimer's Disease International estimates that in 2015 there are 46.8 million people with dementia in the world, the number is predicted to double every 20 years, reaching 74.7 million in 2030 and 131.5 million in 2050 (<LINK REF="REF-World-Alzheimer-Report-2015" TYPE="REFERENCE">World Alzheimer Report 2015</LINK>). These estimates are 12% to 13% higher than those made for the <LINK REF="REF-World-Alzheimer-Report-2009" TYPE="REFERENCE">World Alzheimer Report 2009</LINK>. Therefore, it is a major health concern and any intervention that may reduce risk would have a major public health impact.</P>
<P>There are different subtypes of dementia associated with differing underlying brain pathologies (<LINK REF="REF-World-Alzheimer-Report-2009" TYPE="REFERENCE">World Alzheimer Report 2009</LINK>; <LINK REF="REF-Burns-2009" TYPE="REFERENCE">Burns 2009</LINK>). The most common subtypes in older people are AD, vascular dementia (VaD) and mixed dementia (a mixture of AD and VaD pathology). AD is the most common subtype accounting for 60% to 70% of all cases; it has a prevalence of approximately 1% among 60- to 64-year olds rising to 40% in people aged 85 years and older. Although AD occurs later in life there is a long preclinical stage characterised by progressive neuropathological changes. These include amyloid plaques composed primarily of &#946;-amyloid peptide (A&#946;), neurofibrillary tangles (NFTs), neuroinflammation, neuronal dysfunction and cell death (<LINK REF="REF-Cole-2007" TYPE="REFERENCE">Cole 2007</LINK>). According to the influential amyloid cascade hypothesis, A&#946; accumulation is a critical first step in the sequence of pathological changes that ultimately lead to cognitive dysfunction (<LINK REF="REF-Glenner-1984" TYPE="REFERENCE">Glenner 1984</LINK>).</P>
<P>VaD is characterised by both large- and small-vessel lesions. Subcortical ischaemic vascular disease is now thought to be more prevalent than multi-infarct dementia caused by large-vessel lesions (<LINK REF="REF-Ballard-2000" TYPE="REFERENCE">Ballard 2000</LINK>; <LINK REF="REF-Esiri-1997" TYPE="REFERENCE">Esiri 1997</LINK>). VaD accounts for approximately 17% of cases of dementia; prevalence estimates are 1.6% in Europe in people over 65 years of age (<LINK REF="REF-Rizzi-2014" TYPE="REFERENCE">Rizzi 2014</LINK>), and correspondingly 1.7% in China (<LINK REF="REF-Ji-2015" TYPE="REFERENCE">Ji 2015</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Cholesterol and Alzheimer's disease</HEADING>
<P>There is a close relationship between AD and cardiovascular disease with coronary heart disease and hypertension being significant risk factors for AD (<LINK REF="REF-Kivipelto-2002" TYPE="REFERENCE">Kivipelto 2002</LINK>; <LINK REF="REF-Skoog-1998" TYPE="REFERENCE">Skoog 1998</LINK>). Several epidemiological studies have shown an association between high serum cholesterol levels and an increased susceptibility to AD (<LINK REF="REF-Hayden-2006" TYPE="REFERENCE">Hayden 2006</LINK>; <LINK REF="REF-Jarvik-1995" TYPE="REFERENCE">Jarvik 1995</LINK>; <LINK REF="REF-Kalmijn-2000" TYPE="REFERENCE">Kalmijn 2000</LINK>; <LINK REF="REF-Kivipelto-2002" TYPE="REFERENCE">Kivipelto 2002</LINK>; <LINK REF="REF-Kivipelto-2005" TYPE="REFERENCE">Kivipelto 2005</LINK>; <LINK REF="REF-Notkola-1998" TYPE="REFERENCE">Notkola 1998</LINK>; <LINK REF="REF-Solomon-2009" TYPE="REFERENCE">Solomon 2009</LINK>; <LINK REF="REF-Whitmer-2005" TYPE="REFERENCE">Whitmer 2005</LINK>), while other studies have shown no association (<LINK REF="REF-Mainous-2005" TYPE="REFERENCE">Mainous 2005</LINK>; <LINK REF="REF-Mielke-2010" TYPE="REFERENCE">Mielke 2010</LINK>; <LINK REF="REF-Romas-1999" TYPE="REFERENCE">Romas 1999</LINK>; <LINK REF="REF-Tan-2003" TYPE="REFERENCE">Tan 2003</LINK>), or a negative association (<LINK REF="REF-Mielke-2005" TYPE="REFERENCE">Mielke 2005</LINK>; <LINK REF="REF-Moroney-1999" TYPE="REFERENCE">Moroney 1999</LINK>; <LINK REF="REF-Reitz-2004" TYPE="REFERENCE">Reitz 2004</LINK>). There have been inconsistencies between studies, for example, in study design and follow-up period, making it difficult to compare studies directly.</P>
<P>The best established genetic risk factor for sporadic and late-onset AD is the &#949;4 allele of apolipoprotein E (ApoE); this is a protein that is involved in cholesterol transport in the brain and that also binds directly to the A&#946; peptide and influences its aggregation and clearance in vitro (<LINK REF="REF-Strittmatter-1993" TYPE="REFERENCE">Strittmatter 1993</LINK>) and in vivo (<LINK REF="REF-Naslund-1995" TYPE="REFERENCE">Naslund 1995</LINK>; <LINK REF="REF-Wisniewski-1995" TYPE="REFERENCE">Wisniewski 1995</LINK>). Meta-analysis has shown that the ApoE &#949;4 allele increases the risk of the disease by three times in heterozygotes and by 15 times in homozygotes (<LINK REF="REF-Farrer-1997" TYPE="REFERENCE">Farrer 1997</LINK>). Each copy of the allele lowers the age of onset of AD by almost 10 years (<LINK REF="REF-Corder-1993" TYPE="REFERENCE">Corder 1993</LINK>). The &#949;4 allele is associated with higher plasma concentrations of total and low-density lipoprotein (LDL) cholesterol as well as a higher risk of atherosclerosis. Other genes involved in cholesterol metabolism have been found to be associated with AD through Genome Wide Association Studies (GWAS): Apo J or clusterin (<LINK REF="REF-Harold-2009" TYPE="REFERENCE">Harold 2009</LINK>), adenosine triphosphate (ATP)-binding cassette subfamily A member 7 (ABCA7) (<LINK REF="REF-Beecham-2014" TYPE="REFERENCE">Beecham 2014</LINK>), and sortilin-related receptor (SORL1) (<LINK REF="REF-Meng-2007" TYPE="REFERENCE">Meng 2007</LINK>).</P>
<P>Generation of cerebral A&#946; in vitro (<LINK REF="REF-Mizuno-1999" TYPE="REFERENCE">Mizuno 1999</LINK>; <LINK REF="REF-Simons-1998" TYPE="REFERENCE">Simons 1998</LINK>) and in vivo is cholesterol dependent (<LINK REF="REF-Burns-2003" TYPE="REFERENCE">Burns 2003</LINK>; <LINK REF="REF-Refolo-2000" TYPE="REFERENCE">Refolo 2000</LINK>; <LINK REF="REF-Sparks-1994" TYPE="REFERENCE">Sparks 1994</LINK>). A&#946; is a cleavage product of amyloid precursor protein (APP). APP can be cleaved in several ways but A&#946; derives from the sequential proteolytic activities of beta and gamma secretase (the amyloidogenic processing pathway) (<LINK REF="REF-Marks-2003" TYPE="REFERENCE">Marks 2003</LINK>). Both beta and gamma secretases are active in lipid rafts-specialised cell membrane microdomains rich in cholesterol and sphingolipids, and it appears that APP processing within these lipid rafts determines the level of A&#946; production (<LINK REF="REF-Ehehalt-2003" TYPE="REFERENCE">Ehehalt 2003</LINK>; <LINK REF="REF-Vetrivel-2004" TYPE="REFERENCE">Vetrivel 2004</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Cholesterol and vascular dementia</HEADING>
<P>Risk factors for VaD are similar to risk factors for all types of vascular disease, namely hypertension, diabetes, smoking and hypercholesterolaemia (<LINK REF="REF-Ott-1998" TYPE="REFERENCE">Ott 1998</LINK>; <LINK REF="REF-Posner-2002" TYPE="REFERENCE">Posner 2002</LINK>; <LINK REF="REF-Stewart-1999" TYPE="REFERENCE">Stewart 1999</LINK>). Several studies have found an association of VaD with decreased levels of high-density lipoprotein (HDL) cholesterol (<LINK REF="REF-Kuriyama-1994" TYPE="REFERENCE">Kuriyama 1994</LINK>; <LINK REF="REF-Muckle-1985" TYPE="REFERENCE">Muckle 1985</LINK>; <LINK REF="REF-Reitz-2004" TYPE="REFERENCE">Reitz 2004</LINK>; <LINK REF="REF-Zuliani-2001" TYPE="REFERENCE">Zuliani 2001</LINK>). The role of LDL cholesterol remains controversial, with some studies finding an association between increased LDL cholesterol and risk of VaD (<LINK REF="REF-Klich_x002d_Raczka-2002" TYPE="REFERENCE">Klich-Raczka 2002</LINK>; <LINK REF="REF-Moroney-1999" TYPE="REFERENCE">Moroney 1999</LINK>; <LINK REF="REF-Paragh-2002" TYPE="REFERENCE">Paragh 2002</LINK>; <LINK REF="REF-Reitz-2004" TYPE="REFERENCE">Reitz 2004</LINK>), and other studies reporting a negative association (<LINK REF="REF-van-Exel-2002" TYPE="REFERENCE">van Exel 2002</LINK>; <LINK REF="REF-Yoshitake-1995" TYPE="REFERENCE">Yoshitake 1995</LINK>). Plasma lipids could be associated with the risk of VaD through several mechanisms. High levels of LDL cholesterol and low levels of HDL cholesterol are established risk factors for coronary heart disease (<LINK REF="REF-Moroney-1999" TYPE="REFERENCE">Moroney 1999</LINK>) and carotid artery atherosclerosis (<LINK REF="REF-Sharrett-1994" TYPE="REFERENCE">Sharrett 1994</LINK>). These may lead to cognitive impairment through cerebral hypoperfusion or embolism (<LINK REF="REF-Breteler-1994" TYPE="REFERENCE">Breteler 1994</LINK>). HDL cholesterol may interact with ApoE to cause small-vessel disease (<LINK REF="REF-Dantoine-2002" TYPE="REFERENCE">Dantoine 2002</LINK>).</P>
<P>Stroke is also a major risk factor for VaD. Lowering of cholesterol concentrations using statins reduces the risk of stroke in high-risk populations and in people with non-cardioembolic stroke or transient ischaemic attack. Each 1 mmol/L decrease in LDL cholesterol equates to a reduction in risk ratio for stroke of 21.1% (<LINK REF="REF-Amarenco-2009" TYPE="REFERENCE">Amarenco 2009</LINK>). By reducing the risk of stroke, statins may also act to reduce the incidence of post-stroke dementia.</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2015-12-15 14:15:25 +0000" MODIFIED_BY="Anne Lawson">
<P>Statins are a class of drugs that inhibit the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyses the rate-limiting step in cholesterol synthesis. Statins thereby reduce formation and entry of LDL cholesterol into the circulation and upregulate LDL receptor activity, which in turn lowers LDL cholesterol and triglycerides and increases HDL cholesterol. They have also been shown to lower serum fatty acid concentrations and to alter the relative percentages of important polyunsaturated fatty acids (<LINK REF="REF-Harris-2004" TYPE="REFERENCE">Harris 2004</LINK>). Statins also have multiple other cholesterol-independent effects since they:</P>
<UL>
<LI>improve the endothelial function of atherosclerotic vessels (<LINK REF="REF-Wassmann-2001" TYPE="REFERENCE">Wassmann 2001</LINK>);</LI>
<LI>have antithrombotic and anti-inflammatory effects (<LINK REF="REF-Reitz-2004" TYPE="REFERENCE">Reitz 2004</LINK>);</LI>
<LI>may reduce apoptosis and cell death (<LINK REF="REF-Ruocco-2002" TYPE="REFERENCE">Ruocco 2002</LINK>).</LI>
</UL>
<P>Statins are widely prescribed for the treatment of hypercholesterolaemia and for the secondary prevention of cardiovascular and cerebrovascular disease. There has been controversy about the level of cardiovascular risk that justifies treatment. Some guidelines advocate treatment for primary prevention in people with a high 10-year cardiovascular disease risk and in people with a high lifetime cardiovascular disease risk estimated from heart age and other JBS3 calculator metrics, and in whom lifestyle changes alone are considered insufficient by the physician and person concerned (<LINK REF="REF-Heart-2014" TYPE="REFERENCE">Heart 2014</LINK>). Statins are taken once a day by mouth. Most are available generically, decreasing their cost. They are classified according to their solubility in lipids (lipophilic) or water (hydrophilic). Lipophilic statins (lovastatin, simvastatin, cervistatin) cross the blood-brain barrier (BBB) and penetrate cell membranes more effectively than the hydrophilic statins (atorvastatin, pravastatin, fluvastatin).</P>
<SUBSECTION>
<HEADING LEVEL="3">Statins and dementia: observational studies</HEADING>
<P>When the first version of this review was written in 2001, two clinical reports had been published describing an association between statin therapy and a reduction in the occurrence of AD by as much as 70% (<LINK REF="REF-Jick-2000" TYPE="REFERENCE">Jick 2000</LINK>; <LINK REF="REF-Wolozin-2000" TYPE="REFERENCE">Wolozin 2000</LINK>). Since then, several more observational studies (cross-sectional and longitudinal) assessing the relationship between statin therapy and dementia have been conducted. These have been systematically reviewed by several groups. <LINK REF="REF-Wong-2013" TYPE="REFERENCE">Wong 2013</LINK> performed a meta-analysis of observational studies and concluded that statins may provide a slight benefit in the prevention of AD and all-type dementia but that the studies were subject to bias and so should be interpreted with caution. <LINK REF="REF-Swiger-2013" TYPE="REFERENCE">Swiger 2013</LINK> evaluated the effects of statins on short-term cognitive function and long-term incidence of dementia in RCTs or high-quality prospective cohort studies. There was no consistent effect of statin therapy on cognitive end points in the short term. Pooled results assessing long-term cognitive effects revealed a 29% reduction in incident dementia in people treated with statins with the caveat of heterogeneity in study design, exposure and outcomes. <LINK REF="REF-Song-2013" TYPE="REFERENCE">Song 2013</LINK> carried out a meta-analysis of eight prospective cohort studies; the risk ratio of dementia was reduced in the statin users but again the authors commented on significant heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse effects of statins</HEADING>
<P>Statins have known adverse effects; headache; altered liver-function tests; paraesthesia and gastrointestinal effects including abdominal pain, flatulence, constipation, diarrhoea, nausea and vomiting, are the most commonly reported. Reversible myositis is a rare but significant adverse effect of statins; myalgia and myopathy have also been reported. There has also been controversy about the level of cardiovascular risk that justifies treatment. Some guidelines advocate treatment for primary prevention in people with a high 10-year cardiovascular disease risk and in people with a high lifetime cardiovascular disease risk estimated from heart age and other JBS3 calculator metrics, in whom lifestyle changes alone are considered insufficient by the physician and person concerned (<LINK REF="REF-Heart-2014" TYPE="REFERENCE">Heart 2014</LINK>).</P>
<P>It is also possible that treatment with statins may <I>cause</I> neurocognitive deficits. Cognitive impairment has been cited on post-marketing surveillance reports, case reports, observational studies and RCTs (<LINK REF="REF-Bettermann-2012" TYPE="REFERENCE">Bettermann 2012</LINK>; <LINK REF="REF-Evans-2009" TYPE="REFERENCE">Evans 2009</LINK>; <LINK REF="REF-Orsi-2001" TYPE="REFERENCE">Orsi 2001</LINK>; <LINK REF="REF-Wagstaff-2003" TYPE="REFERENCE">Wagstaff 2003</LINK>; <LINK REF="REF-Zamrini-2004" TYPE="REFERENCE">Zamrini 2004</LINK>; <LINK REF="REF-Zandi-2005" TYPE="REFERENCE">Zandi 2005</LINK>), and following a review, the US Food and Drug Administration (FDA) issued a new warning for the labelling of statin drugs regarding potential adverse effects on cognition in 2012. The FDA advised the reports about memory loss, forgetfulness and confusion spanned all statin products and all age groups. In general, the symptoms were not serious and were reversible within a few weeks after the person stopped taking the medication; people affected may have been taking the medication for a few days; others affected had been taking it for years. Other groups have systematically assessed the evidence available in an effort to address the question 'do statins impair cognition?'; they concluded there is no significant evidence that statins cause or contribute towards cognitive decline (<LINK REF="REF-Kelley-2014" TYPE="REFERENCE">Kelley 2014</LINK>; <LINK REF="REF-Ott-2015" TYPE="REFERENCE">Ott 2015</LINK>; <LINK REF="REF-Richardson-2013" TYPE="REFERENCE">Richardson 2013</LINK>).</P>
</SUBSECTION>
</INTERVENTION>
<THEORY MODIFIED="2015-12-15 14:24:39 +0000" MODIFIED_BY="Anne Lawson">
<P>Lack of understanding as to the true pathophysiology of AD limits our understanding of the role of statins in the possible prevention of AD. In vitro and in vivo studies have been carried out that have resulted in a number of proposed mechanisms of action including: action on APP metabolism, reduction of chronic neuroinflammation, reductions in brain oxidative stress, gamma-secretase relocation in lipid rafts, and reduced amyloid plaques and phosphorylated tau-positive dystrophic neuritis (<LINK REF="REF-McFarland-2014" TYPE="REFERENCE">McFarland 2014</LINK>).</P>
<P>The range of cholesterol-dependent and cholesterol-independent actions described above may all be relevant to an effect of statins on the incidence of VaD. They could also reduce the incidence of post-stroke dementia through efficacy in the primary and secondary prevention of stroke and other pleiotropic effects. Clinical trials indicate that statins significantly decrease stroke risk. The meta-analysis carried out by The Cholesterol Treatment Trialists' Collaborators including 90,056 participants found that the use of statins caused a significant 17% proportional reduction in the incidence of first-ever stroke of any type per 1 mmol/l LDL cholesterol reduction (<LINK REF="REF-CTTC-2005" TYPE="REFERENCE">CTTC 2005</LINK>). In secondary prevention of stroke, the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study showed that treatment with atorvastatin reduced the risk of recurrent cerebrovascular events in people with recent stroke or transient ischaemic attack but no history of heart disease (<LINK REF="REF-SPARCL-Investigators-2006" TYPE="REFERENCE">SPARCL Investigators 2006</LINK>). A more recent meta-analysis included 18 RCTs and concluded that statins may be beneficial in reducing the overall incidence of stroke (<LINK REF="REF-Wang-2014" TYPE="REFERENCE">Wang 2014</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2015-12-22 10:06:50 +0000" MODIFIED_BY="[Empty name]">
<P>In 2015 over 46 million people live with dementia worldwide. This number is estimated to increase to 131.5 million by 2050. Dementia also has a huge economic impact. In 2015 the total estimated worldwide cost of dementia is USD 818 billion, and it will become a trillion dollar disease by 2018 (<LINK REF="REF-World-Alzheimer-Report-2015" TYPE="REFERENCE">World Alzheimer Report 2015</LINK>). Therefore, any medication that may have an impact in preventing onset of the disease will be of immense interest to the public, healthcare workers and policy makers. Debate continues about risks and benefits of widespread statin use with controversy concerning primary prevention of vascular disease in particular. This review will add to the knowledge base concerning primary prevention of dementia.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2015-12-14 17:16:01 +0000" MODIFIED_BY="Anne Lawson">
<P>To evaluate the efficacy and safety of statins for the prevention of dementia in people at risk of dementia due to their age and to determine whether the efficacy and safety of statins for this purpose depends on cholesterol level, ApoE genotype or cognitive level.</P>
</OBJECTIVES>
<METHODS MODIFIED="2015-12-29 20:21:50 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2015-12-15 13:50:50 +0000" MODIFIED_BY="Anne Lawson">
<CRIT_STUDIES MODIFIED="2015-12-14 17:16:41 +0000" MODIFIED_BY="Anne Lawson">
<P>Randomised, double-blind, placebo-controlled trials in which a statin was given for at least 12 months. We considered it unlikely that any preventive effect on dementia incidence could be detected in trials with shorter treatment periods.</P>
<P>We excluded trials comparing two different statins without a placebo.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2015-12-14 17:17:34 +0000" MODIFIED_BY="Anne Lawson">
<P>People with objectively normal cognitive function and of sufficient age to be at risk of AD (mean age 65 years or over). We also included people with evidence of cerebrovascular disease or at high risk of cerebrovascular disease.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2015-09-08 08:41:43 +0100" MODIFIED_BY="[Empty name]">
<P>Any member of the statin family given within the licensed dose range with parallel concomitant placebo.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2015-12-15 13:50:50 +0000" MODIFIED_BY="Anne Lawson">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2015-12-14 17:20:28 +0000" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Objective diagnosis of dementia.</LI>
<LI>Objective diagnosis of AD according to standard criteria.</LI>
<LI>Objective diagnosis of VaD according to standard criteria.</LI>
<LI>Change in Mini Mental State Examination (MMSE), Alzheimer's Disease Assessment Scale - Cognition (ADAS-Cog) or other accepted objective and standardised tests of cognitive performance in people at risk of AD/VaD on treatment with statins.</LI>
<LI>Incidence and severity of adverse effects.</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2015-12-15 13:50:50 +0000" MODIFIED_BY="Anne Lawson">
<UL>
<LI>Change in cognitive status accounting for prior cholesterol level, ApoE genotype and cognitive level.</LI>
<LI>Participant-perceived quality of life.</LI>
<LI>Change in ADLs.</LI>
<LI>Change in behaviour.</LI>
</UL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2015-12-29 20:21:50 +0000" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2015-12-29 20:21:50 +0000" MODIFIED_BY="[Empty name]">
<P>We searched ALOIS - the Cochrane Dementia and Cognitive Improvement Group's (CDCIG) specialised register on 11 November 2015 (<A HREF="http://www.medicine.ox.ac.uk/alois">www.medicine.ox.ac.uk/alois</A>). We used the following search terms: statin*, simvastatin*, lovastatin*, pravastatin*, fluvastatin*, atorvastatin* and rosuvastatin*.</P>
<P>The Trials Search Co-ordinator for the CDCIG maintains ALOIS, which contains studies that fall within the areas of dementia prevention, dementia treatment and management, and cognitive enhancement in healthy elderly populations. The studies are identified through:</P>
<UL>
<LI>monthly searches of a number of major healthcare databases: MEDLINE, EMBASE, CINAHL, PsycINFO and Lilacs;</LI>
<LI>monthly searches of a number of trial registers: ISRCTN; UMIN (Japan's Trial Register); the World Health Organization (WHO) portal (which covers ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register; the German Clinical Trials Register; the Iranian Registry of Clinical Trials and the Netherlands National Trials Register, plus others);</LI>
<LI>quarterly searches of the Central Register of Controlled Trials (CENTRAL);</LI>
<LI>six-monthly searches of a number of grey literature sources: ISI Web of Knowledge Conference Proceedings; Index to Theses and Australasian Digital Theses.</LI>
</UL>
<P>To view a list of all sources searched for ALOIS see <A HREF="http://www.medicine.ox.ac.uk/alois/content/about-alois">About ALOIS</A> on the ALOIS website (<A HREF="http://www.medicine.ox.ac.uk/alois">www.medicine.ox.ac.uk/alois</A>).</P>
<P>We ran additional searches in MEDLINE, EMBASE, PsycINFO, CINAHL, ClinicalTrials.gov and WHO Portal/ICTRP to ensure that the search was as comprehensive and as up-to-date as possible. <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK> shows the search strategies used for the retrieval of reports of trials.</P>
</ELECTRONIC_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2015-12-14 19:20:06 +0000" MODIFIED_BY="Anne Lawson">
<STUDY_SELECTION MODIFIED="2015-12-14 18:05:38 +0000" MODIFIED_BY="Anne Lawson">
<P>Two authors (BMcG and PP) independently undertook searching and screening of publications.</P>
<P>Two authors (BMcG and PP) agreed upon and tested the MeSH terms and search strategy. The other authors (DC and RB) acted as adjudicators and reviewed the process. BMcG and PP screened the citations and independently selected trials for relevance against the defined inclusion criteria. We resolved any disagreements in the independent selection by discussion. We excluded those trials that did not fulfil the criteria from further analysis. We referred to excluded studies in the <LINK TAG="DISCUSSION" TYPE="SECTION">Discussion</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2015-12-14 18:06:54 +0000" MODIFIED_BY="Anne Lawson">
<P>We extracted data from the published reports using a data collection form that was piloted by the team. We extracted available data on demographics of participants (age, gender, lipid values at baseline), statin regimen (type of statin, daily dosage, starting time, duration) and follow-up duration. For continuous outcomes, neither the mean scores nor the mean changes from baseline in the individual treatment groups were reported. Therefore, we extracted the mean difference (MD) between groups and the standard error of the MD. For dichotomous data, we extracted the number of participants in each treatment group and the number of participants experiencing the outcome of interest.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2015-12-14 19:20:06 +0000" MODIFIED_BY="Anne Lawson">
<P>We assessed methodological quality of the included trials using Cochrane's tool for assessing risk of bias. We assessed the following domains: selection bias, performance bias, detection bias, attrition bias, reporting bias and other bias.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2015-12-14 18:07:28 +0000" MODIFIED_BY="Anne Lawson">
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>We used the MD to measure the treatment effect. If the same outcome was assessed using different scales, then we used the standardised mean difference (SMD). We reported 95% confidence intervals (CI).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>We reported results of dichotomous outcomes as an odds ratio (OR) with 95% CI.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<MISSING_DATA MODIFIED="2015-12-14 18:09:28 +0000" MODIFIED_BY="Anne Lawson">
<P>For each outcome measure, we sought data on every participant assessed. To allow an intention-to-treat analysis, we sought the data irrespective of compliance, whether or not the participant was subsequently deemed ineligible, or otherwise excluded from treatment or follow-up. If intention-to-treat data were not available in the publications, we sought 'on-treatment' or the data of participants who completed the trial and indicated as such. We did not use data from titration phases prior to the randomised phase to assess safety or efficacy.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2015-12-14 18:16:44 +0000" MODIFIED_BY="Anne Lawson">
<P>We considered clinical heterogeneity between trials (participants, interventions and outcomes) when deciding whether or not to synthesise data. Where we performed a meta-analysis, we used a standard Chi<SUP>2</SUP> test to check for heterogeneity. We also assessed the impact of heterogeneity on the meta-analysis using the I<SUP>2</SUP> statistic.</P>
<P>If heterogeneity still existed with any model, we carried out a sensitivity analysis (excluding studies with conflicting results from the rest) thereby assessing the robustness of the results of fixed-effect versus random-effects models.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2015-12-14 18:17:42 +0000" MODIFIED_BY="Anne Lawson">
<P>Where data were suitable for a meta-analysis, we presented the overall estimate from a fixed-effect model. If we found substantial heterogeneity (I<SUP>2</SUP> greater than 30%), we also presented results from a random-effects model and reported this as the main result.</P>
<SUBSECTION>
<HEADING LEVEL="3">Presentation of results - 'Summary of findings' table</HEADING>
<P>We used the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) approach to assess the quality of the supporting evidence behind each estimate of treatment effect. We presented primary outcomes of the review in a 'Summary of findings' table including, for each outcome, a summary of the amount of data, the magnitude of the effect size and the overall quality of the evidence (<LINK REF="REF-Schunemann-2011" TYPE="REFERENCE">Schunemann 2011</LINK>).</P>
</SUBSECTION>
</DATA_SYNTHESIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2015-12-22 10:27:42 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2015-12-22 10:16:39 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2015-12-14 18:18:41 +0000" MODIFIED_BY="Anne Lawson">
<P>For this update, the electronic searches retrieved 346 references. We obtained 36 papers in full-test form and considered eight studies potentially eligible after screening (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2015-12-22 10:16:39 +0000" MODIFIED_BY="[Empty name]">
<P>We identified two RCTs with 26,340 participants (<LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>; <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002). For full details, see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> trial included adults aged 40 to 80 years at high risk of vascular events (past medical history of coronary heart disease, other occlusive arterial disease, diabetes or hypertension (if also male and aged at least 65 years, in order to be at similar risk to the other disease categories)). A total of 20,536 people were randomised, with 5806 (28.3%) participants aged at least 70 years at study entry. A total of 1820 participants had cerebrovascular disease defined by past history of non-disabling stroke not thought to be haemorrhagic or transient cerebral ischaemia.</P>
<P>The <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> study included 5804 adults aged 70 to 82 years (mean age 75.4 years) with a history of, or risk factors for, vascular disease. A total of 649 had a history of stroke or transient Ischaemic attack.</P>
<P>Participants were recruited from industrialised countries. <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> recruited participants from the UK and <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002 recruited participants from Scotland, Ireland and the Netherlands.</P>
<P>Study participants predominantly consisted of ambulatory participants recruited from the community or primary care facilities. <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> did not assess cognition at baseline but excluded people with dementia or any other condition that might limit long-term compliance (e.g. severely disabling stroke, psychiatric disorder). <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002 excluded participants with poor cognitive function (MMSE less than 24) at baseline.</P>
<P>Mean non-fasting blood concentration of total cholesterol in <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> was 5.9 mmol/L (standard deviation (SD) 1.0), directly measured LDL cholesterol of 3.4 mmol/L (SD 0.8), HDL cholesterol of 1.06 mmol/L (SD 0.33) and triglycerides of 2.1 mmol/L (SD 1.4).</P>
<P>For inclusion in the <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002 trial, plasma total cholesterol was required to be 4.0 to 9.0 mmol/L and triglycerides concentrations less than 6.0 mmol/L. Mean cholesterol at entry in both groups was 5.7 mmol/L (SD 0.9), LDL cholesterol 3.8 mmol/L (SD 0.8), HDL cholesterol 1.3 mmol/L (SD 0.35) and triglycerides 1.5 mmol/L (SD 0.7).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Treatment in <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> consisted of simvastatin 40 mg daily or matching placebo. Mean compliance with simvastatin was 85%. Mean non-study statin use in the placebo group was 17%. Mean duration of follow-up was five years for all randomised participants. There was a mean difference in LDL cholesterol of 1.0 mmol/L between participants allocated simvastatin and participants allocated placebo during the study. The proportional reduction in LDL cholesterol produced by actual use of simvastatin 40 mg daily was approximately independent of the presenting cholesterol concentration.</P>
<P>Treatment in <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002 consisted of pravastatin 40 mg or matching placebo. Adherence was 94% in both the placebo and pravastatin groups. About 10% of the placebo group and 5% of the pravastatin group initiated non-study statin therapy. Mean duration of follow-up was 3.2 years (range 2.8 to 4.0) for participants who did not die or withdraw consent. At the second annual visit post-randomisation, the pravastatin-induced decrease in LDL cholesterol was 33% in compliant participants and 27% in the entire cohort.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes - primary</HEADING>
<P>
<B>Incidence of dementia</B> was an outcome in <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> although it was not clear from the study results or the protocol what criteria were used to diagnose dementia.</P>
<P>
<B>Cognition: </B>
<LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> assessed cognitive outcomes using the modified Telephone Interview for Cognitive Status (TICS-m) questionnaire, administered to participants at final follow-up, either face-to-face in the clinic or over the telephone. A TICS-m score below 22 out of 39 was pre-specified as indicative of some cognitive impairment.</P>
<P>Cognition was a tertiary outcome in <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002. The difference was reported between last-on-treatment and second baseline values for a number of cognitive tests: MMSE, number of correct letter digit codes, number of words remembered in the Picture-Word Learning Test (immediate and delayed) and time needed to complete the Stroop test. The first baseline measure was used as a practice measurement to reduce possible learning effects. Cognitive function was measured after nine, 18 and 30 months and at the end of the study (mean 42 months). A cognitive re-analysis was published in 2010 (<LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2010).</P>
<P>
<B>Adverse effects</B> that were serious were reported by both studies (<LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>; <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002). <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> reported on development of psychiatric disorders and attempted suicide.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes - secondary</HEADING>
<P>
<LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002 measured function in ADLs using the Barthel Index and the Instrumental Activities of Daily Living (IADL) scale.</P>
<P>Neither study provided data on quality of life or behaviour.</P>
<P>Change in cognition accounting for prior cholesterol level, ApoE genotype and cognitive function provided by <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2007.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2015-12-15 14:26:03 +0000" MODIFIED_BY="Anne Lawson">
<P>We excluded three new studies from this updated review. For full details see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. We excluded 26 non-randomised trials from the outset as per <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>.</P>
<P>
<LINK REF="STD-Sparks-2010" TYPE="STUDY">Sparks 2010</LINK> assessed cognitive outcomes following the elective use of statins in people diagnosed with mild cognitive impairment after enrolment in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). This was a pilot study in which use of statin was not randomly assigned.</P>
<P>
<LINK REF="STD-Tendolkar-2012" TYPE="STUDY">Tendolkar 2012</LINK> was an exploratory hypothesis-generating trial in which 34 stroke-free elderly participants with atrial fibrillation were randomly assigned to treatment with both atorvastatin and ezetimibe (inhibits the intestinal absorption of cholesterol) or placebo for one year on top of normal anticoagulation. We excluded the study as it was not possible to assess the effect attributable to statin treatment.</P>
<P>
<LINK REF="STD-Summers-2007" TYPE="STUDY">Summers 2007</LINK> was a cognitive sub-study within the Lipid Lowering and Onset of Renal Disease (LORD) randomised double-blind placebo-controlled trial. Participants were randomly assigned to atorvastatin 10 mg/day or matching placebo and all had chronic kidney disease. We excluded the trial due to its short duration.</P>
<P>Three studies were excluded from the 2009 review and this update (<LINK REF="STD-Muldoon-2000" TYPE="STUDY">Muldoon 2000</LINK>; <LINK REF="STD-Muldoon-2004" TYPE="STUDY">Muldoon 2004</LINK>; <LINK REF="STD-Santanello-1997" TYPE="STUDY">Santanello 1997</LINK>). All three studies followed participants for only six months and so failed to meet our duration criteria. In addition, participants in <LINK REF="STD-Muldoon-2000" TYPE="STUDY">Muldoon 2000</LINK> had a mean age of 46 years and <LINK REF="STD-Muldoon-2004" TYPE="STUDY">Muldoon 2004</LINK> had a mean age of 53 years and so were not considered to be at risk of dementia over the follow-up period.</P>
<SUBSECTION>
<HEADING LEVEL="3">Ongoing studies</HEADING>
<P>Two further studies are ongoing: <LINK REF="STD-PODCAST-2013" TYPE="STUDY">PODCAST 2013</LINK> (Prevention of Decline in Cognition after Stroke Trial) and The European Society of Hypertension - Chinese Hypertension League Stroke in Hypertension Optimal Treatment (<LINK REF="STD-ESH_x002d_CHL_x002d_SHOT-2014" TYPE="STUDY">ESH-CHL-SHOT 2014</LINK>) randomised trial.</P>
<P>
<LINK REF="STD-PODCAST-2013" TYPE="STUDY">PODCAST 2013</LINK> is a multi-centre, prospective, randomised, open-label, blinded-endpoint, controlled partial-factorial phase IV trial in secondary and primary care aiming to recruit 100 participants who are post-ischaemic stroke by three to seven months from 30 UK Stroke Research Network sites. Participants with ischaemic stroke are randomised to intensive versus guideline lipid lowering with ezetimibe and a resin. The primary outcome is cognitive function measured by the Addenbrooke's Cognitive Examination-Revised (ACE-R), which includes the MMSE. There are also other cognitive secondary outcomes: MoCA (Montreal Cognitive Assessment), TICS, Stroop test and Trail Making A &amp; B; there is also a blood pressure lowering arm of the trial. As there is no placebo arm, it will not be suitable for inclusion in this review.</P>
<P>
<LINK REF="STD-ESH_x002d_CHL_x002d_SHOT-2014" TYPE="STUDY">ESH-CHL-SHOT 2014</LINK> is a prospective multi-national RCT with a 3 x 2 factorial design comparing three different systolic blood pressure targets and two different LDL cholesterol targets in participants with hypertension and a stroke or transient Ischaemic attack one to six months before randomisation. Cognitive decline as measured by the Montreal Cognitive Assessment (MoCA) and dementia are secondary outcomes. The study aims to recruit 925 participants with four years of follow-up. Investigators are free to choose the statin (among those approved in each country). As there is no placebo arm, it will not be suitable for inclusion in this review.</P>
</SUBSECTION>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2015-12-22 10:27:42 +0000" MODIFIED_BY="[Empty name]">
<P>For full details, see 'Risk of bias' tables and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK> and <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation (selection bias)</HEADING>
<P>In <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>, potentially eligible people entered a pre randomisation 'run-in' phase, which was intended chiefly to limit subsequent randomisation to people likely to take the randomly allocated study medication for at least five years. A central telephone randomisation system using a minimisation algorithm was used to balance the treatment groups; this appeared adequate.</P>
<P>
<LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002 used a computerised pseudo-random number generator, which consisted of balanced blocks of size 4. Randomisation was done by telephone call or through fax exchange with the study data centre. This appeared satisfactory.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding (performance bias and detection bias)</HEADING>
<P>In <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>, blinding of participants and key study personnel occurred and it was unlikely that the blinding could have been broken except in a medical emergency. Comment: probably done.</P>
<P>In <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2000, all study personnel, including the endpoint adjudication committee, remained unaware of the allocated study medication status of the participants throughout the study. Emergency unblinding was available via an interactive voice response telephone system. There were only two requests for emergency unblinding. Comment: appeared adequate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data (attrition bias)</HEADING>
<P>In <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>, small numbers in both groups were lost to follow-up; 37 in the simvastatin group: three due to death, 34 due to morbidity and 30 in the placebo group: four due to death, 26 due to morbidity. In total, there were 1328 (12.9%) deaths in the simvastatin group and 1507 (14.7%) deaths in the placebo group during the scheduled treatment period.</P>
<P>In <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2000, similar numbers in both groups discontinued with similar reasons, with approximately 25% in each group over the 3.2-year follow-up. A total of 725 participants discontinued in the placebo group: 116 due to a non-fatal adverse event, 240 died, 311 refused to participate or did not attend, 58 other reasons. In addition seven withdrew consent. A total of 724 discontinued in the pravastatin group: 107 due to non-fatal adverse events, 219 died, 346 refused to participate or did not attend, 52 other reasons. In addition five withdrew consent. In total, there were 298 (10.3%) deaths in the pravastatin group and 306 (10.5%) deaths in the placebo group over the mean follow-up of 3.2 years.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective reporting (reporting bias)</HEADING>
<P>There was no evidence of selective reporting.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other potential sources of bias</HEADING>
<P>We identified no other potential sources of bias.</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2015-12-15 14:26:34 +0000" MODIFIED_BY="Anne Lawson">
<P>We judged that efficacy data could not be combined from the two studies as they measured different cognitive outcomes at different time points. We synthesised adverse events data. Please refer to <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>.</P>
<P>
<B>Incidence of dementia:</B> there was no evidence of a difference in the incidence of dementia between the statin group (31 cases, 0.3%) and the placebo group (31 cases, 0.3%), but the result was imprecise and we downgraded the evidence to moderate (OR 1.00, 98% CI 0.61 to 1.65, 20,536 participants, moderate quality evidence) (<LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>).</P>
<P>
<B>Cognitive change from baseline:</B> the MD between groups (pravastatin-placebo) in change from baseline to last on-treatment visit for various cognitive tests was as follows: change in MMSE MD 0.06 (95% CI -0.04 to 0.16, 5804 participants, high quality evidence), number of correct letter digit codes MD -0.01 (95% CI -0.25 to 0.23, 5804 participants, high quality evidence), number of words remembered in the Picture-Word Learning Test MD 0.02 (95% CI -0.12 to 0.16, 5804 participants, high quality evidence), time needed to complete the Stroop test MD 0.8 seconds (95% CI -0.4 to 2.0, 5804 participants, high quality evidence) (<LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002).</P>
<P>
<B>Difference in mean TICS-m score:</B> between the two treatment groups at final visit (MD 0.02, 95% CI -0.12, to 0.16, 20,536 participants, high quality evidence). A TICS-m score below 22 out of 39 was pre-specified as indicative of some cognitive impairment. No significant difference observed between the treatment groups in percentage of participants classified as cognitively impaired either overall (OR 0.97, 95% CI 0.91 to 1.04, 20,536 participants, high quality evidence) or in subgroups defined with respect to their age at study entry (under 65 years: OR 0.95, 95% CI 0.85 to 1.05, 9839 participants; 65 to 69 years: OR 1.02, 95% CI 0.90 to 1.16, 4891 participants; 70 to 80 years: OR 0.93, 95% CI 0.84 to 1.04, 2045 participants, high quality evidence) (<LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>).</P>
<P>
<B>Incidence and severity of adverse events:</B> in <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>, discontinuation of allocated treatment was attributed to adverse events for similar numbers of participants in the two groups (4.8% with simvastatin-allocated versus 5.1% with placebo-allocated). In <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002, 107 (3.7%) pravastatin-allocated participants and 116 (3.98%) placebo-allocated participants withdrew due to a non-fatal adverse event. When data were combined in a meta-analysis, there was no evidence of a difference in withdrawal rates between groups (OR 0.94, 95% CI 0.83 to 1.05, 26,340 participant, high quality of evidence). In <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002, there was an increased incidence of newly diagnosed cancers in the pravastatin group (25% more frequent compared to placebo) (see <LINK TAG="AGREEMENT" TYPE="SECTION">Agreements and disagreements with other studies or reviews</LINK>).</P>
<P>
<LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002 reported serious adverse events. One or more events were reported by 1604 (55%) participants allocated to placebo and by 1608 (56%) participants allocated to pravastatin (OR 1.02, 95% CI 0.92 to 1.13, 5804 participants, high quality evidence).</P>
<P>
<B>Effect on liver and muscle enzymes:</B> in <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002 there were no reported cases of rhabdomyolysis; in <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>, rhabdomyolysis developed in five simvastatin-allocated and three placebo-allocated participants (combined analysis OR 1.67, 95% CI 0.40 to 6.98, 26,340 participants, moderate quality of evidence, downgraded due to imprecision). In <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002, there were 36 instances of reported myalgia in the pravastatin group and 32 in the placebo group (OR 1.14, 95% CI 0.70 to 1.83, 5804 participants, moderate quality evidence, downgraded due to imprecision); in <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>, myopathy developed in five simvastatin-allocated and one placebo-allocated participants (OR 5.00, 95% CI 0.58 to 42.81, 20,536 participants).</P>
<P>In <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002, the three month visit was the only formal safety laboratory assessment and there were no participants in either group with creatine kinase concentrations higher than 10 times the upper limit of normal (ULN). There was one participant in each group with greater than three times ULN plasma concentrations of alanine and aspartate transaminases. In <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>, 19 simvastatin-allocated and 13 placebo-allocated participants had creatine kinase four to 10 times ULN and 11 simvastatin-allocated versus six placebo-allocated participants had creatine kinase greater than 10 times ULN.</P>
<P>
<LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> measured blood concentrations of alanine aminotransferase at each follow-up visit. There was no significant difference between the groups in the numbers of participants whose study treatment was stopped because of elevated liver enzymes (OR 1.39, 95% CI 0.90 to 2.15, 5804 participants, moderate quality of evidence, downgraded due to imprecision). In <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002, one participant in each group (pravastatin and placebo) had increased plasma concentrations of alanine and aspartate transaminases (greater than three times ULN).</P>
<P>In <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>, 14 simvastatin-allocated and 11 placebo-allocated participants had attempted suicide; 67 simvastatin-allocated and 60 placebo-allocated participants had developed some other psychiatric disorder.</P>
<P>In <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002, there were no significant differences between the groups in function over time as measured by the Barthel index (MD 0.06, 95% CI -0.03 to 0.15, 5804 participants, high quality of evidence) or in the IADL questionnaire (MD 0.03, 95% CI -0.08 to 0.14, 5804 participants, high quality of evidence).</P>
<P>
<B>Subgroups</B>
</P>
<P>
<B>Effect of ApoE genotype:</B> one follow-up prospective study from <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> assessed the association between ApoE4 and cognitive decline in elderly adults. Of the 5804 participants recruited into the study, ApoE genotyping was available for 95.5%; 4155 were classified as E4- and 1389 as E4+. At baseline, participants in the E4+ group performed significantly less well on the Stroop test and Picture-Word Recall (immediate and delayed) than participants in the E4- group and had marginally, but significantly, poorer scores on the MMSE. Over the mean 3.2 years of follow-up, ApoE4 status significantly influenced change in scores on the cognitive tests associated with memory (immediate and delayed Picture-Word Recall) but not those for attention and information processing (Stroop, Letter-Digit Coding). Participants in the E4+ group had significantly greater decrements than participants in the E4- group on MMSE, Barthel Index, and IADL scores. Treatment assignment (i.e. to placebo or pravastatin) was included in the multi-variate models and there was no significant interaction between ApoE4 genotype, treatment and cognition. There were no significant associations with any of the tests, confirming the lack of effect of statin therapy on cognition.</P>
<P>From the further analysis published in <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2010, there was no difference in pravastatin and placebo groups in cognitive decline in men or women, people with or without a history of vascular disease or history of diabetes, with low or high HDL and total cholesterol levels (all P value &gt; 0.05). There was an effect of pravastatin on processing speed within the ApoE2 carriers and within the low cholesterol group but this finding lost statistical significance after correction for multiple testing, and there was no consistent parallel change in other cognitive performance tests.</P>
<P>In <A HREF="https://archie.cochrane.org/sections/documents/view?version=z1507241128209160300326837577742&amp;format=REVMAN#STD-HPS-2002">HPS 2002</A>, age at study entry was not associated with any significant difference between the treatment groups in percentage of participants defined as cognitively impaired, that is, in participants aged under 65 years, statin users were no less likely to develop dementia than participants in the placebo group, likewise for participants in the 65- to 69-years age group and the 70- to 80-years age group.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2015-12-15 14:16:55 +0000" MODIFIED_BY="Anne Lawson">
<SUMMARY_OF_RESULTS MODIFIED="2015-12-14 20:37:57 +0000" MODIFIED_BY="Anne Lawson">
<P>Two studies including 26,340 people contributed data relevant to the primary outcomes of this review. The evidence showed that statins given in late life to people at risk of vascular disease have no effect on the incidence of dementia or on cognitive decline.</P>
<P>
<LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> evaluated simvastatin in the prevention of heart disease among 20,536 older adults, including 5806 people aged 70 to 80 years at baseline. Despite significantly reduced rates of myocardial infarction, stroke and revascularisation procedures, there was no significant difference between treatment groups in the percentages of participants classified as cognitively impaired either in the whole study population or in subgroups classified by their age at study entry, or their previous history of cerebrovascular disease. The same numbers of participants in each treatment group were reported to have developed dementia during follow-up (31 in each group).</P>
<P>In <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002, 5804 people aged 70 to 82 years were randomised to either pravastatin or placebo. These participants were considered to be at moderate risk of developing dementia over the mean 3.2 years of follow-up. Despite a 34% reduction in LDL cholesterol and a significant reduction in the primary endpoint of composite coronary death, non-fatal myocardial infarction and fatal or non-fatal stroke in the pravastatin group, there was no significant effect on cognitive function measured using several cognitive tests.</P>
<P>Rates of treatment discontinuation due to non-fatal adverse events were less than 5% in both studies. There was no difference between statin and placebo groups in the risk of withdrawal due to adverse events. <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> reported serious adverse events separately and, again, these did not differ between treatment groups.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2015-12-15 14:16:55 +0000" MODIFIED_BY="Anne Lawson">
<P>This review provided some evidence towards the answer to the review question. However, the studies identified were not sufficient to answer all of the objectives of the review. Our primary interest was in the prevention of dementia. Neither study systematically ascertained dementia at baseline although both attempted to exclude people with pre-existing dementia or significant cognitive impairment. Only <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> included incidence of dementia as an outcome, but the criteria used to identify dementia were not clear.</P>
<P>Cognition was a tertiary endpoint in both included studies and neither included a comprehensive cognitive assessment although <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002, which used the MMSE and several neuropsychological tests, was more informative in cognitive terms than the <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> study, which used a telephone interview only. Decline in cognition was very low in both studies and this may relate to careful control of cardiovascular risk factors. This parallels the absence of decline in two VaD clinical trials; the control of cardiovascular risk factors is common in both (<LINK REF="REF-Black-2003" TYPE="REFERENCE">Black 2003</LINK>; <LINK REF="REF-Wilkinson-2003" TYPE="REFERENCE">Wilkinson 2003</LINK>).</P>
<P>Both studies included a large number of participants at risk of cognitive decline, follow-up was sufficient, one study included the lipophilic statin simvastatin (<LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>), and one study included the hydrophilic statin pravastatin (<LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002). There were adequate data on adverse effects in both studies. There were data on function in ADL and on change in cognition accounting for prior cholesterol level, ApoE genotype and cognitive level along with functional performance from <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002 only. There were no data on quality of life or behaviour.</P>
<P>Both studies included participants at moderate to high risk of vascular events; therefore, the results may not apply to people at low vascular risk.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2015-12-14 20:50:13 +0000" MODIFIED_BY="Anne Lawson">
<P>Both studies were at low risk of bias. However, there were key methodological limitations concerning cognitive outcomes as cognition was a tertiary endpoint in both studies. <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> had no baseline cognitive data and included only one cognitive test (TICS-m), it recorded incidence of dementia but event rates were very low. Our estimate for the effect of statin treatment on dementia incidence was imprecise (OR 1.00, 95% CI 0.61 to 1.65), so we downgraded the quality of the evidence for this outcome to moderate. <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002 used different cognitive tests at different time points and incidence of dementia was not an outcome. Loss to follow-up was low in <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK>, but most cases of mortality were not included in this statistic (three participants in the simvastatin group lost to follow-up due to mortality, 1328 participants died in total in the simvastatin group; four participants in the placebo group lost to follow-up due to mortality, 1507 participants died in total in the placebo group). In <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002, 724 participants in the pravastatin group and 725 participants in the placebo group withdrew due to various reasons; 219 participants died in the pravastatin group and 240 participants died in the placebo group. All analyses were by intention to treat.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2015-12-14 20:50:44 +0000" MODIFIED_BY="Anne Lawson">
<P>It is likely that we identified all relevant studies and obtained all relevant data due to the strengths of the search strategy and review process. We do not believe that we introduced bias using our review methods.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2015-12-14 21:02:41 +0000" MODIFIED_BY="Anne Lawson">
<P>The question of whether statins were of benefit in the prevention of dementia stemmed from cross-sectional studies in the early 2000s; initial evidence was very promising with some estimates of risk reduction of more than two-thirds (<LINK REF="REF-Jick-2000" TYPE="REFERENCE">Jick 2000</LINK>; <LINK REF="REF-Wolozin-2000" TYPE="REFERENCE">Wolozin 2000</LINK>). However, these studies were subject to important limitations. How representative people in these databases were of the general population was unclear and information on important confounding factors, such as education, was unavailable. Cross-sectional studies are subject to indication bias, which occurs when a drug is prescribed for a reason that itself is associated with an outcome of interest. Of note from the <LINK REF="REF-Wolozin-2000" TYPE="REFERENCE">Wolozin 2000</LINK> study, while the data were being collected (1996 to 1998), physicians were more likely to have prescribed statins to people who were 'more highly educated, attentive, inquisitive and concerned about their future health' (<LINK REF="REF-Haley-2000" TYPE="REFERENCE">Haley 2000</LINK>), than people at higher risk of dementia. This may also explain why an effect was seen for pravastatin and lovastatin but not simvastatin, sales of which lagged behind the former two.</P>
<P>Subsequent systematic reviews have been carried out. <LINK REF="REF-Wong-2013" TYPE="REFERENCE">Wong 2013</LINK> identified 20 relevant studies, comprising 16 cohort studies, three case-control studies and one RCT. In one meta-analysis, there were modest protective effects of statin use for any dementia (random effects pooled RR 0.82, 95% CI 0.69 to 0.97) and AD (random effects pooled RR 0.70, 95% CI 0.60 to 0.80). There was substantial heterogeneity in the effect sizes for any dementia, but not for AD. Of note, effect sizes were smaller and closer to the null in studies that had controlled for more confounders, and where a clinical diagnosis as opposed to linkage to health records was used to establish dementia incidence. <LINK REF="REF-Song-2013" TYPE="REFERENCE">Song 2013</LINK> performed a meta-analysis of prospective cohort studies but was much less comprehensive and several studies were missed. They found a reduced incidence of dementia in statin users but there was considerable heterogeneity (RR 0.62, 95% CI 0.43 to 0.81, I<SUP>2</SUP> = 70.8%)<I>.</I>
</P>
<P>When considering the increased cancer incidence in <LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> 2002 in the pravastatin group compared to the placebo group, a meta-analysis carried out by the study authors of cancer rates in previous randomised placebo-controlled studies lasting more than three years revealed no increased incidence in pravastatin or all statin users, which is reassuring, but this outcome should be included in future RCTs of statins. There was no increased incidence of newly diagnosed cancer in <LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> in the simvastatin group compared to the placebo group (814 simvastatin-allocated participants versus 803 placebo-allocated participants; RR 1.0, 95% CI 0.91 to 1.11). Subsequently, one systematic review found six meta-analyses of RCTs and two meta-analyses of RCTs and observational studies found no association between statin use and overall incident cancer risk (<LINK REF="REF-Bondreau-2010" TYPE="REFERENCE">Bondreau 2010</LINK>).</P>
<P>Overall, it is still unclear how dyslipidaemia exerts its effects on dementia risk; the association may vary depending upon the age at which cholesterol level is assessed and the follow-up interval. The World Alzheimer Report found studies where the exposure was assessed in mid-life were more likely to report a positive association than short latency studies where exposure was assessed in late-life shortly before the onset of dementia (<LINK REF="REF-Prince-2014" TYPE="REFERENCE">Prince 2014</LINK>). It is postulated that cholesterol levels may decline more rapidly from mid-life to late-life in people who go on to develop dementia, particularly AD. Of note in the Honolulu Asia Aging Study (HASS) (<LINK REF="REF-Stewart-2007" TYPE="REFERENCE">Stewart 2007</LINK>), the Baltimore Longitudinal Study of Aging in the USA (<LINK REF="REF-Beydoun-2011" TYPE="REFERENCE">Beydoun 2011</LINK>), the Prospective Population Study of Women in Sweden (<LINK REF="REF-Mielke-2010" TYPE="REFERENCE">Mielke 2010</LINK>), and Cardiovascular Risk Factors, Aging and Dementia (CAIDE) in Finland (<LINK REF="REF-Solomon-2007" TYPE="REFERENCE">Solomon 2007</LINK>), a more rapid decline in total cholesterol from mid to late life was predictive of the onset of AD. The only study which did not replicate this finding was the Framingham Heart Study (<LINK REF="REF-Tan-2003" TYPE="REFERENCE">Tan 2003</LINK>). This decline in total cholesterol could be causal, could reflect reverse causality or could be accounted for by confounding. In order to address this question, ideally large RCTs would run for many years assessing cognitive decline in statin users compared to non-users but these would be extremely expensive and labour intensive. It is also unfeasible, as many people at risk of dementia will be prescribed statins for other reasons.</P>
<SUBSECTION>
<HEADING LEVEL="2">Limitations</HEADING>
<P>This review is limited primarily by the lack of evidence from well-designed RCTs in which cognition is a primary outcome. Ideally, large RCTs would run for many years in order to assess cognitive decline in statin users compared to non-users but this is not feasible due to costs involved and as many participants at risk of dementia will be prescribed statins for other reasons.</P>
</SUBSECTION>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2015-12-14 21:05:30 +0000" MODIFIED_BY="Anne Lawson">
<IMPLICATIONS_PRACTICE MODIFIED="2015-12-14 21:03:02 +0000" MODIFIED_BY="Anne Lawson">
<P>There is good evidence that statins given in late life to people at risk of vascular disease have no effect in preventing cognitive decline or dementia. Inclusion of statins for this indication on national or local formularies is not currently warranted.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2015-12-14 21:05:30 +0000" MODIFIED_BY="Anne Lawson">
<P>Statins to date have not been shown to be beneficial in the prevention of dementia in randomised controlled trials (RCTs), the gold standard of clinical research. However, there remain unanswered questions, as there were insufficient data in the current trials to address the following questions.</P>
<UL>
<LI>Whether there is a relationship between the occurrence of disease and the level of cholesterol - as one's cholesterol rises does the risk of disease rise in some graded fashion or does a rapid decline in total cholesterol from mid to late life predict onset of Alzheimer's disease (AD)?</LI>
<LI>Whether lowering of cholesterol levels judged normal in the developed parts of the world might influence the onset of disease.</LI>
<LI>Whether people with a family history of AD might preferentially benefit from therapy compared to people without a family history.</LI>
<LI>Whether therapy started in middle life has an advantage over therapy started people in their 60s or early 70s.</LI>
</UL>
<P>Further RCTs may address these questions but costs and logistics make this difficult.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2015-12-14 21:07:10 +0000" MODIFIED_BY="Anne Lawson">
<P>We are grateful to Professor H Denman Scott and Professor Knut Laake (deceased), who prepared the original and updated iterations of this review (Scott HD, Laake K. Statins for the prevention of Alzheimer's disease. Cochrane Database of Systematic Reviews 2001, Issue 3. Art. No.: CD003160. DOI: 10.1002/14651858.CD003160). The Group deeply regrets the death of Knut Laake in May 2003.</P>
<P>We wish to thank Reem Malouf from the Cochrane Dementia and Cognitive Improvement Group's editorial base for her statistical advice.</P>
<P>We appreciate the contributions of consumer editor, Corinne Cavender.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2015-12-15 14:03:39 +0000" MODIFIED_BY="Anne Lawson">
<P>BMcG: none known.</P>
<P>DC: none known.</P>
<P>RB: none known.</P>
<P>PP: none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2015-12-14 21:08:20 +0000" MODIFIED_BY="Anne Lawson">
<P>BMcG: all work concerned with review.</P>
<P>DC: commenting on draft review.</P>
<P>RB: commenting on draft review.</P>
<P>PP: selection of studies, commenting on draft review.</P>
<P>Contact editors: J Grimley Evans and Lon Schneider (for 2008 update).</P>
<P>Consumer editor: Corinne Cavender.</P>
<P>This review was peer reviewed anonymously.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2015-12-22 10:33:45 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2015-12-15 14:28:11 +0000" MODIFIED_BY="Anne Lawson">
<INCLUDED_STUDIES MODIFIED="2015-12-14 21:36:37 +0000" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-HPS-2002" MODIFIED="2015-12-14 21:34:27 +0000" MODIFIED_BY="Anne Lawson" NAME="HPS 2002" YEAR="2002">
<REFERENCE MODIFIED="2015-12-14 21:34:27 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heart Protection Study Collaborative Group</AU>
<TI>MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<PG>7-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PROSPER" MODIFIED="2015-12-14 21:36:37 +0000" MODIFIED_BY="Anne Lawson" NAME="PROSPER" YEAR="2002">
<REFERENCE MODIFIED="2015-12-14 21:34:38 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Packard CJ, Westendorp RG, Stott DJ, Caslake MJ, Murray HM, Shepherd J, et al</AU>
<TI>Association between apolipoprotein E4 and cognitive decline in elderly adults</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2007</YR>
<VL>11</VL>
<PG>1777-85</PG>
<IDENTIFIERS MODIFIED="2008-12-11 17:03:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-14 21:35:30 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Shepherd J, Blauw GJ, Murphy MB, Bollen ELEM, Buckley BM, Cobbe SM, et al</AU>
<TI>Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial</TI>
<SO>Lancet</SO>
<YR>2002</YR>
<VL>360</VL>
<PG>1623-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-14 21:35:19 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shepherd J, Blauw GJ, Murphy MB, Cobbe SM, Bollen EL, Buckley BM, et al</AU>
<TI>The design of a prospective study of pravastatin in the elderly at risk (PROSPER)</TI>
<SO>American Journal of Cardiology</SO>
<YR>1999</YR>
<VL>84</VL>
<PG>1192-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-14 21:36:37 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trompet S, van Vilet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, et al</AU>
<TI>Pravastatin and cognitive function in the elderly. Results of the PROSPER study</TI>
<SO>Journal of Neurology</SO>
<YR>2010</YR>
<VL>257</VL>
<NO>1</NO>
<PG>85-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2015-12-15 14:28:11 +0000" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-Muldoon-2000" MODIFIED="2015-12-14 21:37:00 +0000" MODIFIED_BY="Anne Lawson" NAME="Muldoon 2000" YEAR="2000">
<REFERENCE MODIFIED="2015-12-14 21:37:00 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muldoon MF, Barger SD, Ryan CM, Flory JD, Lehoczky JP, Matthews, KA, et al</AU>
<TI>Effects of lovastatin on cognitive function and psychological well-being</TI>
<SO>American Journal of Medicine</SO>
<YR>2000</YR>
<VL>108</VL>
<PG>538-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muldoon-2004" MODIFIED="2015-12-14 21:37:20 +0000" MODIFIED_BY="Anne Lawson" NAME="Muldoon 2004" YEAR="2004">
<REFERENCE MODIFIED="2015-12-14 21:37:20 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck, SB</AU>
<TI>Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults</TI>
<SO>American Journal of Medicine</SO>
<YR>2004</YR>
<VL>117</VL>
<PG>823-829</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santanello-1997" MODIFIED="2015-12-14 21:38:23 +0000" MODIFIED_BY="Anne Lawson" NAME="Santanello 1997" YEAR="1997">
<REFERENCE MODIFIED="2015-12-14 21:37:41 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>LaRosa JC, Applegate W, Crouse JR 3rd, Hunninghake DB, Grimm R, Knopp R, et al</AU>
<TI>Cholesterol lowering in the elderly. results of the Cholesterol Reduction In Seniors Program (CRISP) pilot study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>1994</YR>
<VL>154</VL>
<PG>529-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2015-12-14 21:38:23 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Santanello NC, Barber BL, Applegate WB, Elam J, Curtis C, Hunninghake DB, et al</AU>
<TI>Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction In Seniors Program (CRISP) pilot study</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>1997</YR>
<VL>45</VL>
<PG>8-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sparks-2010" MODIFIED="2015-12-14 21:39:09 +0000" MODIFIED_BY="Anne Lawson" NAME="Sparks 2010" YEAR="2010">
<REFERENCE MODIFIED="2015-12-14 21:39:09 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sparks DL, Kryscio RJ, Connor DJ, Sabbagh MN, Sparks LM, Lin Y, et al</AU>
<TI>Cholesterol and cognitive performance in normal controls and the influence of elective statin use after conversion to mild cognitive impairment: results in a clinical trial cohort</TI>
<SO>Neuro-degenerative Diseases</SO>
<YR>2010</YR>
<VL>7</VL>
<PG>183-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Summers-2007" MODIFIED="2015-12-15 14:28:11 +0000" MODIFIED_BY="Anne Lawson" NAME="Summers 2007" YEAR="2007">
<REFERENCE MODIFIED="2015-12-15 14:28:11 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Summers MJ, Oliver KR, Coombes JS, Fassett RG</AU>
<TI>Effect of atorvastatin on cognitive function in patients from the Lipid Lowering and Onset of Renal Disease (LORD) trial</TI>
<SO>Pharmacotherapy</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>2</NO>
<PG>183-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tendolkar-2012" MODIFIED="2015-12-14 21:40:13 +0000" MODIFIED_BY="Anne Lawson" NAME="Tendolkar 2012" YEAR="2012">
<REFERENCE MODIFIED="2015-12-14 21:40:13 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tendolkar I, Enajat M, Zwiers MP, van Wingen G, de Leeuw FE, van Kuilenburg J, et al</AU>
<TI>One-year cholesterol lowering treatment reduces medial temporal lobe atrophy and memory decline in stroke-free elderly with atrial fibrillation: evidence from a parallel group randomized trial</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2012</YR>
<VL>27</VL>
<NO>1</NO>
<PG>49-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-12-10 11:06:50 +0000" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2015-12-14 21:41:51 +0000" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-ESH_x002d_CHL_x002d_SHOT-2014" MODIFIED="2015-12-14 21:40:49 +0000" MODIFIED_BY="Anne Lawson" NAME="ESH-CHL-SHOT 2014" YEAR="2014">
<REFERENCE MODIFIED="2015-12-14 21:40:49 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zanchetti A, Liu L, Mancia M, Parati G, Grassi G, Stramba-Badiale M, et al</AU>
<TI>Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension - Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial</TI>
<SO>Journal of Hypertension</SO>
<YR>2014</YR>
<VL>32</VL>
<PG>1888</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2015-03-05 15:20:52 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2015-03-05 15:20:52 +0000" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PODCAST-2013" MODIFIED="2015-12-14 21:41:51 +0000" MODIFIED_BY="Anne Lawson" NAME="PODCAST 2013" YEAR="2013">
<REFERENCE MODIFIED="2015-12-14 21:41:51 +0000" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blackburn DJ, Krishnan K, Fox L, Ballard C, Burns A, Ford GA, et al</AU>
<TI>Prevention of Decline in Cognition after Stroke Trial (PODCAST): a study protocol for a factorial randomised controlled trial of intensive versus guideline lowering of blood pressure and lipids</TI>
<SO>Trials</SO>
<YR>2013</YR>
<VL>14</VL>
<PG>401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2015-12-22 10:33:45 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2015-12-22 10:33:45 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abner-2015" MODIFIED="2015-12-14 21:42:50 +0000" MODIFIED_BY="Anne Lawson" NAME="Abner 2015" TYPE="JOURNAL_ARTICLE">
<AU>Abner EL, Kryscio RJ, Caban-Holt AM , Schmitt FA</AU>
<TI>Baseline subjective memory complaints associate with increased risk of incident dementia: the PREADVISE trial</TI>
<SO>Journal of Prevention of Alzheimer's Disease</SO>
<YR>2015</YR>
<VL>2</VL>
<PG>11-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Amarenco-2009" MODIFIED="2015-12-14 21:43:06 +0000" MODIFIED_BY="Anne Lawson" NAME="Amarenco 2009" TYPE="JOURNAL_ARTICLE">
<AU>Amarenco P, Goldstein LB, Messig M, O'Neill BJ, Callahan A 3rd, Sillesen H, et al; SPARCL Investigators</AU>
<TI>Relative and cumulative effects of lipid and blood pressure control in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial</TI>
<SO>Stroke</SO>
<YR>2009</YR>
<VL>40</VL>
<PG>2486-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ballard-2000" MODIFIED="2015-12-15 14:28:53 +0000" MODIFIED_BY="Anne Lawson" NAME="Ballard 2000" TYPE="JOURNAL_ARTICLE">
<AU>Ballard C, McKeith I, O'Brien J, Kalaria R, Jaros E, Ince P, et al</AU>
<TI>Neuropathological substrates of dementia and depression in vascular dementia, with a particular focus on cases with small infarct volumes</TI>
<SO>Dementia and Geriatric Cognitive Disorders</SO>
<YR>2000</YR>
<VL>11</VL>
<PG>59-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beecham-2014" MODIFIED="2015-12-14 21:43:41 +0000" MODIFIED_BY="Anne Lawson" NAME="Beecham 2014" TYPE="JOURNAL_ARTICLE">
<AU>Beecham GW, Hamilton K, Naj AC, Martin ER, Huentelman M, Myers AJ, et al</AU>
<TI>Genome-wide association meta-analysis of neuropathologic features of Alzheimer's disease and related dementias</TI>
<SO>PLoS Genetics</SO>
<YR>2014</YR>
<VL>10</VL>
<NO>9</NO>
<PG>e1004606</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bettermann-2012" MODIFIED="2015-12-14 21:44:36 +0000" MODIFIED_BY="Anne Lawson" NAME="Bettermann 2012" TYPE="JOURNAL_ARTICLE">
<AU>Bettermann K, Arnold AM, Williamson J, Rapp S, Sink K, Toole JF, et al</AU>
<TI>Statins, risk of dementia and cognitive function: secondary analysis of the ginkgo evaluation of memory study</TI>
<SO>Journal of Stroke and Cerebrovascular Diseases</SO>
<YR>2012</YR>
<VL>21</VL>
<NO>6</NO>
<PG>436-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beydoun-2011" MODIFIED="2015-12-14 21:45:20 +0000" MODIFIED_BY="Anne Lawson" NAME="Beydoun 2011" TYPE="JOURNAL_ARTICLE">
<AU>Beydoun MA, Beason-Held LL, Kitner-Triolo MH, Beydoun HA, Ferrucci L, Resnick SM, et al</AU>
<TI>Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment</TI>
<SO>Journal of Epidemiology and Community Health</SO>
<YR>2011</YR>
<VL>65</VL>
<NO>11</NO>
<PG>949-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Black-2003" MODIFIED="2015-12-14 21:45:37 +0000" MODIFIED_BY="Anne Lawson" NAME="Black 2003" TYPE="JOURNAL_ARTICLE">
<AU>Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al. and the Donepezil 307 Vascular Dementia Study Group</AU>
<TI>Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial</TI>
<SO>Stroke</SO>
<YR>2003</YR>
<VL>34</VL>
<PG>2323-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bondreau-2010" MODIFIED="2015-12-14 21:46:17 +0000" MODIFIED_BY="Anne Lawson" NAME="Bondreau 2010" TYPE="JOURNAL_ARTICLE">
<AU>Bondreau DM, Yu O, Johnson J</AU>
<TI>Statin use and cancer risk: a comprehensive review</TI>
<SO>Expert Opinions on Drug Safety</SO>
<YR>2010</YR>
<VL>9</VL>
<NO>4</NO>
<PG>603-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Breteler-1994" MODIFIED="2015-12-14 21:46:34 +0000" MODIFIED_BY="Anne Lawson" NAME="Breteler 1994" TYPE="JOURNAL_ARTICLE">
<AU>Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, et al</AU>
<TI>Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: The Rotterdam Study</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44</VL>
<PG>1246-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burns-2003" MODIFIED="2015-12-15 14:29:52 +0000" MODIFIED_BY="Anne Lawson" NAME="Burns 2003" TYPE="JOURNAL_ARTICLE">
<AU>Burns MP, Noble WJ, Olm V, Gaynor K, Casey E, LaFrancois J, et al</AU>
<TI>Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques</TI>
<SO>Brain Research. Molecular Brain Research</SO>
<YR>2003</YR>
<VL>110</VL>
<PG>119-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burns-2009" MODIFIED="2015-10-06 12:44:36 +0100" MODIFIED_BY="[Empty name]" NAME="Burns 2009" TYPE="JOURNAL_ARTICLE">
<AU>Burns A, Iliffe S</AU>
<TI>Dementia</TI>
<SO>BMJ</SO>
<YR>2009</YR>
<VL>338</VL>
<PG>b75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cole-2007" MODIFIED="2015-12-14 21:47:01 +0000" MODIFIED_BY="Anne Lawson" NAME="Cole 2007" TYPE="JOURNAL_ARTICLE">
<AU>Cole SL, Vassar R</AU>
<TI>The Alzheimer's disease beta-secretase enzyme, BACE1</TI>
<SO>Molecular Neurodegeneration</SO>
<YR>2007</YR>
<VL>2</VL>
<PG>22</PG>
<IDENTIFIERS MODIFIED="2008-10-30 15:59:27 +0000" MODIFIED_BY="Helen Collins">
<IDENTIFIER MODIFIED="2008-10-30 15:59:25 +0000" MODIFIED_BY="Helen Collins" TYPE="DOI" VALUE="10.1186/1750-1326-2-22"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Corder-1993" MODIFIED="2015-12-14 21:47:22 +0000" MODIFIED_BY="Anne Lawson" NAME="Corder 1993" TYPE="JOURNAL_ARTICLE">
<AU>Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, et al</AU>
<TI>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families</TI>
<SO>Science</SO>
<YR>1993</YR>
<VL>261</VL>
<PG>921-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CTTC-2005" MODIFIED="2015-12-14 21:47:32 +0000" MODIFIED_BY="Anne Lawson" NAME="CTTC 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cholesterol Treatment Trialists' Collaborators</AU>
<TI>Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins</TI>
<SO>Lancet</SO>
<YR>2005</YR>
<VL>366</VL>
<PG>1267</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dantoine-2002" MODIFIED="2015-12-14 21:47:45 +0000" MODIFIED_BY="Anne Lawson" NAME="Dantoine 2002" TYPE="JOURNAL_ARTICLE">
<AU>Dantoine TF, Debord J, Merle L, Lacroix-Ramiandrisoa H, Bourzeix L, Charmes JP</AU>
<TI>Paraoxonase 1 activity: a new vascular marker of dementia?</TI>
<SO>Annals of the New York Academy of Sciences</SO>
<YR>2002</YR>
<VL>977</VL>
<PG>96-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ehehalt-2003" MODIFIED="2015-12-14 21:47:58 +0000" MODIFIED_BY="Anne Lawson" NAME="Ehehalt 2003" TYPE="JOURNAL_ARTICLE">
<AU>Ehehalt R, Keller P, Haass C, Thiele C, Simons K</AU>
<TI>Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts</TI>
<SO>Journal of Cell Biology</SO>
<YR>2003</YR>
<VL>160</VL>
<PG>113-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Esiri-1997" MODIFIED="2008-10-30 16:06:34 +0000" MODIFIED_BY="Helen Collins" NAME="Esiri 1997" TYPE="JOURNAL_ARTICLE">
<AU>Esiri MM, Wilcock GK, Morris JH</AU>
<TI>Neuropathological assessment of the lesions of significance in vascular dementia</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1997</YR>
<VL>63</VL>
<PG>749-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Evans-2009" MODIFIED="2015-06-22 15:56:32 +0100" MODIFIED_BY="[Empty name]" NAME="Evans 2009" TYPE="JOURNAL_ARTICLE">
<AU>Evans MA, Golomb BA</AU>
<TI>Statin-associated adverse cognitive effects: survey results from 171 patients</TI>
<SO>Pharmacotherapy</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>7</NO>
<PG>800-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Farrer-1997" MODIFIED="2015-12-14 21:48:43 +0000" MODIFIED_BY="Anne Lawson" NAME="Farrer 1997" TYPE="JOURNAL_ARTICLE">
<AU>Farrer LA, Cupples LA, Haines JL, Hyman B, Kukull WA, Mayeux R, et al</AU>
<TI>Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. ApoE and Alzheimer Disease Meta Analysis Consortium</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>278</VL>
<PG>1349-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glenner-1984" MODIFIED="2015-12-14 21:48:53 +0000" MODIFIED_BY="Anne Lawson" NAME="Glenner 1984" TYPE="JOURNAL_ARTICLE">
<AU>Glenner GG, Wong CW</AU>
<TI>Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein</TI>
<SO>Biochemistry Biophysics Research Communications</SO>
<YR>1984</YR>
<VL>20</VL>
<PG>885-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Haley-2000" MODIFIED="2008-11-02 19:40:37 +0000" MODIFIED_BY="[Empty name]" NAME="Haley 2000" TYPE="JOURNAL_ARTICLE">
<AU>Haley R, Dietschy JM</AU>
<TI>Is there a connection between the concentration of cholesterol circulating in plasma and the rate of neuritic plaque formation in Alzheimer's disease</TI>
<SO>Archives of Neurology</SO>
<YR>2000</YR>
<VL>57</VL>
<PG>1410-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harold-2009" MODIFIED="2015-12-14 21:49:46 +0000" MODIFIED_BY="Anne Lawson" NAME="Harold 2009" TYPE="JOURNAL_ARTICLE">
<AU>Harold D, Abraham R, Hollingworth P, Sims R, Gerish A, Hamshere ML, et al</AU>
<TI>Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease</TI>
<SO>Nature Genetics</SO>
<YR>2009</YR>
<VL>41</VL>
<NO>10</NO>
<PG>1088-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harris-2004" MODIFIED="2015-12-14 21:51:51 +0000" MODIFIED_BY="Anne Lawson" NAME="Harris 2004" TYPE="JOURNAL_ARTICLE">
<AU>Harris, JI. Hibbeln JR, Mackey RH, Muldoon MF</AU>
<TI>Statin treatment alters serum n-3 and n-6 fatty acids in hypercholesterolemic patients</TI>
<SO>Prostaglandins, Leukotrienes and Essential Fatty Acids</SO>
<YR>2004</YR>
<VL>71</VL>
<PG>263-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayden-2006" MODIFIED="2015-12-14 21:52:48 +0000" MODIFIED_BY="Anne Lawson" NAME="Hayden 2006" TYPE="JOURNAL_ARTICLE">
<AU>Hayden KM, Zandi PP, Lyketsos CG, Khachaturian AS, Bastian LA, Charoonruk G, et al</AU>
<TI>Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County study</TI>
<SO>Alzheimer Disease and Associated Disorders</SO>
<YR>2006</YR>
<VL>20</VL>
<NO>2</NO>
<PG>93-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heart-2014" MODIFIED="2015-12-14 21:53:05 +0000" MODIFIED_BY="Anne Lawson" NAME="Heart 2014" TYPE="JOURNAL_ARTICLE">
<AU>JBS3 Board</AU>
<TI>Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3)</TI>
<SO>Heart</SO>
<YR>2014</YR>
<VL>100</VL>
<PG>ii1-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jarvik-1995" MODIFIED="2008-11-02 19:45:10 +0000" MODIFIED_BY="[Empty name]" NAME="Jarvik 1995" TYPE="JOURNAL_ARTICLE">
<AU>Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB</AU>
<TI>Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case control study</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45</VL>
<PG>1092-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ji-2015" MODIFIED="2015-12-14 21:54:08 +0000" MODIFIED_BY="Anne Lawson" NAME="Ji 2015" TYPE="JOURNAL_ARTICLE">
<AU>Ji Y, Shi Z, Zhang Y, Liu S, Liu S, Yue W, et al</AU>
<TI>Prevalence of dementia and main subtypes in rural northern China</TI>
<SO>Dementia and Geriatric Cognitive Disorders</SO>
<YR>2015</YR>
<VL>39</VL>
<PG>294-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jick-2000" NAME="Jick 2000" TYPE="JOURNAL_ARTICLE">
<AU>Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA</AU>
<TI>Statins and the risk of dementia</TI>
<SO>Lancet</SO>
<YR>2000</YR>
<VL>356</VL>
<PG>1627-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kalmijn-2000" MODIFIED="2015-12-22 10:02:06 +0000" MODIFIED_BY="[Empty name]" NAME="Kalmijn 2000" TYPE="JOURNAL_ARTICLE">
<AU>Kalmijn S, Foley D, White L, Burchfiel CM, Curb JD, Petrovitch H et al</AU>
<TI>Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men. The Honolulu-Asia aging study</TI>
<SO>Arterioscler Thromb Vasc Biol</SO>
<YR>2000</YR>
<VL>20</VL>
<NO>10</NO>
<PG>2255-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kelley-2014" MODIFIED="2015-06-22 16:03:20 +0100" MODIFIED_BY="[Empty name]" NAME="Kelley 2014" TYPE="JOURNAL_ARTICLE">
<AU>Kelley BJ, Glasser S</AU>
<TI>Cognitive effects of statin medications</TI>
<SO>CNS Drugs</SO>
<YR>2014</YR>
<VL>28</VL>
<NO>5</NO>
<PG>411-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kivipelto-2002" MODIFIED="2015-12-22 09:56:36 +0000" MODIFIED_BY="[Empty name]" NAME="Kivipelto 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I Winblad B et al</AU>
<TI>Apolipoprotein E &#603;4 allele, elevated midlife total cholesterol level and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer's disease</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2002</YR>
<VL>137</VL>
<NO>3</NO>
<PG>149-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kivipelto-2005" MODIFIED="2015-12-14 21:54:37 +0000" MODIFIED_BY="Anne Lawson" NAME="Kivipelto 2005" TYPE="JOURNAL_ARTICLE">
<AU>Kivipelto M, Ngandu T, Fratiglioni L, Viitanen M, Kareholt I, Winblad B, et al</AU>
<TI>Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease</TI>
<SO>Archives of Neurology</SO>
<YR>2005</YR>
<VL>62</VL>
<NO>10</NO>
<PG>1556-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Klich_x002d_Raczka-2002" MODIFIED="2015-12-14 21:56:24 +0000" MODIFIED_BY="Anne Lawson" NAME="Klich-Raczka 2002" TYPE="JOURNAL_ARTICLE">
<AU>Klich-Raczka A, Necki M, Wizner B, Baron T, Adamkiewicz-Piejko A, Gryglewska B, et al</AU>
<TI>Vascular dementia and systemic changes [in Polish]</TI>
<SO>Przegla&#807;d Lekarski</SO>
<YR>2002</YR>
<VL>59</VL>
<PG>269-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuriyama-1994" MODIFIED="2015-12-14 21:56:41 +0000" MODIFIED_BY="Anne Lawson" NAME="Kuriyama 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kuriyama M, Takahashi K, Yamano T, Hokezu Y, Togo S, Osame M, et al</AU>
<TI>Low levels of serum apolipoprotein A I and A II in senile dementia</TI>
<SO>Japanese Journal of Psychiatry and Neurology</SO>
<YR>1994</YR>
<VL>48</VL>
<PG>589-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lopez-2005" MODIFIED="2015-12-14 21:57:11 +0000" MODIFIED_BY="Anne Lawson" NAME="Lopez 2005" TYPE="JOURNAL_ARTICLE">
<AU>Lopez OL, Becker JT, Saxton J, Sweet RA, Klunk W, De Kosky ST</AU>
<TI>Alteration of a clinically meaningful outcome in the natural history of Alzheimer's disease by cholinesterase inhibition</TI>
<SO>Journal of the American Geriatric Society</SO>
<YR>2005</YR>
<VL>53</VL>
<PG>83-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mainous-2005" MODIFIED="2015-12-22 10:30:40 +0000" MODIFIED_BY="[Empty name]" NAME="Mainous 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mainous AG 3rd, Eschenbach SL, Wells BJ, Everett CJ, Gill JM</AU>
<TI>Cholesterol, transferrin saturation, and the development of dementia and Alzheimer's disease: results from an 18-year population-based cohort</TI>
<SO>Family Medicine</SO>
<YR>2005</YR>
<VL>37</VL>
<NO>1</NO>
<PG>36-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marks-2003" MODIFIED="2015-12-14 22:01:11 +0000" MODIFIED_BY="Anne Lawson" NAME="Marks 2003" TYPE="JOURNAL_ARTICLE">
<AU>Marks N, Berg MJ</AU>
<TI>APP processing enzymes (secretases) as therapeutic targets: insights from the use of transgenics (tgs) and transfected cells</TI>
<SO>Neurochemistry Research</SO>
<YR>2003</YR>
<VL>28</VL>
<PG>1049-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McFarland-2014" MODIFIED="2015-12-14 22:01:55 +0000" MODIFIED_BY="Anne Lawson" NAME="McFarland 2014" TYPE="JOURNAL_ARTICLE">
<AU>McFarland AJ, Anoopkumar-Dukie S, Arora DS, Grant GD, McDermott CM, Perkins AV, et al</AU>
<TI>Molecular mechanisms underlying the effects of statins in the central nervous system</TI>
<SO>International Journal of Molecular Sciences</SO>
<YR>2014</YR>
<VL>15</VL>
<PG>20607-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meng-2007" MODIFIED="2015-06-22 12:31:01 +0100" MODIFIED_BY="[Empty name]" NAME="Meng 2007" TYPE="JOURNAL_ARTICLE">
<AU>Meng Y, Lee JH, Cheng R, St George-Hyslop P, Mayeux R, Farrer LA</AU>
<TI>Association between SORL1 and Alzheimer's disease in a genome-wide study</TI>
<SO>Neuroreport</SO>
<YR>2007</YR>
<VL>18</VL>
<NO>17</NO>
<PG>1761-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mielke-2005" MODIFIED="2015-12-14 22:02:28 +0000" MODIFIED_BY="Anne Lawson" NAME="Mielke 2005" TYPE="JOURNAL_ARTICLE">
<AU>Mielke MM, Zandi PP, Sjogren M, Gustafson D, Ostling S, Steen B, et al</AU>
<TI>High total cholesterol levels in late life associated with a reduced risk of dementia</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>10</NO>
<PG>1689-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mielke-2010" MODIFIED="2015-12-14 22:02:43 +0000" MODIFIED_BY="Anne Lawson" NAME="Mielke 2010" TYPE="JOURNAL_ARTICLE">
<AU>Mielke MM, Zandi PP, Shao H, Waern M, Ostling S, Guo X, et al</AU>
<TI>The 32-year relationship between cholesterol and dementia from midlife to late life</TI>
<SO>Neurology</SO>
<YR>2010</YR>
<VL>75</VL>
<NO>21</NO>
<PG>1888-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mizuno-1999" MODIFIED="2008-11-02 20:54:20 +0000" MODIFIED_BY="[Empty name]" NAME="Mizuno 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mizuno T, Nakata M, Naiki H, Michikawa M, Wang R, Haass C</AU>
<TI>Cholesterol-dependent generation of a seeding amyloid beta-protein in cell culture</TI>
<SO>Journal of Biological Chemistry</SO>
<YR>1999</YR>
<VL>274</VL>
<PG>15110-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moroney-1999" MODIFIED="2008-11-02 20:55:52 +0000" MODIFIED_BY="[Empty name]" NAME="Moroney 1999" TYPE="JOURNAL_ARTICLE">
<AU>Moroney JT, Tang MX, Berglund L, Small S, Merchant C, Bell K, et al</AU>
<TI>Low-density lipoprotein cholesterol and the risk of dementia with stroke</TI>
<SO>JAMA</SO>
<YR>1999</YR>
<VL>282</VL>
<PG>254-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Muckle-1985" MODIFIED="2008-11-02 20:57:01 +0000" MODIFIED_BY="[Empty name]" NAME="Muckle 1985" TYPE="JOURNAL_ARTICLE">
<AU>Muckle TJ, Roy JR</AU>
<TI>High-density lipoprotein cholesterol in differential diagnosis of senile dementia</TI>
<SO>Lancet</SO>
<YR>1985</YR>
<VL>1</VL>
<PG>1191-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Naslund-1995" MODIFIED="2015-12-14 22:03:32 +0000" MODIFIED_BY="Anne Lawson" NAME="Naslund 1995" TYPE="JOURNAL_ARTICLE">
<AU>Naslund J, Thyberg J, Tjernberg LO, Wernstedt C, Karlstrom AR, Bogdanovic N, et al</AU>
<TI>Characterization of stable complexes involving apolipoprotein E and the amyloid beta peptide in Alzheimer's disease brain</TI>
<SO>Neuron</SO>
<YR>1995</YR>
<VL>15</VL>
<PG>219-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NICE-2006" MODIFIED="2015-12-22 09:36:31 +0000" MODIFIED_BY="[Empty name]" NAME="NICE 2006" TYPE="OTHER">
<TI>Dementia. supporting people with dementia and their carers in health and social care.</TI>
<SO>NICE clinical guideline 42, November 2006. Available at: http://www.guidance.nice.org.uk/CG42.</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Notkola-1998" MODIFIED="2015-12-22 10:04:35 +0000" MODIFIED_BY="[Empty name]" NAME="Notkola 1998" TYPE="JOURNAL_ARTICLE">
<AU>Notkola IL, Sulkava R, Pekkanen J et al</AU>
<TI>Serum total cholesterol, apolipoprotein E &#400;4 allele and Alzheimer's disease</TI>
<SO>Neuroepidemiology</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>14-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Orsi-2001" MODIFIED="2015-06-22 15:54:34 +0100" MODIFIED_BY="[Empty name]" NAME="Orsi 2001" TYPE="JOURNAL_ARTICLE">
<AU>Orsi A, Sherman O, Woldeselassie Z</AU>
<TI>Simvastatin-associated memory loss</TI>
<SO>Pharmacotherapy</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>6</NO>
<PG>767-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ott-1998" MODIFIED="2015-12-14 22:03:58 +0000" MODIFIED_BY="Anne Lawson" NAME="Ott 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ott A, Slooter AJ, Hofman A, van Harskamp F, Witteman JC, Van Broeckhoven C, et al</AU>
<TI>Smoking and risk of dementia and Alzheimer's disease in a population-based cohort study: the Rotterdam study</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>351</VL>
<PG>1840-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ott-2015" MODIFIED="2015-12-15 14:09:38 +0000" MODIFIED_BY="Anne Lawson" NAME="Ott 2015" TYPE="JOURNAL_ARTICLE">
<AU>Ott BR, Daiello LA, Dahabreh IJ, Springate BA, Bixby K, Murali M, et al</AU>
<TI>Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials</TI>
<SO>Journal of General Internal Medicine</SO>
<YR>2015</YR>
<VL>30</VL>
<NO>3</NO>
<PG>348-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Paragh-2002" MODIFIED="2015-12-14 22:05:18 +0000" MODIFIED_BY="Anne Lawson" NAME="Paragh 2002" TYPE="JOURNAL_ARTICLE">
<AU>Paragh G, Balla P, Katona E, Seres I, Egerhazi A, Degrell I</AU>
<TI>Serum paraoxonase activity changes in patients with Alzheimer's disease and vascular dementia</TI>
<SO>European Archives of Psychiatry and Clinical Neuroscience</SO>
<YR>2002</YR>
<VL>252</VL>
<PG>63-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Posner-2002" MODIFIED="2008-11-02 21:12:03 +0000" MODIFIED_BY="[Empty name]" NAME="Posner 2002" TYPE="JOURNAL_ARTICLE">
<AU>Posner HB, Tang MX, Luchsinger J, Lantigua R, Stern Y, Mayeux R</AU>
<TI>The relationship of hypertension in the elderly to AD, vascular dementia, and cognitive function</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>58</VL>
<PG>1175-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Prince-2014" MODIFIED="2015-12-14 22:08:24 +0000" MODIFIED_BY="Anne Lawson" NAME="Prince 2014" TYPE="OTHER">
<AU>Prince M, Albanese E, Guerchet M, Prina M</AU>
<TI>World Alzheimer report 2014. Dementia and risk reduction. An analysis of protective and modifiable factors, 2014</TI>
<SO>www.alz.co.uk/research/world-report-2014</SO>
<YR>(accessed 14 December 2015)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Refolo-2000" MODIFIED="2015-12-14 22:08:39 +0000" MODIFIED_BY="Anne Lawson" NAME="Refolo 2000" TYPE="JOURNAL_ARTICLE">
<AU>Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, et al</AU>
<TI>Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model</TI>
<SO>Neurobiological Disorders</SO>
<YR>2000</YR>
<VL>7</VL>
<PG>321-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reitz-2004" MODIFIED="2015-12-14 22:08:52 +0000" MODIFIED_BY="Anne Lawson" NAME="Reitz 2004" TYPE="JOURNAL_ARTICLE">
<AU>Reitz C, Tang MX, Luchsinger J, Mayeux R</AU>
<TI>Relation of plasma lipids to Alzheimer disease and vascular dementia</TI>
<SO>Archives of Neurology</SO>
<YR>2004</YR>
<VL>61</VL>
<PG>705-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Richardson-2013" MODIFIED="2015-12-14 22:09:17 +0000" MODIFIED_BY="Anne Lawson" NAME="Richardson 2013" TYPE="JOURNAL_ARTICLE">
<AU>Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, Arnold SE, et al</AU>
<TI>Statins and cognitive function: a systematic review</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2013</YR>
<VL>159</VL>
<NO>10</NO>
<PG>688-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rizzi-2014" MODIFIED="2015-12-14 22:10:19 +0000" MODIFIED_BY="Anne Lawson" NAME="Rizzi 2014" TYPE="JOURNAL_ARTICLE">
<AU>Rizzi L, Rosset I, Roriz-Cruz M</AU>
<TI>Global epidemiology of dementia: Alzheimer's and vascular types</TI>
<SO>BioMed Research International</SO>
<YR>2014</YR>
<VL>2014</VL>
<PG>908915</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Romas-1999" MODIFIED="2015-12-14 22:10:37 +0000" MODIFIED_BY="Anne Lawson" NAME="Romas 1999" TYPE="JOURNAL_ARTICLE">
<AU>Romas Sn, Tang MX, Berglund L, Mayeux R</AU>
<TI>APOE genotype, plasma lipids, lipoproteins, and AD in community elderly</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>3</NO>
<PG>517-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ruocco-2002" MODIFIED="2008-11-02 21:30:58 +0000" MODIFIED_BY="[Empty name]" NAME="Ruocco 2002" TYPE="JOURNAL_ARTICLE">
<AU>Ruocco A, Postiglione A, Santillo M, Seru R, Avvedimento EV, Cuda G, et al</AU>
<TI>New possible role of statins in age-related diseases</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2002</YR>
<VL>50</VL>
<PG>2099-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schunemann-2011" MODIFIED="2015-12-14 22:12:36 +0000" MODIFIED_BY="Anne Lawson" NAME="Schunemann 2011" TYPE="OTHER">
<AU>Schunemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH</AU>
<TI>Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sharrett-1994" MODIFIED="2015-12-14 22:13:02 +0000" MODIFIED_BY="Anne Lawson" NAME="Sharrett 1994" TYPE="JOURNAL_ARTICLE">
<AU>Sharrett AR, Patsch W, Sorlie PD, Heiss G, Bond MG, Davis CE</AU>
<TI>Associations of lipoprotein cholesterols, apolipoproteins A-I and B, and triglycerides with carotid atherosclerosis and coronary heart disease. The Atherosclerosis Risk In Communities (ARIC) study</TI>
<SO>Arteriosclerosis and Thrombosis</SO>
<YR>1994</YR>
<VL>14</VL>
<PG>1098-104</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simons-1998" MODIFIED="2015-12-14 22:14:24 +0000" MODIFIED_BY="Anne Lawson" NAME="Simons 1998" TYPE="JOURNAL_ARTICLE">
<AU>Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, Simons K</AU>
<TI>Cholesterol depletion inhibits the generation of B-amyloid in hippocampal neurons</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1998</YR>
<VL>95</VL>
<PG>6460-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skoog-1998" MODIFIED="2015-12-22 09:57:56 +0000" MODIFIED_BY="[Empty name]" NAME="Skoog 1998" TYPE="JOURNAL_ARTICLE">
<AU>Skoog I</AU>
<TI>Status of risk factors for vascular dementia</TI>
<SO>Neuroepidemiology</SO>
<YR>1998</YR>
<VL>17</VL>
<PG>2-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Solomon-2007" MODIFIED="2015-12-14 22:14:36 +0000" MODIFIED_BY="Anne Lawson" NAME="Solomon 2007" TYPE="JOURNAL_ARTICLE">
<AU>Solomon A, Kareholt I, Ngandu T, Winblad B, Nissinen A, Tuomilehto J, et al</AU>
<TI>Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study</TI>
<SO>Neurology</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>10</NO>
<PG>751-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Solomon-2009" MODIFIED="2015-12-15 14:37:25 +0000" MODIFIED_BY="Anne Lawson" NAME="Solomon 2009" TYPE="JOURNAL_ARTICLE">
<AU>Solomon A, Kivipelto M, Wolozin B, Zhou J, Whitmer RA</AU>
<TI>Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later</TI>
<SO>Dementia and Geriatric Cognitive Disorders</SO>
<YR>2009</YR>
<VL>28</VL>
<NO>1</NO>
<PG>75-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Song-2013" MODIFIED="2015-12-14 22:15:35 +0000" MODIFIED_BY="Anne Lawson" NAME="Song 2013" TYPE="JOURNAL_ARTICLE">
<AU>Song Y, Nie H, Xu Y, Zhang L, Wu Y</AU>
<TI>Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies</TI>
<SO>Geriatrics &amp; Gerontology International</SO>
<YR>2013</YR>
<VL>13</VL>
<NO>4</NO>
<PG>817-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-SPARCL-Investigators-2006" MODIFIED="2008-11-07 14:46:07 +0000" MODIFIED_BY="Helen Collins" NAME="SPARCL Investigators 2006" TYPE="JOURNAL_ARTICLE">
<AU>SPARCL Investigators</AU>
<TI>High-dose atorvastatin after stroke or transient ischaemic attack</TI>
<SO>New England Journal of Medicine</SO>
<YR>2006</YR>
<VL>355</VL>
<PG>549-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sparks-1994" MODIFIED="2015-12-14 22:16:00 +0000" MODIFIED_BY="Anne Lawson" NAME="Sparks 1994" TYPE="JOURNAL_ARTICLE">
<AU>Sparks DL, Scheff SW, Hunsaker JC 3rd, Liu H, Landers T, Gross DR</AU>
<TI>Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol</TI>
<SO>Experimental Neurology</SO>
<YR>1994</YR>
<VL>126</VL>
<PG>88-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stewart-1999" MODIFIED="2008-11-07 15:25:56 +0000" MODIFIED_BY="Helen Collins" NAME="Stewart 1999" TYPE="JOURNAL_ARTICLE">
<AU>Stewart R, Liolitsa D</AU>
<TI>Type 2 diabetes mellitus, cognitive impairment and dementia</TI>
<SO>Diabetic Medicine</SO>
<YR>1999</YR>
<VL>16</VL>
<PG>93-112</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stewart-2007" MODIFIED="2015-12-14 22:16:24 +0000" MODIFIED_BY="Anne Lawson" NAME="Stewart 2007" TYPE="JOURNAL_ARTICLE">
<AU>Stewart R, White LR, Xue QL, Launer LJ</AU>
<TI>Twenty-six-year change in total cholesterol levels and incident dementia: the Honolulu-Asia Aging Study</TI>
<SO>Archives of Neurology</SO>
<YR>2007</YR>
<VL>64</VL>
<PG>103-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Strittmatter-1993" MODIFIED="2015-12-14 22:16:47 +0000" MODIFIED_BY="Anne Lawson" NAME="Strittmatter 1993" TYPE="JOURNAL_ARTICLE">
<AU>Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, et al</AU>
<TI>Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1993</YR>
<VL>90</VL>
<PG>8098-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Swiger-2013" MODIFIED="2015-12-14 22:17:05 +0000" MODIFIED_BY="Anne Lawson" NAME="Swiger 2013" TYPE="JOURNAL_ARTICLE">
<AU>Swiger KJ, Manalac RJ, Blumenthall RS, Blaha MJ, Martin SS</AU>
<TI>Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>2013</YR>
<VL>88</VL>
<NO>11</NO>
<PG>1213-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tan-2003" MODIFIED="2015-12-14 22:17:28 +0000" MODIFIED_BY="Anne Lawson" NAME="Tan 2003" TYPE="JOURNAL_ARTICLE">
<AU>Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, et al</AU>
<TI>Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<NO>9</NO>
<PG>1053-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-Exel-2002" MODIFIED="2008-11-07 15:28:59 +0000" MODIFIED_BY="Helen Collins" NAME="van Exel 2002" TYPE="JOURNAL_ARTICLE">
<AU>van Exel E, de Craen AJ, Gussekloo J, Houx P, Bootsma-van der Wiel A, Macfarlane PW, et al</AU>
<TI>Association between high-density lipoprotein and cognitive impairment in the oldest old</TI>
<SO>Annals of Neurology</SO>
<YR>2002</YR>
<VL>51</VL>
<PG>716-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vetrivel-2004" MODIFIED="2015-12-15 14:40:20 +0000" MODIFIED_BY="Anne Lawson" NAME="Vetrivel 2004" TYPE="JOURNAL_ARTICLE">
<AU>Vetrivel KS, Cheng H, Lin W, Sakurai T, Li T, Nukina N, et al</AU>
<TI>Association of gamma-secretase with lipid rafts in post-Golgi and endosome membranes</TI>
<SO>Journal of Biological Chemistry</SO>
<YR>2004</YR>
<VL>279</VL>
<PG>44945-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wagstaff-2003" MODIFIED="2015-12-15 13:27:22 +0000" MODIFIED_BY="Anne Lawson" NAME="Wagstaff 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM</AU>
<TI>Statin-associated memory loss: analysis of 60 case reports and review of the literature</TI>
<SO>Pharmacotherapy</SO>
<YR>2003</YR>
<VL>23</VL>
<PG>871-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wang-2014" MODIFIED="2015-06-22 15:48:11 +0100" MODIFIED_BY="[Empty name]" NAME="Wang 2014" TYPE="JOURNAL_ARTICLE">
<AU>Wang W, Zhang B</AU>
<TI>Statins for the prevention of stroke: a meta-analysis of randomized controlled trials</TI>
<SO>PLoS One</SO>
<YR>2014</YR>
<VL>9</VL>
<NO>3</NO>
<PG>e92388</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wassmann-2001" MODIFIED="2008-11-07 16:00:25 +0000" MODIFIED_BY="Helen Collins" NAME="Wassmann 2001" TYPE="JOURNAL_ARTICLE">
<AU>Wassmann S, Laufs U, Baumer AT, Muller K, Ahlbory K, Linz W, et al</AU>
<TI>HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species</TI>
<SO>Hypertension</SO>
<YR>2001</YR>
<VL>37</VL>
<PG>1450-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Whitmer-2005" MODIFIED="2015-12-15 13:27:55 +0000" MODIFIED_BY="Anne Lawson" NAME="Whitmer 2005" TYPE="JOURNAL_ARTICLE">
<AU>Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K</AU>
<TI>Midlife cardiovascular risk factors and risk of dementia in late life</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>2</NO>
<PG>277-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wilkinson-2003" MODIFIED="2015-12-15 13:28:11 +0000" MODIFIED_BY="Anne Lawson" NAME="Wilkinson 2003" TYPE="JOURNAL_ARTICLE">
<AU>Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. and Donepezil 308 Study Group</AU>
<TI>Donepezil in vascular dementia: a randomized, placebo-controlled study</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>61</VL>
<PG>479-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wisniewski-1995" MODIFIED="2015-12-15 13:28:21 +0000" MODIFIED_BY="Anne Lawson" NAME="Wisniewski 1995" TYPE="JOURNAL_ARTICLE">
<AU>Wisniewski T, Lalowski M, Golabek A, Vogel T, Frangione B</AU>
<TI>Is Alzheimer's disease an apolipoprotein E amyloidosis?</TI>
<SO>Lancet</SO>
<YR>1995</YR>
<VL>345</VL>
<PG>956-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolozin-2000" MODIFIED="2015-12-15 13:29:33 +0000" MODIFIED_BY="Anne Lawson" NAME="Wolozin 2000" TYPE="JOURNAL_ARTICLE">
<AU>Wolozin B, Kelllman W, Ruosseau P, Celesia GG, Siegel G</AU>
<TI>Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors</TI>
<SO>Archives of Neurology</SO>
<YR>2000</YR>
<VL>57</VL>
<PG>1439-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wong-2013" MODIFIED="2015-12-15 13:31:03 +0000" MODIFIED_BY="Anne Lawson" NAME="Wong 2013" TYPE="JOURNAL_ARTICLE">
<AU>Wong WB, Lin VW, Boudreau D, Devine EB</AU>
<TI>Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding</TI>
<SO>Pharmacoepidemiology and Drug Safety</SO>
<YR>2013</YR>
<VL>22</VL>
<NO>4</NO>
<PG>345-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-World-Alzheimer-Report-2009" MODIFIED="2015-12-22 09:48:52 +0000" MODIFIED_BY="[Empty name]" NAME="World Alzheimer Report 2009" TYPE="CORRESPONDENCE">
<AU>Alzheimer&#8217;s Disease International</AU>
<SO>World Alzheimer Report 2009.London: Alzheimer&#8217;s Disease International</SO>
<YR>2009</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-World-Alzheimer-Report-2015" MODIFIED="2015-12-03 13:05:06 +0000" MODIFIED_BY="[Empty name]" NAME="World Alzheimer Report 2015" TYPE="CORRESPONDENCE">
<AU>Prince M, Wimo A, Guerchet M, Ali GC, Wu YT, Prina M</AU>
<SO>World Alzheimer Report</SO>
<YR>2015</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yoshitake-1995" MODIFIED="2015-12-15 14:41:41 +0000" MODIFIED_BY="Anne Lawson" NAME="Yoshitake 1995" TYPE="JOURNAL_ARTICLE">
<AU>Yoshitake T, Kiyohara Y, Kato I, Ohmura T, Iwamoto H, Nakayama K, et al</AU>
<TI>Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama study</TI>
<SO>Neurology</SO>
<YR>1995</YR>
<VL>45</VL>
<PG>1161-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zamrini-2004" MODIFIED="2015-12-15 13:32:05 +0000" MODIFIED_BY="Anne Lawson" NAME="Zamrini 2004" TYPE="JOURNAL_ARTICLE">
<AU>Zamrini E, McGwin G, Roseman JM</AU>
<TI>Association between statin use and Alzheimer's disease</TI>
<SO>Neuroepidemiology</SO>
<YR>2004</YR>
<VL>23</VL>
<PG>94-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zandi-2005" MODIFIED="2015-12-15 13:32:38 +0000" MODIFIED_BY="Anne Lawson" NAME="Zandi 2005" TYPE="JOURNAL_ARTICLE">
<AU>Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, Steinberg M, et al. and Cache County Study investigators</AU>
<TI>Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County Study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2005</YR>
<VL>62</VL>
<PG>217-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zuliani-2001" MODIFIED="2015-12-15 13:32:53 +0000" MODIFIED_BY="Anne Lawson" NAME="Zuliani 2001" TYPE="JOURNAL_ARTICLE">
<AU>Zuliani G, Ble A, Zanca R, Munari MR, Zurlo A, Vavalle C, et al</AU>
<TI>Lipoprotein profile in older patients with vascular dementia and Alzheimer's disease</TI>
<SO>BMC Geriatrics</SO>
<YR>2001</YR>
<VL>1</VL>
<PG>5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2015-12-15 14:57:59 +0000" MODIFIED_BY="Anne Lawson">
<REFERENCE ID="REF-McGuinness-2009" MODIFIED="2015-12-15 14:57:59 +0000" MODIFIED_BY="Anne Lawson" NAME="McGuinness 2009" TYPE="COCHRANE_REVIEW">
<AU>McGuinness B, Craig D, Bullock R, Passmore P</AU>
<TI>Statins for the prevention of dementia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2015-12-15 14:57:59 +0000" MODIFIED_BY="Anne Lawson">
<IDENTIFIER MODIFIED="2015-12-15 14:57:59 +0000" MODIFIED_BY="Anne Lawson" TYPE="DOI" VALUE="10.1002/14651858.CD003160.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Scott-2001" NAME="Scott 2001" TYPE="COCHRANE_REVIEW">
<AU>Scott HD, Laake K</AU>
<TI>Statins for the prevention of Alzheimer's disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2008-12-11 16:50:49 +0000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2015-12-22 10:28:28 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2015-12-22 10:28:28 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2015-12-14 21:15:23 +0000" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-HPS-2002">
<CHAR_METHODS MODIFIED="2015-12-14 21:09:22 +0000" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-14 21:15:23 +0000" MODIFIED_BY="Anne Lawson">
<P>20,536 participants (10,269 in intervention group, 10,267 in control group) with coronary heart disease, other occlusive arterial disease, diabetes or hypertension</P>
<P>Aged 40-80 years, 5806 participants &gt; 70 years of age</P>
<P>Baseline total cholesterol at least 3.5 mmol/L, mean total cholesterol 5.9 mmol/L, LDL cholesterol 3.4 mmol/L</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-14 21:10:59 +0000" MODIFIED_BY="Anne Lawson">
<P>Intervention: simvastatin 40 mg</P>
<P>Control: matching placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-14 21:11:47 +0000" MODIFIED_BY="Anne Lawson">
<P>Those analysed in review: Telephone Interview for Cognitive Status (TICS-m) score (mean); presence of cognitive impairment overall, presence of cognitive impairment with respect to age or previous history of cerebrovascular disease; incidence of dementia; adverse events; cholesterol level</P>
<P>Those not analysed in review: all-cause mortality, major vascular event (first major coronary event, stroke, revascularisation), first stroke, first ever vascular event</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2015-12-15 13:41:03 +0000" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-PROSPER">
<CHAR_METHODS MODIFIED="2015-12-14 21:13:19 +0000" MODIFIED_BY="Anne Lawson">
<P>Randomised controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-14 21:15:27 +0000" MODIFIED_BY="Anne Lawson">
<P>5804 participants (2804 men and 3000 women; 2891 in intervention group, 2913 in placebo group) with history of, or risk factors for, vascular disease</P>
<P>Aged 70-82 years</P>
<P>Baseline cholesterol 4.0-9.0 mmol/L, mean total cholesterol 5.7 mmol/L, LDL cholesterol 3.8 mmol/L</P>
<P>Mean follow-up 3.2 years (range 2.8-4.0 years)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-14 21:15:40 +0000" MODIFIED_BY="Anne Lawson">
<P>Intervention: pravastatin 40 mg</P>
<P>Control: placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-15 13:41:03 +0000" MODIFIED_BY="Anne Lawson">
<P>Those analysed in review: difference between the last 'on-treatment' and the second baseline value in MMSE score, correct letter digit codes, number of words remembered in Picture-Word Learning Test, time needed to complete Stroop test; difference between the last 'on-treatment' and second baseline value in Barthel Index and instrumental ADL score; serious adverse events; serum lipid concentrations</P>
<P>Those not analysed in review: coronary heart disease death or non-fatal myocardial infarction, or fatal or non-fatal stroke; transient ischaemic attack; coronary angioplasty and coronary artery bypass graft; peripheral arterial surgery/angioplasty; heart failure hospitalisation; deaths due to coronary heart disease, stroke, vascular and non-vascular causes, cancer, trauma or suicide; all-cause mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ADL: activities of daily living; LDL: low-density lipoprotein; MMSE: Mini Mental State Examination.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2015-12-14 21:22:44 +0000" MODIFIED_BY="Anne Lawson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2015-12-14 21:21:59 +0000" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Muldoon-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-14 21:21:59 +0000" MODIFIED_BY="Anne Lawson">
<P>Participants not of sufficient age to be at risk of dementia (aged 24-60 years, mean age 46 years); participants only followed for 6 months so insufficient follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-14 21:22:11 +0000" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Muldoon-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-14 21:22:11 +0000" MODIFIED_BY="Anne Lawson">
<P>Participants not of sufficient age to be of risk of dementia (aged 35-70 years, mean 54 years); participants only followed for 6 months so insufficient follow-up</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-14 21:22:28 +0000" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Santanello-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-14 21:22:28 +0000" MODIFIED_BY="Anne Lawson">
<P>Pilot study and funding ended before all participants could complete their 12-month visit. Data provided for 6-month follow-up only so of insufficient duration</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-14 21:22:31 +0000" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Sparks-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-14 21:22:31 +0000" MODIFIED_BY="Anne Lawson">
<P>Use of statin not randomly assigned</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-14 21:22:34 +0000" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Summers-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-14 21:22:34 +0000" MODIFIED_BY="Anne Lawson">
<P>Cognitive follow-up only 12 weeks so of insufficient duration for inclusion</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2015-12-14 21:22:44 +0000" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Tendolkar-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2015-12-14 21:22:44 +0000" MODIFIED_BY="Anne Lawson">
<P>Exploratory hypothesis-generating trial. All participants in treatment group received statin and ezetimibe so not possible to ascertain what treatment effect due to</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-12-10 11:06:50 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2015-12-15 14:47:04 +0000" MODIFIED_BY="Anne Lawson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2015-12-15 14:47:04 +0000" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-ESH_x002d_CHL_x002d_SHOT-2014">
<CHAR_STUDY_NAME MODIFIED="2015-03-05 15:29:29 +0000" MODIFIED_BY="[Empty name]">
<P>ESH-CHL-SHOT</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-12-15 14:47:04 +0000" MODIFIED_BY="Anne Lawson">
<P>Prospective multinational randomised trial with a 3 x 2 factorial design comparing 3 different systolic BP targets and 2 different LDL cholesterol targets</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-14 21:23:26 +0000" MODIFIED_BY="Anne Lawson">
<P>7500 participants (2500 in Europe and 5000 in China) at least 65 years old with hypertension and a stroke or transient ischaemic attack 1-6 months before randomisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-14 21:24:04 +0000" MODIFIED_BY="Anne Lawson">
<P>Antihypertensive and statin treatments modified using suitable registered agents chosen by the investigator in order to maintain participants within the randomised SBP and LDL cholesterol windows</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-14 21:24:11 +0000" MODIFIED_BY="Anne Lawson">
<P>Primary: time to stroke (fatal and non-fatal)</P>
<P>Secondary: time to first major cardiovascular event; cognitive decline and dementia</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-03-05 16:38:23 +0000" MODIFIED_BY="[Empty name]">
<P>2014</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-07-24 11:02:50 +0100" MODIFIED_BY="[Empty name]">
<P>alberto.zanchetti@auxologico.it</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2015-12-15 14:17:36 +0000" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-PODCAST-2013">
<CHAR_STUDY_NAME MODIFIED="2015-03-05 16:38:31 +0000" MODIFIED_BY="[Empty name]">
<P>PODCAST</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2015-03-05 16:39:45 +0000" MODIFIED_BY="[Empty name]">
<P>Multi-centre prospective randomised open-label blinded endpoint controlled partial-factorial phase IV trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2015-12-14 21:24:35 +0000" MODIFIED_BY="Anne Lawson">
<P>100 participants from 30 UK Stroke Research Network sites who were post ischaemic stroke by 3-7 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2015-12-15 14:17:36 +0000" MODIFIED_BY="Anne Lawson">
<P>Intensive vs. guideline BP lowering (target systolic &lt; 125 mmHg vs. &lt; 140 mmHg); intensive vs. guideline lipid lowering (target LDL cholesterol &lt; 1.4 mmol/L vs. &lt; 3 mmol/L)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2015-12-14 21:26:02 +0000" MODIFIED_BY="Anne Lawson">
<P>Primary: cognitive decline as measured by the Addenbrooke's Cognitive Examination - Revised</P>
<P>Secondary: feasibility of recruitment and retention of participants, tolerability and safety of the interventions, achieving and maintaining the BP and lipid targets, maintaining differences in SBP (&gt; 10 mmHg) and LDL cholesterol (&gt; 1 mmol/L) between the treatment groups, and performing clinic and telephone follow-up of cognition measures</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2015-03-05 16:48:04 +0000" MODIFIED_BY="[Empty name]">
<P>2013</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2015-07-24 11:03:48 +0100" MODIFIED_BY="[Empty name]">
<P>philip.bath@nottingham.ac.uk</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES>
<P>BP: blood pressure; LDL: low-density lipoprotein; SBP: systolic blood pressure.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2015-12-22 10:28:28 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2015-12-14 21:18:06 +0000" MODIFIED_BY="Anne Lawson" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-14 21:12:00 +0000" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-HPS-2002">
<DESCRIPTION>
<P>Central randomisation system using a minimisation algorithm. Comment: probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-14 21:18:06 +0000" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-PROSPER">
<DESCRIPTION>
<P>Computerised pseudo-random number generator, balanced blocks of size 4. Comment: probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2015-12-14 21:18:10 +0000" MODIFIED_BY="Anne Lawson" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-14 21:12:04 +0000" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-HPS-2002">
<DESCRIPTION>
<P>Central telephone allocation. Comment: probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-14 21:18:10 +0000" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-PROSPER">
<DESCRIPTION>
<P>Telephone call or fax exchange with the study data centre. Comment: probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2015-10-15 09:45:28 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2015-12-15 14:27:18 +0000" MODIFIED_BY="Anne Lawson" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-14 21:12:13 +0000" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-HPS-2002">
<DESCRIPTION>
<P>Blinding of participants and key study personnel ensured and unlikely that the blinding could have been broken except in a medical emergency. Comment: probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2015-12-15 14:27:18 +0000" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-PROSPER">
<DESCRIPTION>
<P>All study personnel remained unaware of the allocated study medication status of the participants throughout the study. Only 2 requests for emergency unblinding were implemented - emergency unblinding was available via an interactive voice response telephone system</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2015-12-14 21:18:49 +0000" MODIFIED_BY="Anne Lawson" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-14 21:12:33 +0000" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-HPS-2002">
<DESCRIPTION>
<P>"The Steering Committee, the collaborators, the funding agencies, and the coordinating centre staff (except those supplying the confidential analyses) remained unaware of the results on mortality and morbidity until completion of the scheduled treatment period." Comment: probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2015-12-14 21:18:49 +0000" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-PROSPER">
<DESCRIPTION>
<P>All study personnel, including the endpoint adjudication committee, remained unaware of the allocated study medication status of the participants throughout the study. Comment: probably done</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2015-12-22 10:28:28 +0000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-14 21:12:50 +0000" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-HPS-2002">
<DESCRIPTION>
<P>Small numbers in both groups lost to follow-up. 37 in simvastatin group lost to follow-up: 3 due to death, 34 due to morbidity; 30 in placebo group lost to follow-up: 4 due to death, 26 due to morbidity</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2015-12-22 10:28:28 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-PROSPER">
<DESCRIPTION>
<P>Similar numbers in both groups discontinued with similar reasons, approximately 25% in each group over the 3.2-year follow-up. 725 discontinued in placebo group: 116 due to a non-fatal adverse event, 240 died, 311 refused to participate or did not attend, 58 other reasons. In addition 7 withdrew consent. 724 discontinued in the pravastatin group: 107 due to non-fatal adverse events, 219 died, 346 refused to participate or did not attend, 52 other reasons. In addition 5 withdrew consent</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2015-12-14 21:20:41 +0000" MODIFIED_BY="Anne Lawson" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-14 21:13:03 +0000" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-HPS-2002">
<DESCRIPTION>
<P>Study protocol was available and all of the study's pre-specified outcomes were reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2015-12-14 21:20:41 +0000" MODIFIED_BY="Anne Lawson" RESULT="YES" STUDY_ID="STD-PROSPER">
<DESCRIPTION>
<P>Study protocol was available and all of the study's pre-specified outcomes (primary, secondary and tertiary) were reported in the pre-specified way</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2015-12-15 14:05:03 +0000" MODIFIED_BY="Anne Lawson">
<SOF_TABLE ID="SOF-01" MODIFIED="2015-12-15 14:05:03 +0000" MODIFIED_BY="Anne Lawson" NO="1">
<TITLE MODIFIED="2015-12-14 21:26:17 +0000" MODIFIED_BY="Anne Lawson">Statins compared with placebo for prevention of dementia</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Statins compared with placebo for prevention of dementia</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> older people with normal cognition<SUP>a</SUP>
</P>
<P>
<B>Setting:</B> community</P>
<P>
<B>Intervention:</B> any statin</P>
<P>
<B>Comparison:</B> placebo</P>
</TD>
</TR>
<TR>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Placebo</P>
</TH>
<TH VALIGN="TOP">
<P>Statin</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Incidence of dementia</B>
</P>
<P>Range of scale yes/no</P>
<P>Follow-up 5 years</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Number developing dementia 31/10,267 (0.3%)</P>
</TD>
<TD VALIGN="TOP">
<P>Number developing dementia 31/10,269 (0.3%)</P>
</TD>
<TD VALIGN="TOP">
<P>OR 1.0 (0.61 to 1.65)</P>
</TD>
<TD VALIGN="TOP">
<P>20,536 participants (1 study)</P>
<P>
<LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> only</P>
</TD>
<TD VALIGN="TOP">
<P>Moderate<SUP>b</SUP>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Mini Mental State Examination Score</B>
</P>
<P>Score out of 30 (higher score better)</P>
<P>Measures global cognitive function</P>
<P>Follow-up 42 months</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.06 (-0.04 to 0.16)</P>
</TD>
<TD VALIGN="TOP">
<P>5804 participants</P>
<P>(1 study)</P>
<P>
<LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> only</P>
</TD>
<TD VALIGN="TOP">
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>2 points of difference may be considered clinically relevant (<LINK REF="REF-Lopez-2005" TYPE="REFERENCE">Lopez 2005</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Stroop Colour Word Test</B>
</P>
<P>Total number of seconds required to complete the third Stroop card containing 40 items Measures attention</P>
<P>Follow-up 42 months</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.8 (-0.4 to 2.0)</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>5804 participants</P>
<P>(1 study)</P>
<P>
<LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> only</P>
</TD>
<TD VALIGN="TOP">
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Picture-Word Learning Test</B>
</P>
<P>15 Picture Learning Test</P>
<P>Measures immediate and delayed recall</P>
<P>Follow-up 42 months</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.02 (-0.12 to 0.16)</P>
</TD>
<TD VALIGN="TOP">
<P>5804 participants</P>
<P>(1 study)</P>
<P>
<LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> only</P>
</TD>
<TD VALIGN="TOP">
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Letter Digit Coding Test</B>
</P>
<P>Total number of correct entries completed in 60 seconds</P>
<P>Measures processing speed</P>
<P>Follow-up 42 months</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>MD -0.01 (-0.24 to 0.23)</P>
</TD>
<TD VALIGN="TOP">
<P>5804 participants</P>
<P>(1 study)</P>
<P>
<LINK REF="STD-PROSPER" TYPE="STUDY">PROSPER</LINK> only</P>
</TD>
<TD VALIGN="TOP">
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Mean Modified Telephone Interview for Cognitive Status Score</B>
</P>
<P>Score out of 39</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
<TD VALIGN="TOP">
<P>MD 0.02 (-0.12 to 0.16)</P>
</TD>
<TD VALIGN="TOP">
<P>20,536</P>
<P>(1 study)</P>
<P>
<LINK REF="STD-HPS-2002" TYPE="STUDY">HPS 2002</LINK> only</P>
</TD>
<TD VALIGN="TOP">
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>Score &#8804; 35 clinically relevant (<LINK REF="REF-Abner-2015" TYPE="REFERENCE">Abner 2015</LINK>)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Adverse events leading to discontinuation of therapy</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>641/13,180 (4.8%)</P>
</TD>
<TD VALIGN="TOP">
<P>600/13,160 (4.5%)</P>
</TD>
<TD VALIGN="TOP">
<P>OR 0.94 (0.83 to 1.05)</P>
</TD>
<TD VALIGN="TOP">
<P>26,340 participants</P>
<P>(2 studies)</P>
</TD>
<TD VALIGN="TOP">
<P>High</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>MD:</B> mean difference; <B>OR: </B>odds ratio; <B>RR:</B> risk ratio</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
<P>If evidence was downgraded it was because of imprecision.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>a All participants had a history of, or risk factors for, vascular disease.</P>
<P>b Downgraded due to imprecision.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2015-12-15 13:41:31 +0000" MODIFIED_BY="Anne Lawson">
<COMPARISON ID="CMP-001" MODIFIED="2015-10-06 15:12:29 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Incidence of dementia</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.646067622815657" CI_START="0.6072711248297088" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9998046493455753" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="31" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.21644767268210655" LOG_CI_START="-0.21661736868026404" LOG_EFFECT_SIZE="-8.484799907875031E-5" METHOD="MH" MODIFIED="2015-10-06 15:12:29 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.9993872171765881" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10269" TOTAL_2="10267" WEIGHT="100.0" Z="7.680094511045342E-4">
<NAME>Number of cases of dementia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.646067622815657" CI_START="0.6072711248297088" EFFECT_SIZE="0.9998046493455753" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="31" LOG_CI_END="0.21644767268210655" LOG_CI_START="-0.21661736868026404" LOG_EFFECT_SIZE="-8.484799907875031E-5" MODIFIED="2008-07-22 14:14:03 +0100" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.25438454900278445" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.06471149877135005" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2015-12-15 13:41:31 +0000" MODIFIED_BY="Anne Lawson" NO="2">
<NAME>Cognitive change from baseline</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.1579981992270027" CI_START="-0.03799819922700272" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.06" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="-0.8013478628571764" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-1.2218487496163564" MODIFIED="2015-12-15 13:33:26 +0000" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.23013936226878062" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2891" TOTAL_2="2913" WEIGHT="100.00000000000001" Z="1.2">
<NAME>Change in Mini Mental State Examination</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.1579981992270027" CI_START="-0.03799819922700272" EFFECT_SIZE="0.06" ESTIMABLE="YES" ESTIMATE="0.06" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-22 14:20:25 +0100" MODIFIED_BY="[Empty name]" ORDER="14" SE="0.05" STUDY_ID="STD-PROSPER" TOTAL_1="2891" TOTAL_2="2913" WEIGHT="100.00000000000001"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="1.9759783907240325" CI_START="-0.3759783907240324" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.8" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.29578219083833684" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2015-12-14 19:25:13 +0000" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.1824224394582603" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2891" TOTAL_2="2913" WEIGHT="100.0" Z="1.3333333333333335">
<NAME>Stroop test (seconds)</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours statin</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="1.9759783907240325" CI_START="-0.3759783907240324" EFFECT_SIZE="0.8" ESTIMABLE="YES" ESTIMATE="0.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-22 14:21:56 +0100" MODIFIED_BY="[Empty name]" ORDER="15" SE="0.6" STUDY_ID="STD-PROSPER" TOTAL_1="2891" TOTAL_2="2913" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.4565432964122904E-33" CI_END="0.15719747891780383" CI_START="-0.11719747891780381" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.020000000000000004" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="-0.8035544233148421" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-1.6989700043360187" MODIFIED="2015-12-15 13:41:31 +0000" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.7750969625511079" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2891" TOTAL_2="2913" WEIGHT="100.0" Z="0.28571428571428575">
<NAME>Picture-Word Learning Task</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.1571974789178038" CI_START="-0.11719747891780381" EFFECT_SIZE="0.02" ESTIMABLE="YES" ESTIMATE="0.02" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-22 14:23:49 +0100" MODIFIED_BY="[Empty name]" ORDER="16" SE="0.07" STUDY_ID="STD-PROSPER" TOTAL_1="2891" TOTAL_2="2913" WEIGHT="100.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.22519567814480648" CI_START="-0.2451956781448065" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="-0.01" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.6474399485270541" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2008-07-22 14:25:03 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.9335864962975284" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2891" TOTAL_2="2913" WEIGHT="100.0" Z="0.08333333333333334">
<NAME>Letter Digit</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.22519567814480648" CI_START="-0.2451956781448065" EFFECT_SIZE="-0.01" ESTIMABLE="YES" ESTIMATE="-0.01" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-07-22 14:25:03 +0100" MODIFIED_BY="[Empty name]" ORDER="17" SE="0.12" STUDY_ID="STD-PROSPER" TOTAL_1="2891" TOTAL_2="2913" WEIGHT="100.0"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2015-12-15 13:35:01 +0000" MODIFIED_BY="Anne Lawson" NO="3">
<NAME>Modified Telephone Interview for Cognitive Status (TICS-m) at final visit</NAME>
<IV_OUTCOME CHI2="2.4565432964122904E-33" CI_END="0.15719747891780383" CI_START="-0.11719747891780381" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.020000000000000004" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="-0.8035544233148421" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="-1.6989700043360187" MODIFIED="2008-10-08 14:37:24 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="1.0" P_Z="0.7750969625511079" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="10269" TOTAL_2="10267" WEIGHT="100.0" Z="0.28571428571428575">
<NAME>Mean TICS-m Score</NAME>
<GROUP_LABEL_1>Simvastatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.1571974789178038" CI_START="-0.11719747891780381" EFFECT_SIZE="0.02" ESTIMABLE="YES" ESTIMATE="0.02" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2008-10-08 14:37:24 +0100" MODIFIED_BY="[Empty name]" ORDER="7" SE="0.07" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" WEIGHT="100.0"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="4.9187389629182666E-30" CI_END="1.049948644781922" CI_START="0.8523558172234067" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9460073124271838" ESTIMABLE="YES" EVENTS_1="834" EVENTS_2="879" I2="100.00000000000001" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.021168057323966715" LOG_CI_START="-0.06937907049395133" LOG_EFFECT_SIZE="-0.024105506584992314" METHOD="MH" MODIFIED="2015-12-15 13:34:49 +0000" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.2966865239916411" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="4903" TOTAL_2="4936" WEIGHT="99.99999999999999" Z="1.0435653979148902">
<NAME>Aged &lt; 65 years at study entry</NAME>
<GROUP_LABEL_1>Simvastatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [statin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0499486447819222" CI_START="0.8523558172234067" EFFECT_SIZE="0.9460073124271839" ESTIMABLE="YES" EVENTS_1="834" EVENTS_2="879" LOG_CI_END="0.021168057323966805" LOG_CI_START="-0.06937907049395133" LOG_EFFECT_SIZE="-0.024105506584992265" MODIFIED="2015-09-16 16:10:02 +0100" MODIFIED_BY="[Empty name]" ORDER="11" O_E="0.0" SE="0.05318783109575651" STUDY_ID="STD-HPS-2002" TOTAL_1="4903" TOTAL_2="4936" VAR="0.0028289453766707235" WEIGHT="99.99999999999999"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1598146461170928" CI_START="0.8970746376787209" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0200197563968871" ESTIMABLE="YES" EVENTS_1="631" EVENTS_2="621" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.06438858870920733" LOG_CI_START="-0.047171421634279176" LOG_EFFECT_SIZE="0.008608583537464083" METHOD="MH" MODIFIED="2015-12-15 13:34:43 +0000" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.762283749399846" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2447" TOTAL_2="2444" WEIGHT="100.0" Z="0.3024831862131344">
<NAME>Aged 65-69 years at study entry</NAME>
<GROUP_LABEL_1>Simvastatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [statin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1598146461170928" CI_START="0.8970746376787209" EFFECT_SIZE="1.0200197563968871" ESTIMABLE="YES" EVENTS_1="631" EVENTS_2="621" LOG_CI_END="0.06438858870920733" LOG_CI_START="-0.047171421634279176" LOG_EFFECT_SIZE="0.008608583537464083" MODIFIED="2015-09-16 16:15:03 +0100" MODIFIED_BY="[Empty name]" ORDER="12" O_E="0.0" SE="0.06553090230672146" STUDY_ID="STD-HPS-2002" TOTAL_1="2447" TOTAL_2="2444" VAR="0.004294299157133071" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0385270266053852" CI_START="0.83745168072861" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9325857622292791" ESTIMABLE="YES" EVENTS_1="1010" EVENTS_2="1045" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.016417803088598658" LOG_CI_START="-0.07704024148313235" LOG_EFFECT_SIZE="-0.030311219197266877" METHOD="MH" MODIFIED="2015-12-15 13:35:01 +0000" MODIFIED_BY="Anne Lawson" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.2036045261447077" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2919" TOTAL_2="2887" WEIGHT="100.0" Z="1.271349047080578">
<NAME>Aged 70-80 years at study entry</NAME>
<GROUP_LABEL_1>Simvastatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [statin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0385270266053852" CI_START="0.83745168072861" EFFECT_SIZE="0.9325857622292791" ESTIMABLE="YES" EVENTS_1="1010" EVENTS_2="1045" LOG_CI_END="0.016417803088598658" LOG_CI_START="-0.07704024148313235" LOG_EFFECT_SIZE="-0.030311219197266877" MODIFIED="2015-09-16 16:16:32 +0100" MODIFIED_BY="[Empty name]" ORDER="13" O_E="0.0" SE="0.05489771800621652" STUDY_ID="STD-HPS-2002" TOTAL_1="2919" TOTAL_2="2887" VAR="0.0030137594422900696" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.0366929774906903" CI_START="0.9119580753719647" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9723273792833571" ESTIMABLE="YES" EVENTS_1="2433" EVENTS_2="2485" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.015650156655102616" LOG_CI_START="-0.04002512664211755" LOG_EFFECT_SIZE="-0.01218748499350749" METHOD="MH" MODIFIED="2015-10-06 15:15:25 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.39084615480151064" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10269" TOTAL_2="10267" WEIGHT="100.0" Z="0.8580838833590531">
<NAME>Cognitive impairment</NAME>
<GROUP_LABEL_1>Simvastatin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [statin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0366929774906903" CI_START="0.9119580753719647" EFFECT_SIZE="0.9723273792833571" ESTIMABLE="YES" EVENTS_1="2433" EVENTS_2="2485" LOG_CI_END="0.015650156655102616" LOG_CI_START="-0.04002512664211755" LOG_EFFECT_SIZE="-0.01218748499350749" MODIFIED="2015-09-17 14:12:10 +0100" MODIFIED_BY="[Empty name]" ORDER="14" O_E="0.0" SE="0.032703937005884226" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.0010695474956848436" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2015-10-06 15:11:53 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incidence and severity of adverse effects</NAME>
<DICH_OUTCOME CHI2="0.006037285657426622" CI_END="1.0487767140395263" CI_START="0.834757959670879" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.9356680554352402" ESTIMABLE="YES" EVENTS_1="600" EVENTS_2="640" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.020683036160662843" LOG_CI_START="-0.07843943112395471" LOG_EFFECT_SIZE="-0.028878197481645954" METHOD="MH" MODIFIED="2009-02-17 15:41:15 +0000" MODIFIED_BY="Helen Collins" NO="1" P_CHI2="0.9380667164665423" P_Q="1.0" P_Z="0.2534431512470112" Q="0.0" RANDOM="NO" SCALE="2.31384864037843" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13160" TOTAL_2="13180" WEIGHT="99.99999999999999" Z="1.1420261935155633">
<NAME>Adverse effects requiring discontinuation of treatment</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0637198399168304" CI_START="0.8265459921146089" EFFECT_SIZE="0.9376637832485851" ESTIMABLE="YES" EVENTS_1="493" EVENTS_2="524" LOG_CI_END="0.02682725953834667" LOG_CI_START="-0.08273297564866447" LOG_EFFECT_SIZE="-0.02795285805515887" MODIFIED="2008-10-20 14:33:15 +0100" MODIFIED_BY="[Empty name]" ORDER="7" O_E="0.0" SE="0.06435622448076114" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.00414172362941812" WEIGHT="81.76208628134383"/>
<DICH_DATA CI_END="1.2114257550766345" CI_START="0.7089265561753614" EFFECT_SIZE="0.9267210414189457" ESTIMABLE="YES" EVENTS_1="107" EVENTS_2="116" LOG_CI_END="0.08329680258530021" LOG_CI_START="-0.1493987548027124" LOG_EFFECT_SIZE="-0.03305097610870608" MODIFIED="2008-10-20 14:33:54 +0100" MODIFIED_BY="[Empty name]" ORDER="8" O_E="0.0" SE="0.13668652227130468" STUDY_ID="STD-PROSPER" TOTAL_1="2891" TOTAL_2="2913" VAR="0.018683205370623873" WEIGHT="18.237913718656156"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1343446326251387" CI_START="0.9222407773096953" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.0228093056524705" ESTIMABLE="YES" EVENTS_1="1608" EVENTS_2="1604" I2="0.0" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.0547450204375397" LOG_CI_START="-0.035155679157309654" LOG_EFFECT_SIZE="0.00979467064011505" METHOD="MH" MODIFIED="2015-10-06 15:10:45 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6693241993315155" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2891" TOTAL_2="2913" WEIGHT="100.0" Z="0.4270756908805464">
<NAME>Serious adverse event</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [statin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1343446326251387" CI_START="0.9222407773096953" EFFECT_SIZE="1.0228093056524705" ESTIMABLE="YES" EVENTS_1="1608" EVENTS_2="1604" LOG_CI_END="0.0547450204375397" LOG_CI_START="-0.035155679157309654" LOG_EFFECT_SIZE="0.00979467064011505" MODIFIED="2015-09-17 14:26:57 +0100" MODIFIED_BY="[Empty name]" ORDER="15" O_E="0.0" SE="0.05280811595765463" STUDY_ID="STD-PROSPER" TOTAL_1="2891" TOTAL_2="2913" VAR="0.0027886971109970975" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.8327891164408492" CI_START="0.703180532871907" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1352451838879158" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="32" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="0.2631124972399854" LOG_CI_START="-0.1529331609481307" LOG_EFFECT_SIZE="0.05508966814592736" METHOD="MH" MODIFIED="2015-10-06 15:09:36 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.6037274987250332" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2891" TOTAL_2="2913" WEIGHT="100.0" Z="0.5190476735486589">
<NAME>Myalgia incidence</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [statin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.8327891164408492" CI_START="0.703180532871907" EFFECT_SIZE="1.1352451838879158" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="32" LOG_CI_END="0.2631124972399854" LOG_CI_START="-0.1529331609481307" LOG_EFFECT_SIZE="0.05508966814592736" MODIFIED="2015-09-17 14:31:39 +0100" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.24438727907892194" STUDY_ID="STD-PROSPER" TOTAL_1="2891" TOTAL_2="2913" VAR="0.05972514217559887" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.975767733800803" CI_START="0.39820388002859775" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="0.8435920118316282" LOG_CI_START="-0.39989451259891545" LOG_EFFECT_SIZE="0.2218487496163564" METHOD="MH" MODIFIED="2015-10-06 15:11:53 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.48433392587937096" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="13160" TOTAL_2="13180" WEIGHT="100.0" Z="0.6993490491783608">
<NAME>Rhabdomyolysis</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [statin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.975767733800804" CI_START="0.39820388002859763" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.8435920118316284" LOG_CI_START="-0.3998945125989156" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2015-09-17 14:38:51 +0100" MODIFIED_BY="[Empty name]" ORDER="17" O_E="0.0" SE="0.7304301398080698" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="0.5335281891400364" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2015-09-17 14:39:24 +0100" MODIFIED_BY="[Empty name]" ORDER="18" O_E="0.0" SE="0.0" STUDY_ID="STD-PROSPER" TOTAL_1="2891" TOTAL_2="2913" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="42.8129238063147" CI_START="0.5841634141293096" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="5.000974279033515" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="1.6315748879508454" LOG_CI_START="-0.23346564616306398" LOG_EFFECT_SIZE="0.6990546208938906" METHOD="MH" MODIFIED="2015-10-06 15:11:22 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.14176020212964402" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="10269" TOTAL_2="10267" WEIGHT="100.0" Z="1.4692676701842078">
<NAME>Myopathy incidence</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [statin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<DICH_DATA CI_END="42.8129238063147" CI_START="0.5841634141293096" EFFECT_SIZE="5.000974279033515" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6315748879508454" LOG_CI_START="-0.23346564616306398" LOG_EFFECT_SIZE="0.6990546208938906" MODIFIED="2015-09-17 14:52:05 +0100" MODIFIED_BY="[Empty name]" ORDER="19" O_E="0.0" SE="1.0955340418380475" STUDY_ID="STD-HPS-2002" TOTAL_1="10269" TOTAL_2="10267" VAR="1.200194836826009" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="2.152877682038895" CI_START="0.8952717696704953" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3883121451183358" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.33301935563648855" LOG_CI_START="-0.04804510976557685" LOG_EFFECT_SIZE="0.14248712293545585" METHOD="MH" MODIFIED="2015-10-06 15:10:12 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.14272068521332748" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2891" TOTAL_2="2913" WEIGHT="100.0" Z="1.4657343025651268">
<NAME>Elevated liver enzymes causing discontinuation of treatment</NAME>
<GROUP_LABEL_1>Statin</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours [statin]</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours [placebo]</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.152877682038895" CI_START="0.8952717696704953" EFFECT_SIZE="1.3883121451183358" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="35" LOG_CI_END="0.33301935563648855" LOG_CI_START="-0.04804510976557685" LOG_EFFECT_SIZE="0.14248712293545585" MODIFIED="2015-09-17 17:13:54 +0100" MODIFIED_BY="[Empty name]" ORDER="20" O_E="0.0" SE="0.22383915327669876" STUDY_ID="STD-PROSPER" TOTAL_1="2891" TOTAL_2="2913" VAR="0.050103966539629445" WEIGHT="100.0"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2015-12-22 10:28:29 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2015-12-15 13:36:33 +0000" MODIFIED_BY="Anne Lawson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAODCAYAAACWl4ftAABfI0lEQVR42u2dD4RVzf/HfyRJkmXl
sZJHJEmSSLKSRLLy+EokSb6+IslKsjySZCWSJEkkSZJIkiSxkqxkSZKVRFaSrEiSJPPb93y/c5+5
s+fMnHPv3d375/XiqnvPvzlnPvN5nzlzdt7/Zzz+7//+j08HfZoN6oT4g9bk//xGDB1W+U1U58Qf
8QctLiRUKI2ZhALUPdRRj1QkQfB/HXlsIP4AIQGEBIg/QEgAISH+iD9iACEBGjJJBIgBhARoyCQR
IAYAIQGEBIg/QEgAIWkFXr16RdAgJFBUSAYGBsz8+fPN3LlzzY4dO8ynT58y17t161ZmMNy4ccP8
+eefZs6cOWbt2rXm5cuXBDnnWOjY379/N/v37zfz5s2z8aP4+/Lly7Set7/c/7/KM1PXrx3jESFp
YyE5ffq0OX/+vPn9+7f9DA4Omo0bN05ab2xszP4e7uf58+dm3bp15v3793b769evm+XLlxPknGOh
Y/f395sLFy5U4k83NRKTmRISenCcE9QgJEuWLLF3hT6zZ8+etN6WLVvMmzdvJgXDrl27rBiVCaZn
z56ZhQsXmjVr1lR+P3HihFmwYIG9Mz106FDVNj9//jR79uyxPaZly5aZ4eHhST0qbaflErsPHz5E
j6eEdeDAAdsL6+npsT0q/7zu379vr8GsWbPMypUrzePHj2nIU3Tsrq4uWx+OX79+TeoJ+Lx7985s
27bN1rXqSPFw586dyvJU3aaWu/9nzRcVnkMq7q5cuWIWL15s40hlffDgQeHzQEigpYTE5+vXrzah
Sxx81EtRryUrGNRQyjxL1vYHDx60Dfrjx4/2t4sXL9pGp9+USNS4T506Vdnm2LFj9rGauHfvXlWP
58yZM1U9Ku1LohM73tmzZ83Jkyftb58/fza9vb1V5+U3+ocPH1qxpSFPz7F10yDRz2PVqlW21+vq
W3Xvr5+q29TyvP+H34vEnYTCiYviyb9BS50HQgItKSQ7d+60d1f6vHjxourR1ebNm3ODQY1DyVZ3
VG6MJfaMW9v7d25i9erVVXelrqfkkHCEyx0rVqywycdPRN3d3dHjqWfibzMyMlJ1XmrQTrhoyNN7
7GvXrtkbhzLojr9o3aaWFxWSWuIudQ3880BIoGV7JK67rsc54tu3b7bh+YPvWY1Lg6Xqzbg7s7BH
kwomiVH4KMFvVFmP2rIaX9b6ecfzUbn99SSM+i6BO378OA15mo49Pj5ub2jUK42hR5USG8WZEnrY
m4zVbWp5USGpJe7C32LngZBASwuJGrFrEHv37jW3b9+OBoOeNft3ZmqYsWfcWeXIapSxxJ9almqQ
qW1cI9djNI0NHTlyhIY8xcdW3O3evds+bopx9epV20O9fPmyefTokX1cGROK8Nhl4iUmJLXEnf9b
6jwQEmgpIdFjHL/x+l30ImY1W7dunXSHp0dcZYJJPSD1aPJYunRp7qMtbRs+YvCFLOt4esvM3+b1
69e5Qa5XmdulATSrkKgnol6t3vxLoRsXP1a0jb/vVN2mlhcVklrizv8tdR4ICbSUkOhRlh7fuEG/
v//+236KBoPGEvRx2587d87+LUmZYNLApRsA1Uff/VeQ1f3X4yYxNDQ0abBdx3Tb6lVSCU/seBrk
1AsEbsB106ZNVetp/3pzS4SDpDTkxh776dOnZsOGDbl/uxSilzvc200SAcWav+9U3aaW+//XDZHG
OZxghIPtZePO/y11HggJtJSQ6JGC3mrS3ZQG2iUsZYNBDUo9G+1Db6roNeGywXT06FF7l+b24d6w
Ej9+/LCD+EroepasAdJQDN2LAnpz5u3bt8nj6ZVl9bz0yrHGdfz19FhLx3GvbTpRoSE3/tiLFi0q
Zc/65MkT+yKG6kWCn/VHsrG6TS33/683BxWPrqeR9/pv0bjzf0udB0ICLSUk0FFBQBIBYgAQEkBI
gPgDhAQQEiD+ACEBGjJJBIgBhARoyCQRIAYAIQGEBIg/QEgAIQHiDxASoCGTRIAYQEimhWaxLu1U
C1WEpL1otTgmBtpYSGp1j6uFmHWpM5PSjLuNOG5s+5m0UJ3JRoeQTH15O7E9ISQIybRWfmxfoYPc
VB4rNhkfQoKQTGV527E9ISQISSkbUhGzxI3Zi8asS4vYmsaOW6TcfhmzjqX5wvJsUfPsgVNWq6mG
pHNSmWU3K4e8cK6lWJnaRUjazXq509oTQoKQTKrclA1pyhI3ZS8a6wnElqWOmyp3kR5JX19ftNyh
XW8Rq9XYcXU+8jlxZV6/fv2k6xErUzsJSTtZL3die0JIEJJSNqQpS9yUvWitgZ86bqrcRYQkVe5w
eRGr1dhx5YvhT52eZfla1qq1VYWknayXO7E9ISQISWmb0pglbip51hr4Za14w3IXEZIy5Rb1Wq2G
A6Uxy9d2F5Ks69iq1sud2J4QEoSklH1oyhJ3qgK/FiveqRaSeq1Wy3iHd5qQtLL1cie2J4QEISll
Q5qyxJ2qwE8dt4x1bqOEpKzVamilKkc83+L4xYsXCEnB+m5m6+VObE8ICUJSyoY0ZYmbCvyYdWks
8FPHTZU7JFaOokKSslr1B2jHxsbsoGlssF3ng5AUq+9mtl7uxPaEkCAkpW1KY5a4qcCPWZemegmx
4xYpt0/KQrWIkIiY1apLOHqMoESmRBTuR41V5dUrlipz6s65U4QkVd/NbL3cie0JIUFIoElQcpR/
+Uwk85kUEuioJMRFQEigkehuT4O37l1+3UXHBnEREkBIACGBKh49emTf19ejBf1l++HDh62gICSA
kABCAjRkkggQAwgJ0JBJIkAMAEICCAkQf4CQAEICxB8gJEBDJokAMYCQxOlU21oacmOO3Ynxg9Uz
dISQlFk3nMWWYKIhlzl2J9oet8I5IyQwrUJSNjgIJoQk9nsnCEkrnDNCAqWEJGWr+e7dOzsXjyaI
0zxDsja9c+dOJTBCS8/Y+m4bTTTnrFK3bt1aNVdSavuU7WnMQpQgaC4haWfb47zy1HLOqbjOuybE
H0ybkKRsNVetWmVnA3UzhaqRKWDzgqPI+s4dUMtv375t9u7dW3j7mO1pykKUIGiNHkmr2x6XLU9q
/0UsecNrQvzBtApJLbaaKRe31Pp+D0TBL+e5otvHbE9TFqIEQWsISavbHpctT2r/tVjyEn8wrUJS
xFZT3WZ5QOzatcs2ktQU62XXD8sQ2z5me5qyECUIWnOMpNVsj8uWp4ibZllLXuIPZlRIwgq/evWq
Nfa5fPmynWhQXedYIyu7ftiQU9s7ocmyPUU0OlNIms32uGx5UvuvxZKX+INpFZKUraYGIH1bztAy
NtxvkfVHR0eruv2+D0dqe5/Q9jRlIUoQtKeQNJvtcdnypPZfiyUv8QfTKiQpW029SeLempLIqNHF
7D5T6+v/mzdvNuPj4/aYGuj3B9tT28dsT1MWogRB8wlJO9oep8pT9pxrseQl/mBahUTEbDWfPHli
B/bUGJXENdAds/tMra//6xg6lraRqPgDhantU7anKQtRhKS5jt2utsex8pQ951RcIyTQFEICCAlJ
5B+mw/aY+AOEBGjIbZREZsL2mPgDhARoyG2URGbC9pj4A4QEaMgkESAGEBKgIZNEgBgAhAQQEiD+
ACEBhASIP0BIgIZMEgFiACGBemgV61SEBBASaHshSZVxKs+hzL6duZab/j5lN9ws1x4hAYQEOl5I
muXYWa59NGSSCBADHSsk9VjXFrHVDS1ANVGds9nV+sPDw1Xrp2xW/f9rsr2UPWmefWoqyPPOO/SF
yLJOje27SLk7SUhS8VePhW7Z+EvFe6qsgJB0rJDUY11bxFY3tACVYZVzONS0FJqY0V8/ZbPq/18i
lrduyj41FuRFrE3LNJAy5e40IYnFX70WumXjL1XvsbICQtLRQtJo69rQuS20AFXDDfcZWz9v5tfU
uin71FiQF7E2rUdIyti2truQxOKvXgvdsvGXqvdYWQEh6Wghqde6tl5b3VSgxYQktm7KPjW2bVlr
07JCMlMNrBmFJBZ/9Vrolo2/VL3HygoISUcLiRODWqxra7HVnS4hKeJFn7dtWWtThKS+Y+fFX70W
umXjr4hVc15ZASHpeCFxlLWuLWvDK2QsFHu01SghSdmnxrYta22KkDTm2FnxV4+Fbtn4K2PVHJYV
EJKOFpJ6rGuL2OqG6DGYHhGIoaGhSYPtjRKSlH1qbNuy1qahdSpCUvzYqfirx0K3bPyl6j1WVkBI
OlpI6rGuLWKrGyL3uR07dthtdFwNgk+FkIiYfWpq2zLWpqF1KkJS/Nip+KvHQrds/KXqPVVWQEh4
tNXmYJ/KHyQCQgIISSmwT0VIgPgDhKQusE9FSID4A4QEEBIg/gAhARoySQSIAYQEaMgkESAGACEB
hAQQEkBIACEB4g/aQ0ia3Va2VWxvERIg/qBjhKSsrex00+zloyGTRIAY6HghaXZb2Va1vUVIgPiD
thGSmF1uUVvZmD1plt1pXq+irN1qqnx//vmnGR8ft+u6mWGfP39uv8v0SstT1yB2DrHzpiGTRIAY
6BghKWKXGwuGIra0od1prFdRr92q/3337t3m9u3b9v83b960j720vfvu9lOLZXDqvGnIJBEgBjpG
SLIo4wZYxJY2tDsNaaTdqv9dxlv79++3///Pf/5jXRz1EXv37rXJv+g1CM+hFhtihAQQEmhbISlj
lxt+L2tLm0Uj7Vb976Ojo7a3IfTITGZEbgZgPb7S465arkGR86Yhk0SAGOgYISlrlxt+L2tLGxOz
Rtitht81YaOMrZyAyIxLJlz+lPK1WAY3u2ggJED8wbQJSVm73PB7WVvaFPXarYbft2/fbv79739X
Hmm5x1vuey3XoMh505BJJEDdd4yQlLXLDW1ly9rSZlGP3WqqfNpWYyraTly6dMmuo4HyWq9BkfOm
MZNQgDrvGCEpa5ebZStbxpY2i3rsVlPle/r0adVrv7JW1fc3b97UfA2KnDcNOl4OPp3zgQ4QEuDO
ELj+AAgJkMi4/gAICZDIuP4ACAmQyIDrDwgJkMiA6w+AkACJjOsPgJAAiYzrD4CQAIkMuP6AkHQS
nWDRSwxw/QGmTUimIuAbuc8if3VeltCitx0bPYmM6w+AkLRI+UhkwPWHjhISTTh44MABO2dUT0+P
NXsK1y1rKZvaZ1ZZwuWa2l2TLeqYcif88eNHskeiiRo1F5cmZZTfyPDwcGVZGUvhrDLm2f26dTUJ
pCZ/dPOF+T7yJDLg+kNbC8nZs2crs9jKt6O3t7cq4GuxlE3ts4iQyORKyVr7kJD19/cnhUTGVM5p
Ud4mmoDRUY+lcBG7X4mUE5dwBmMSGXD9oa2FZM2aNVV+H252XEctlrKpfRYREr838f379yojqrx9
STjCssYoailcxO43tOJtxqRBIuP6A0yJkIR3zkrE/rq1WMqm9llESEJByLPXDcsao1ZL4bJ2vwgJ
cP2ho4WkSBL118vyHShrj1tkeb1CUo+lcL3nQyIDrj+0tZCsW7eu6rGNHAJDq9uylrKpfYZlybK2
leWu48uXL3bgPpXE5ZyY92irHkvhsna/CAlw/aGjhEQD0IODg5WB8U2bNk0aaC5rKZvap/9W09jY
mB2oDpO6jqFttY+///7beq+nhESPrR4+fGj/PzQ0VDXYnrLTDS16w2tQxu4XIQGuP3SUkIjTp0/b
wWO94qs3ksJ1a7GUje3TvdWkx2ZKyLLWDcVBSf+PP/6wb1YdPnzY9kpSQqJXhHfs2GH3rTEQDfI7
Una6oUVv3uu/Rex+ERLg+kPHCQkNjkQGXH8AhAS4rlx/AITEEc57BSQyrj8AQgIkMq4/1x8QEiCR
AdcfEBIgkQHXHwAhARIZ1x8AIQESGdcfACFpBjrBHpdExvUH6EghiR1Lf8Wuvy7X9PT1Ni5eEyaR
cf0BOlBIGukeSMPkenH9AZpASGIWtC74YzayRax6/X3FLG31f3mGaH4tmWP5PRgdW7PwPn78OHdf
QCLj+gPMgJAUsaCN2cimbHVTjSkUEvmza19uYkhfuDSzr+/OSMMkkXH9AZpASLIILWhjNrIpW92y
QhIeS6LmfNhpmCQyrj9AkwpJGQva8LeUrW5ZIQlRL0S/a3D++PHjNEwSGdcfoNmEpKwFbUpIUg2m
rJA4obt3757ZsmWLOXLkCA2TRMb1B2gmISlrQRv+lrLVbYSQOGS/W2Z9IJFx/QGmQUhSFrQpIUnZ
6tYrJOot6c0tEQ70h/a4QCLj+gPMgJCkLGiL2MimrHrrERI91tK4jXv12ImKCO1xgUTG9QeYASEB
Ehlw/QEQEiCRcf0BEBIgkXH9ARASIJEB1x8QEiCRAdcfACEBEhnXHwAhARIZ1x8AIQESGXD9ASHp
dNrNypcY4PoDICTTTLv9xTwxwPUHQEho+JwP1x+g+YQkZbWbZ3WbWiZOnDhh59+aN2+eOXToUNWy
Wver89CU95rbq6ury9y8edOcOXPGzmKc5QcfK0PMRrgdrXxJZFx/gCkRkpTVbszqNrZMkzcqSWuf
v379sl7ummSx3v3qPPbu3Wv3effuXSsg+/bts9/D2YFTZUjZCNMjAa4/QAEhycK32o1Z3caWydFQ
CdzHF4Ra9xva8eq776fin2eqDCkbYYQEuP4ABYUkZrUbs7qNLdOdffh4yBeoWvcbm4Y+/J4qQ2qK
fIQEuP4ABYQkZbXrhCbL6ja2zE/YMQEru98yQpIqA0ICXH+ABghJymrXJ7S6jS3TILm/3xhl9ltG
SFJlQEiA6w/QACFJWe3GrG5jy/Qm1cmTJyuD+Pq+cePGuvdbRkhSZUgJSbtZ+ZLIuP4AUyIkKavd
mNVtbJk4evSo7fHoD/v0dpQem9W73zJCkipDSkjazcqXRMb1B5gSIQESGXD9ARASIJFx/QEQEiCR
cf0BEBIgkQHXHxASIJEB1x8AIQESGdcfACEBEhnXHwAhARIZcP0BIQESGXD9ARASIJFx/QEQEiCR
cf0BEBIgkXH9uf6AkACJDLj+gJAAiQy4/gAICZDIuP4ACAmQyLj+AK0XwwQySQyoA4C6hYRgJoEB
9QBQt5C4gObTOR9ASAAaLiQ0ZADiDwAhoSED8QeAkNCQgfgDQEhoyADEHyAkNGQA4g8AIaEhA/EH
gJDQkIH4A0BIaMgAxB8gJDRkAOIPACGhIQPxB4CQ0JCB+ANASGjIAMQfICQ0ZADiDwAhoSED8QeA
kNCQgfgDQEhoyED8cREAIaEhAxB/gJDQkAGIPwCEhIYMxB8AQkJDBuIPACFpzYbMh89MfgAQEuCO
GgAQEgCEBAAQEkBIAAAhAYQEABASQEgAACEBQEgAACEBhAQAEBJASAAAIQGEBAAQEgCEBAAQEkBI
AAAhgeYTEOaMAgBaPiAkAICQQHOICQAgJAAICQAgJICQAABCAggJACAk0GliAgAICQBCAgDtLyR4
e/Phgw88ICTc9QLQZgAhoUEAICYALSQkNAQA2hAgJDQCANoQICQ0AgCEBAAhAUBIABASAKANAUJC
IwCgDQFCQiPoPF69esVFQEgA2ktIvn//bvbv32/mzZtn5syZY3bs2GG+fPlSWf7p0yfzr3/9yy6b
O3euXf758+fCyzs9Sdy/f9/Mnj3brF692n7XdSIZU3aAthKS/v5+c+HCBfP792/7GRgYsGLg2LRp
k7l582Zluf6/efPmwss7PUlIRB48eEAyQkgA2ldIurq6rAA4fv36VXXXrESYlRyLLs8qx7Nnz8zC
hQvNmjVrKr+fOHHCLFiwwPaMDh06VLXNz58/zZ49e2yPZ9myZWZ4eLhqucRP22n5xo0bzYcPH6LH
0/keOHDAzJ8/3/T09JgbN25UXR/Xi5g1a5ZZuXKlefz4ce75vHv3zmzbts0eW9uofHfu3Kkcu8gc
TrFzz7te4TqXL1823d3dtj4l5mfOnLHnFwpZrLxuX1euXDGLFy+2519ECP3fiuwfIQFoMyEJUdJW
0gp7HI5bt26ZDRs2FF6eVY6DBw/aZP7x40f728WLF23y0m8SMiX2U6dOVbY5duyY3a+4d++eWb58
eWWZEub58+crPSLtS6ITO97Zs2fNyZMn7W96DNfb21t1ffzk+fDhQ7NkyZLc81m1apW5fv165fgq
i3/9wusefk+de1b5s67p3r177fZ37961ArJv3z77XefhC3uR8koInBiH26eEpOz1QEgA2lBIrl27
ZhO3Y3R01N7lurto/V+/FV2eVQ6/xyA0fuD3ioSfvCUc4XLHihUrrPj5Qqg789jxdGfvbzMyMlJ1
fZT4nHDVgu7kiwpJ6tyzyp+6pvr+9evXwnUfljc8nr99SkjKXg+EBKDNhGR8fNzs3LnT3sk6dHeq
u353h3n69Gmzffv2wsuLlEN3vOFjHz/5xB6V+etlrZ93PB+V219PvRB9V5I/fvx48rrp0ZPEd9eu
XVbYYok3/J469yL1ljpG+L1MeWsRkrL7R0gA2kRIJB67d++e9MaVxkv8O2b9X8+/iy4vUo4sMYgl
/tSyVOJKbeOSoR6jbdmyxRw5ciT3+FevXrU9Jo1RPHr0yD5+KiMkqXNvtJCULW9ZIall/wgJQBsI
iXoiegX4/fv3k5aFoiCh0KBw0eVFyqEBbf9RTMjSpUtzH21p2/DRlv+yQNbx1q1bV7XN69evc6/P
y5cvo9dO4xF+2XUNywhJ6twbLSRly5sSknD7WvaPkAC0uJA8ffrUDo7r70Gy0ECv7i7VY1Ey10C1
3ngqurxIOfRozA1+66PvevvKoccketwkhoaGJg22nzt3rrKtXmWW8MSOp8HgwcHBymC7Xhjw19P+
9eaWCAebQ/R2k3srSYK0du3aaOKU8GoMwglZ6twbLSRlyxv+5r+IMDY2Zh9t1rt/hASgxYVk0aJF
0VdTf/z4YcVCd/n6SCT0W9HlRctx9OhRezerfSg5+W8oaX/62xYlMT1z1+C4j3v9Vx+9sfX27dvk
8TSWo0F5vXarN6f89fRYS8dxr786UcniyZMndnBc60mANEgfS5x6I8tdqyLn3mghKVve8DcnrLo2
Emxdm3r3j5AAtMGjLQCgDQFCQiMAoA0BQkIjAKANAUJCIwBASAAQEgCgDQFCQiMAoA0BQkIjAKAN
AUJCIwBASAAQkk4BC1ygDQFC0sBGMBUNppH7nIq/lA4tcEkagJAAQtIhQkKSAIQEEJIZbgQp21kR
s4KtZZ9FZpjVdOSaC0vH1Fxe/vxdefuKWfKWscTNKmPKzjdmTwsICUBbC0nKdjZlBVvLPosIiUyl
lKy1DwlZf39/Ukhilrz1WOIWsfON2dMCQgLQ1kKSsp1NWcHWss8iQuL3Jr5//25nKU4JScySN4ui
lri12PmSdBASgI4RkpTtbMoKtpZ9FhGSUBDy7HPDssao1RK3Fjtfkg5CAtCxQlIkifrrZXmY1GJ/
W8YetxYhqccSt97zAYQEoK2FJGU7m7KCrWWfKbtW/V8Wt44vX77YgftUEo9Z8tZjiVuLnS9JByEB
6BghSdnOpqxga9lnyq5V/9cxtK328ffff5vt27cnhSRmyZuygA0tcMNrUNbOl6SDkAB0jJCImO2s
iFnB1rLPlF2r/q+k/8cff9g3qw4fPmx7JSkhiVnypixgQwvcvNd/i9r5knQQEoCOEhLKCkBcAkKC
kAAQl4CQ0Agc4bxXALQhQEhoBAAICQBCAoCQACAkAEAbAoSERgBAGwKEhEYAgJAAICQACAkAQgIA
tCFASGgEALQhQEhoBAAICQBCAoCQACAkAEAbAoSERgBAGwKEhEYAQBsChISGAICIALSpkNAgAGgz
gJA0rGHw4cOn2AcAIQHufAEAIQGEBAAQEgCEBAAQEkBIAAAhAYQEABASQEgAACEBQEgAACEBhAQA
EBJASAAAIQGEBAAQEgCEBAAQEkBIAAAhAYQEABASQEgAACEBhAQAEBIAhAQAEBJASAAAIQGEBAAQ
EkBIAAAhAUBIAAAhAYQEABASQEgAACEBhAQAEBIAhAQAEBJASAAAIQGEBAAQEkBIAAAhAUBIAAAh
AYQEABASQEgAACEBhAQAEBJASAAAIQGoSUDCDwAgJAAICQAgJDAzYgIACAkAQgIACAkgJACAkABC
AgAICXSamAAAQgKAkAAAQtIMCZVP53yAuCfuERLuyoE65xpAA+qcKKAxAXXPuUNddU8k0JiAGOCc
oa4YIBpoUEAMcM6AkNCggBjgnAEhoUEBMcA5A0LCxQRigHMGhARoUEAMcM6AkNCggBjgnAEhaYMG
9f37d7N//34zb948M2fOHLNjxw7z5cuXyvJPnz6Zf/3rX3bZ3Llz7fLPnz8XXk7C4RxbMe6/fv0a
/Wvp1PbEBELSUQ2qv7/fXLhwwfz+/dt+BgYGbKNwbNq0ydy8ebOyXP/fvHlz4eU0KM6xFeP+3r17
Vd/Lbk9MICQd1aC6urpsQ3D8+vXL3mE5Zs+ePWkb/7fU8qxyPHv2zCxcuNCsWbOm8vuJEyfMggUL
7B3eoUOHqrb5+fOn2bNnj+3xLFu2zAwPD1ctVyPWdlq+ceNG8+HDh+jxdL4HDhww8+fPNz09PebG
jRtV1+f+/fv2HGbNmmVWrlxpHj9+jJB0WNwPDg6ac+fO5e43tT1xj5B09N2oglfBF/Y4HLdu3TIb
NmwovDyrHAcPHrRB/fHjR/vbxYsXzZUrV+xvapAK8FOnTlW2OXbsmN2vu1Ncvnx5ZdmZM2fM+fPn
K3eG2pcaX+x4Z8+eNSdPnrS/6TFcb29v1fVRY3rw4IH9/8OHD82SJUsQkg6L++3bt9uetZK8Eq+S
dpntiXuEpKMb1LVr12wAO0ZHR+3dl3tGrP/rt6LLs8rh3zmJ1atXV93dCT+I1YDC5Y4VK1bYRuw3
6O7u7ujxdIfmbzMyMlJ1fZQQXAPm0VZnxv0ff/xhf3N38pcuXapantqeuEdIOrZBjY+Pm507d9q7
I8e2bdvs3Y+78zl9+rS9Wyu6vEg5dCcUDmqqe13kUZm/Xtb6ecfzUbn99XQ3pu9q6MePH0dIOjDu
QxQjEpdatyfuEZKOaFBqBLt37570xpWe+/p3Rfq/nskWXV6kHFmNItYAUsuqAqdAg8paT8+X9Thh
y5Yt5siRIwhJh8V90eRddHviHiFp+walOyq9yvj+/ftJy0JRkFBogK/o8iLl0MCeXrfMY+nSpbld
fG0bdvH9Qc+s461bt65qm9evX+den5cvX7ZNAkZIise9HhN9+/atKq404F10e+IeIemoBvX06VM7
OK6/B8lCA3aXL1+2d14Kag3Y6c2PosuLlEOPxtwgoD76rrdQHHr2rG63GBoamjToqLdr3LZ6JVMN
MHa869ev27dy3KCjXhjw19P+9QaL0OBj7M4QIWnPuD98+LB9o8rFlQbBFVtFtyfuEZKOalCLFi2K
/uHVjx8/rFjobkcfiYR+K7q8aDmOHj1q347RPjTu4t40ccfQO/oKbA0yapDQx70GqY/eXHn79m3y
eBrL0V2n3srRGy/+eure6zh69KBjusaFkHRW3O/bt8/Go14gUcIvsz1xj5B0XBcfiAHOGTohBogG
GhQQA5wzICQ0KCAGOGdASGhQQAxwzoCQcDGBGOCcASEBGhQQA5wzICQ0KCAGOGdASGhQQAzM+DnV
8vcbgJAASQSIgSohyfvDQOIeEBKSCOc9BdciL/m266dVYm2mt0dIgCDjvOmRzHCPBCFBSDo2icTs
NWNWn7VYh6aWa59yjFu8eHFlvh/n2FZk+5SVKDHAGEmRWJK3iCZJ9NvI1q1bC7WJ2HH934rEKrGO
kLRMEonZa8asPmuxDk0t1z41cZ1zdgtnIE1tn7ISJQZ4a6tILCme165da5dp4kS1Cef6mWoTRYUk
FavEOkLSUg0qZq8Zs/qsxTo0tTxrn365U9unrESJAYSkaCwpkStZK3n39/cXbhNFhSQVq8Q6QtJS
DSpmrxnzI6jVOjS2PNX4ylqThlaixABCUjSWXDLXlOsysCrbJorEcixWiXWEpOWSSJ69ZlkhSVmH
ppanGl8t1qQ0LoSkllgUfX19tgcyHUJCrCMkbZNEQnvNmNVnLdahqeWpxpfavoyVKDHQ2eeciiU5
DmqMQu6f/qOtom0iPK7seP3fUrFKrCMkLdWgYvaaMavPWqxDU8tTQpLaPmUlSgwgJEViSYPt69ev
r0rqb968KdUm/JdYxsbG7Esk/vJUrBLrCElLNaiYvWbM6rMW69DU8pSQFNl/zEqUGEBIisSSYt5/
/Vf/1/IybcLdlKldqRejdhWWJRWrxDpCQhIBYoBzBoSEBgXEAOcMCAnQoAAhAeIeIaFBATHAOQNC
QoMCYoBzBoSEBgXEAOcMCAkXE4gBzhkQEqBBATHAOQNCQoMCYoBzBoSEBgXEAOcMCAkNCogBzhkQ
EqBBATHAOQNCQoMCYoBzBoSEBgXEAOcMCAkNCogBzhkQEqBBATHAOQNCQqMC6p5zhymqeyKBRgXU
OdcA6qpzoqDBF5hP53yAuCfuERLgrhQAGpEDuASAkAAAQgIICQAgJICQAABCAggJACAkAAgJACAk
gJAAAEICCAkAICSAkAAAQgKAkAAAQgIICQAgJICQAABCAggJACAkAAgJACAkgJAAAEICCAkAICSA
kAAAQgKAkAAAQgIICQAgJICQAABCAggJACAkgJAAAEICgJAAAEICCAkAICSAkAAAQgIICQAgJAAI
CQAgJICQAABCAggJACAkgJAAAEICgJAAAEICCAkAICSAkAAAQgIICQAgJAAICQAgJICQAABCAggJ
ACAkgJAAAEICBBFCAoCQACAkAICQAEICM1b/fDrng5AAQgLUPTS8zokCIJkA9Q511T2RACQUoM6h
rhggGoCkAtQ5ICRAUgHqHBASIKkAdQ4ICRBQQJ0DQgJAUgHqHBASIKkAdZ7m1atXTbWfqd4nQgIk
FWiZOh8YGDDz5883c+fONTt27DCfPn2qLPv+/bvZv3+/mTdvnpkzZ45d/uXLl9x93b9/38yePdus
Xr26fHJLxKWO3wgatZ/YPou2selsiwgJICQwJXV++vRpc/78efP792/7GRwcNBs3bqws7+/vNxcu
XKgsl+hITPKQiDx48KC25JaIy0bF7VTEf637REgAIYGWr/MlS5bYXkcoBo6uri4rII5fv37l3tFn
zfGUOT1HjnjE4jJv/qgTJ06YBQsW2B7ToUOHKr/v3LnTDA0NVfWUtm7dWmgeqnfv3plt27bZHpqu
xbJly8ydO3eqyvLs2TOzcOFCs2bNmuR5//z50+zZs8fuT/saHh7OPee88/F7e7NmzTIrV640jx8/
RkgAIYHmqvOvX7/aRLZr167cdZQUlUCLHqdRQpK1/OLFi+bKlStW6CRwN27cMKdOnbLLPn78aNau
XWuX/fjxwwrm6OhooeOsWrXKXL9+vdILU4/NP2dtf/DgQbtMx0md97Fjx8ytW7fs/+/du2eWL1+e
uV7sfMLe3sOHD+05ISSAkEDT1Lnu4HUXrM+LFy9y17t27ZpNjM0gJBqH8XtLroflJ+azZ8/aZKxH
dPXEv3oB/vYfPnwofN4SjrCcWeulzkdi5gSp3hggAwBCAlNW5xoD0WOTLMbHx63g6G65GYREd+jh
YyU/4bvk3N3dbcte5lro0ZUEU72zFStWJMsZO2//UWFsu9T5qBei33ROx48fR0gAIYHmrHOJRFbi
0++7d+82nz9/LnWcWoQkbxwj3FcoGln09fXZHkEZIbl69ard5vLly+bRo0f28dV0CEmR85HA6fHY
li1bzJEjRxASQEhg5utcj0t8cdAYiO7gw56IXgF+//596eOE37WPRvVI1HPSuE4eettMYw4ShDKP
tvQqtL/fWJmLnPfSpUsLPdpKnY/Py5cvS7djhAQQEpiSOtejLD0mcQPLf//9t/04nj59ajZs2FD1
tyVljuMPEI+Njdm3oWoVEr31pLEJiZ04c+aMOXnyZKXs+u5eXVYvYv369VVJ+s2bN5n7CVm8eHHl
La3Xr1/bQftUOcN9hoPteiwl9CZZ3mB77HyEttObW0LXNNbTQUgAIYFpq3M9stIbSHqlVwPtEhaf
RYsWFbZvzTqOS3h6bKM7cyXCWoVEg+Yqp//68dGjR20PQr9JpNxbVPpbF//1X/1fy/P24/PkyRM7
yK1yK3lrgDtVznCf/jp6a0zl0f403jIyMpK7r7zzcY+1tL2upfblRAUhAYQEqHOY9hggGoCkAtQ5
ICRAUgHqHBASIKkAdQ4ICRBQQJ0DQgJAUgHqHBASIKkAdQ4ICZBUgDoHhARIKkCdA0ICQFKBGa/z
eo8109sjJAA0NEBIqHCEBBASmM46L2tXK4rax6ZmytXkhAcOHLDzS/X09FhXwDL2s6ntiXWEBBAS
mOI6r9Wutqh9bEpI5GDoZrzVdPa9vb2l7GdT2wNCAggJTHGd12pXW9Q+NiUka9asqZrOXTPjlrGf
TW0PCAkgJDDFdV6rXW1R17+UkIT7kWiUsZ9NbQ8ICSAkMMV1Xqtd7VQJSbg8Vb7U9oCQAEICU1zn
tdrVFrWPTVntrlu3rurRlBwJy9jPprYHhAQQEpjiOq/VrraofWzKavf69etmcHCwMli+adOmUvaz
qe0BIQGEBKahzmuxqy1qH5uy2hWnT5+2YzB6xVeD+2XsZ1PbE+sICSAkQJ0DQgIkFaDOASEBkgpQ
54CQAJBUqHMgBhASIKkAdQ4ICZBUgDoHhARIKkCdA0ICBBRhRJ0DQgJAUgHqHBASIKkAdQ4ICZBU
gDoHhARIKkCdA0ICQFIB6hwQEiCpAHUOCAmQVIA6B4QESCpAnQNCAkBSAeocEBIgqQB1DggJkFSg
I+r81atXXGCEBEgq0Kl1rt9v3LhRV4zIS72d43oq28t0tkWEBBASmDIhWbNmjfnx40fNMdIs8dSK
cY2QAEICbSEkly5dMsePH4+uPzAwYObNm2fmzp1rNm7caD58+FBZz//kHePZs2dm4cKFVrTEu3fv
zLZt2+z+Zs+ebZYtW2bu3LlTtc2VK1fM4sWLzaxZs+w6Dx48qCz//fu3OXDggJk/f77p6emxvaqi
ZXb7v3z5sunu7jZdXV3m5s2b5syZM3Z/4bH8/d6/f98uV5lWrlxpHj9+XHXMEydOmAULFtjjHjp0
qGpZkTIjJICQQEsKiVi7du2kROtQgj1//rxNhPpcvHjR7Nmzp3A8afnBgwftth8/frS/rVq1yly/
fr2yT+1fQuNvI6FxZVJiVwJ3nD171pw8edJu+/nzZ9Pb21u6zHv37jW/fv0yd+/etcl937599nt4
LH+/vsg8fPjQLFmypLJMx5D46Xjaj4Ti1KlThcuMkABCAi0tJE+ePDE7d+7MXH/FihXm58+fle/6
v+7kywiJL1J56C4/to1/HPVs/DKNjIyULnMonF+/fs1Out7/JXa3bt3KLP/q1autSPj4QpMqM0IC
CAm0tJAICYkEJfzdT/D+nXkZIclCj7uOHTtmdu3aZRN/XvLO6xmEj43qKXPsu/9/9UL0XaIRPg7U
/sNHfX45UmVGSAAhgZYXkrGxMfuIK5W0Y4m26LGvXr1qli9fbscpHj16ZB951SMk9Za5qJA4Abx3
757ZsmWLOXLkSFS88oRsJtoiQgIICUy5kAjdZWvw3f9dg8rhYyL/ld9ahERjEv6jpPfv35cSknXr
1lWV6fXr13WVuYyQOF6+fDnpmP45haTKjJAAQgJtISR6DViPbcKB63PnzlUGri9cuGCWLl1aWa63
ojTe4CfJ1LH1NpZ7S0sJVT2hMkKigfrBwcHKwPWmTZtKlblWIVEvSm9uiXBQXsd0g+n66LveFita
ZoQEEBJoCyERsVdp9dHbT2/fvq0s05tJutvP+8PErGNoLEYD0UrESs4awC4jJOL06dN2AF2v2+qN
qTJlrlVI9FhL4znulWQnKo6jR4/a3pauhd46c2+pFS0zQgIICVDn0BIxQDQASQWoc0BIgKQC1Dkg
JEBSAeocEBIgoIA6B4QEgKQC1DkgJEBSAeocEBIgqQB1DggJkFSg8+ocm1yEBAAhgbrqvIhN7nS5
JWpm3b6+vsr379+/m/3799u/TFc5d+zYYb58+VK1jf4K/88//7TLNc2K5r9y6C/Lh4aGqHyEBBAS
mMo6b3Qs1LM/zfE1Ojpa+d7f32/nyHJzV2nKE4mJ4/nz53YiRE34qOWay0rTrTi0L+fICAgJICQw
BXWeZZObZYvrb1vEIteRsqX1efr0qdm8eXPVb7LA9Y2i5Dro96DkY6K5q2Jon9o3ICSAkMA09Uiy
bHH9dYpY5DpitrQh6n3IoySGZhf2j6UZhFNjPPI70b4BIQGEBKZRSGIWt1mEFrmOmC1tiMY3NJ18
jGvXrllHRV+oJFDqFamHlDWG4qaoB4QEEBKYRiFJrVPUIjdmSxsiIQj9zn3Gx8etFbAeb/nH0mC8
zKS0raZlV5l89LsG6wEhAYQEmkRIylrk5tnSxno1IRKP3bt3WzMoH/l++GZaEo2st9CyLG4REgCE
BGZISGqxyBWhLW3RHol6Iup16DghW7dundT70H5CEaJHgpAAQgJTWOehTW5KSMpY5MZsaUO0n5GR
karf9LbVhg0bzKdPnzK30fiLPm7gX9a64XjIixcvGCNBSAAhgams89AmNyUkZSxyU7a0PnqzSmMc
PosWLZr0inJYPomHBvWdte2bN2+qll+6dIm3thASQEigE+p8eHjYbNy4seH77e3ttYIGCAkgJNAB
da63uxo595cevWmfgJAAQgIdUucaR/nrr78atj/ti7m2EBJASIA6B4QESCpAnQNCAiQVoM4BIQEg
qVDnQAwgJEBSAeocEBIgqQB1DggJkFSAOgeEBAgowog6B4QEgKQC1DkgJEBSAeocEBIgqQB1DggJ
kFSAOgeEBICkAtQ5ICRAUgHqHBASIKkAdQ4ICZBUgDqfGhppWgUICZBUoEnqPMsTPfRGb1S8OF/4
TopD+dTLr74ZnBoREkBIYMqEZLripRPjTiIi50d6JICQAELiceLECbNgwQIzb948c+jQoaplP3/+
NHv27DFz5841y5YtM8PDw5k9H/fbt2/fzKJFi8yPHz8m7WflypWFjlnknPzfXC9h1qxZ9hiPHz8u
fH5ZDAwM2HV1zhs3bjQfPnzIPWeEBBAS6HghuXjxorly5Yr5/fu3+fXrl7lx44Y5depUZfmxY8fM
rVu37P/v3btnli9fnnss933//v3mzJkzVcvOnj1rE3qRY5YVEr+X8PDhQ7NkyZLC5xeicp8/f96u
r4+2l5A2Y1tDSAAhgSkTkjJjJHrWr4Tp4ydiCUe4PCUko6OjtlfittO/f/75Z+XOPnXMskKycOHC
itiFlD3WihUrbO/J70l1d3cjJICQAD2S2N18KDh6ROQvL1oG//uGDRtsT0Bcv37dbNu2rfAxywqJ
eiH6LtE4fvx41Xplj5W1zL8GCAkgJICQBOvEkmo9QqLHYBpTERq3ePToUeFjlhUS8ezZM3vMLVu2
mCNHjtR8rKzznYo33hASQEigbYRESf7r16+56y5durT0oy3H4sWL7diIHmv5pI6ZOs779+9zz/Pl
y5elzi9E64ePtvzXnBESQEgAIQnW0eDyyZMnK4PL+q43lRwabNejIzE0NFQ12K63mjTu4RJveGwN
avf09Ewa3E4dM6uX4AbTx8bG7GMy/1gqk97cElrP71WUPZaWnzt3rrL+hQsXrJgiJICQQEcJSdk/
SDx69KiZP3++vfNWkv748WNlmV7j3bFjh03OGogeGRmpEgpt4+7Yw/2Oj4/bZZ8/f55UztgxQ5w4
6DGVkrpEwz+WHmupbFqu9Zyo1HIs4V7/1UdvbL19+xYhAYQEqHNo7xggGoCkAtQ5ICRAUgHqHBAS
IKkAdQ4ICRBQQJ0DQgJAUgHqHBASIKkAdQ4ICZBUgDoHhARIKkCd+5S1xm1WK10sfhESQEhghuo8
tMYtu/5Mxpl/7LLlatf2gZAAQgLTXudlt2nWuEpNFkmPBAAhgTrqPM92NmverXfv3tm5pzT5orbR
tO937tzJXT+cr0t+I5rh181x5XuZp+xvHZoZWHNyCTer7/Pnz+33T58+VWYO9suQVS5NtJhXljLl
DoldI4QEEBJoyzqP2c6G26xatcqaTrmZbmUxK7fBInf++r8SrHM9DGfdjZXDZ/fu3eb27dv2/zdv
3rSPrWRv6747m9vYpJP63tfXl1uWMuUOSV0jhAQQEmi7Oo/ZzhaJE98IKiUkLhlnLY+Vw+fq1avW
41385z//Mbt27bIfsXfvXuuxXkRIYmUpU+4ilDXLQkgAIYGWqvOY7WzWNpqCXZ4jSt6aij2VsGP7
Kmp/6yN/d931Cz0CkzGV/N6FHiPpcVcRIYkm2RLlziJ2jRASQEigLes8z3Y23Ea9AZlCXb582Vrh
yqejUUISK0dIV1eX9SxxAqLxi9evX1e+z6SQpK4RQgIICbR1nYe2s+E2MnvybWhDC9t6hSSvHCHb
t283//73vyuPtNzjLfd9JoUkdY0QEkBIoO3qPGY7G1rj6s7fvYGkHsDatWur9huz0k0l5Fg5QvTG
VXd3t7W1FZcuXbLH1ttVWftOWfw2UkhS1wghAYQE2q7OY7azoTXukydP7NtUWk+JX4Pj/n5jVrqp
hJyyv/V5+vRp1Wu/svPV9zdv3mTuO2Xx20ghSV0jhAQQEqDOoS1igGgAkgpQ54CQAEkFqHNASICk
AtQ5ICRAQAF1DggJAEkFqHNASICkAtQ5ICRAUgHqHBASIKkAdQ4ICQBJBZqyzqfq+FN5Xu3WThAS
oIEAQkKZERKggUDz1bl+1zxXMpZas2aN/S1lF5uyn5Uz4IEDB+xMuD09PdZsKjz+wMCAmTdvnj3G
xo0bq8yjtK6mYdfEjJoyXs6HZ86csfuL2eKm7HpPnDhhFixYYI976NChqmVFyoyQACAk1HnO7wcP
HrSJVN4Zooilbsx+9uzZs+bkyZN2W/mG9Pb2Vh1foqB9uv3LKtdZ5Lr9y+3w169f5u7duza579u3
z36P2eLG7Hp1DImfjqf9SCg0mWPRMiMkAAgJdR4RktBKNovQUjdmP6uejZuyXbjZeR2a5ddfrv+r
95G3f333PT7yZueN2fXKeVEi4eMLTarMCAkAQkKdR4QkizKWulk9Ax8lcH95lod5Xi8j9b2oXa/2
r2X+xy9HqswICQBCQp2XEJKylropISm7vFYhcQKYZdebJV55Qtau7QQhAYQEpk1Iylrqhr+tW7eu
6jGRnAL95RoIDx9tOdOpeoXEEdr16pj+OYWkyoyQACAk1HkJIUnZxaaERAP1g4ODlYHrTZs2TRps
l12uG2yXZe7SpUvrFpKYXa+O6QbT9dF3vS1WtMwICQBCQp2XEJKUXWwR+9nTp0/bAXS9bqs3pvJe
/9VHb2y9ffu2biFJ2fUePXrU9rbU+9FbZ+4ttaJlRkgAEBLqHIgBhARIKkCdA0ICJBWgzgEhAZIK
UOeAkAABxUWgzgEhASCpAHUOCAmQVIA6B4QESCpAnQNCAiQVoM6ngFevXrXM9WmlsiIkgJBAx9S5
P39WQ5JfnecQ275IWcscP7WuZiru6+ub9PuPHz+qpotx6C/xh4aGEBJASKCz6rwRx5wuIWn09Unt
T1Pdj46OVv0mw63t27dnbqt1nYMlQgIICTRVnWvGW811JctbWeoODw9XLU9Z4uZZ7obeH+630Na3
yDHyzqFR1rlFy+pvX8SOOI+nT5+azZs3T/pd5z42Npa7rbbRtggJICTQVHUu8yrnKigfD03S6Chi
iRuz3M2abDG09S1yjKz/N9o6t0hZ/XWK2BHn0d/fbz1fQuT9EttW/jDaFiEBhASaqs4lHKEFraOs
JW6qB5G1fpFjZP2/0da5RcqaajehHXEempZf0/OXrSs3pT9CAggJNFWdZzkDZiXGrPVT08mnpoMv
e4zQZbGR1rlFyprlxljGjtihx2F54h3bVtvoMR5CAggJtIyQlLXErUVIyhwj5fteZr/1CkktdsRF
yx7bNlZfCAkgJDAjda5XTfPujsta4tYiJGWOMZXWuWWFpBY74np7JBoLokcCCAk0XZ3r0Yz+pkHo
7xTCwfYylrjhb0qYGmdwCT1r/TLHCO16G2mdW6Ss/m+12BE7tK7GbMrW1YsXLxgjAYQEmq/O9Qdw
O3bssI9M9Jw/THBlLHHD3/QWlXoXroeRV4aixwi3b6R1bpGy+r/VYkfs0JtXKk/Zurp06RJvbQFC
AtQ5GPu3On7vqSh6hVkD/AgJkFSAOgf7+nKZ+b30+EzbNCoGiAYgqQB13uLojzf/+uuvwutrXeba
ApIKUOfQNDFANABJBahzQEiApALUOSAkQFIB6hwQEiCggDoHhASApALUOSAkQFIB6hwQEiCpAHUO
CAmQVIA6B4QEgKQC1DkgJEBSAeocEBIgqQB1DggJkFSAOgeEBICkAtQ5ICRAUgHqHBASIKkAdd4E
lDGSQkgASCowxXUur/elS5dO+v379+9m//791n9d/ufyg//y5UtTXAPnxz5V1+Thw4emr68vc1no
6S7kM1+vWRVCAggJtGSd//r1y2zfvj1zn/39/ebChQvm9+/f9jMwMGDFpBmvQaPbgaxwR0dHJ/0+
NjZmPdrD42ndNWvWICRAUoH2qvPh4WGb9GJouZJj1j67urqsgPiiE/YEwnJdvnzZdHd3221v3rxp
zpw5Y+bPn29mz55tLWl9JEzq7cydO9eW48OHD1X7unLlilm8eLGZNWtW1fZa5n/cb+fOnctcX9y/
f9/+pmUrV640jx8/zj2Pp0+fms2bN2cu27Jli3nz5k3m9dI22hYhAYQEWr7OnYBs2rTJ/j/Go0eP
CsfRz58/zcKFC6Pl2rt3rxWcu3fvWgHZt2+f/a6krkTukMCcP3++0tu5ePGi2bNnT9W+9LjIiUu4
fVaPRI+i8tb3hUWPrZYsWZJ7HuqJXb16ddLvg4ODtsx510siqm0REkBIoGXrvIyA1BJH165dM8eO
HYvuI+xVfP36NfMYK1assMLki5R6Mnn7mpQ8M4Qktr4EUGMbRVi7dq15/fp11W/Pnz+v6qVkXS9t
o20REkBIoGXrXL/rTn8q4mh8fNzs3LnT9i6K7iP2XY+YQmI9jiJCEltfvRB919jH8ePHo+eqR23+
I71v377Z8Y9Pnz5Fj6dt9KgOIQGEBFq6R6LeiHoljeyRSDx2795tPn/+XGofse++aBQRinqFRDx7
9szcu3fPjnMcOXIk9zxCkdPjutu3bxe6XlnnhZAAQgItV+e1CErePtUT0SvA79+/L72P2HcNeIeP
tvyB/KkQEsfLly+j1zDskYSD++FAvy+49EgAIYG2qnMnKLXuU28gbdiwoeqRTqOERI/g9JaVG2zX
a8b+37KkhEHJXmMiToxS6y9fvty+uSXCgfgQjXOMjIyUvl4vXrxgjAQQEujcOs/a56JFi5J34bUK
iXCv/+qjN7bevn1bWEhOnTplezCuF5NaX4+1NMDvXg12opKF3rzSW2Rlr9elS5d4awtIKkCdQ7G/
v8mit7fXChZCAiQVoM7Bvt1VZj4vvfqrbWYiBogGIKkAdd6EaBzlr7/+Kry+1mWuLSCpAHUOLRkD
RAOQVIA6B4QESCpAnQNCAiQVoM4BIQECCqhzQEgASCpAnQNCAiQVoM4BIQGSClDngJAASQWoc0BI
AEgqQJ0DQgIkFaDOASEBkgpQ54CQAEkFqHNASABIKkCdA0ICJBWgzgEhAZIKUOeAkABJBdqzzhsZ
C1WJqsR+y2xH7CIkgJBAhwjJVO2D2EVIACGBJhYS/f/KlStm8eLFZtasWWb27NnWPtbnxIkTZsGC
BWbevHnm0KFDhXsW2m7+/Pmmq6vLnD9/Pndd/f/Dhw9mz549Zu7cuWbr1q1mZGQkut+88gBCAggJ
zICQbNu2zSZyIRGRmDguXrxoheb379/m169f5saNG+bUqVNJIdE2R44csdt9/vzZrF+/Piok69at
M58+fbLr37592+zduzdz3VR5ACEBhARmQEiciGQtX716tU3aPkuWLEkKiRMGh3oYMSHxeyA6no5b
S3kAIQGEBGZASGLL1TvRd/+jR2Cpfc2ZM6dqn0r+MSEJ8XtFZcoDCAkgJNBkQpJK0nn78oWgFiHx
hahMeQAhAYQEmkxIVq5cab5+/VpaSNauXWvHRhwvXryICsno6Gjl+8+fP82iRYtqKg8gJICQQJMJ
yZkzZ8zJkydtj0Iffd+4cWNyX+Fgu7aJCcnmzZvN+Pi4XV/HyxtsT5UHEBJASKDJhEQcPXrUvsar
x016w+vjx4+F9jU4OGhf0+3p6bFvW+U9rtL/tVzrah2Jiv8CQJnyAEICCAm0aZ3/+PGj6nEVICRA
UgHqPEp3d7e5d+9e5e89BgYG7KMuQEiApALUeSEePXpk1qxZYx8/6S/bDx8+bAUFEBIgqQB1DggJ
EFBAnQNCAkBSAeocEBIgqQB1DggJkFSAOgeEBEgq0Hl1/urVqyk/9nQcoxmPjZAAQgIdUefhzLxT
wXQco55jP3z40PT19U36XX84uXTp0km/6y/oh4aGEBIgqQB1Pl2xMJPxVuTY8jXxJ4oU+juX7du3
Z26vdfV3MQgJkFSg4+s89PJwvz179swsXLiwKlnGLG3fvXtn79Jljasp45ctW2bu3LkTPcbly5ft
X7zrDxRv3rxpJ1zUnFm12Pvm2QNnHTvk6dOndj6vEE3+ODY2lrudttG2CAmQVIAeSfC7vh88eNBO
Z+ImQExZ2q5atcpcv369MguvPNklRLFjaEZf7evu3btWQPbt22e/12LvG7MHTsV6f3+/uXr16qTf
9df4se0lhNoWIQGSCiAkGUk+tNutxdI2zzkx6xj67vuKlLX3jdkDp2JdXimvX78ufd20jbZFSICk
AghJRpIPKWJpq8dhx44dM7t27TIrVqyIJvMy38vY+9YiJHocFwpVkeumbfSoDSEBkgogJAWEJGVp
q0dDy5cvt4979EhIj8QaJSRl7H1rEZJa9u+LHEICJBVASAoIScrSVmMc/vL37983TEjK2PtOZ49E
4zX0SICkAtT5/xKpxhjkjZ63XsrSVm9Mube03NiBv5/UMWLfy9j7Zv0WHjtEZR0ZGSl93eQ7zxgJ
kFSAOp9Ab0Dpj/bcH+7lrReztH3y5IkdANejHj3iunXrVtV+UsdIfS9q75v1W3jsEL15pTfDyl63
S5cu8dYWkFSAOgdjhoeHq3o4Rent7bUvGCAkQFIB6hzsK8Zl5uTS4ztt08oxQDQASQWo8waiP2L8
66+/Cq+vdZlrC0gqJBXqHDo6BogGIKkAdQ4ICZBUgDoHhARIKkCdA0ICBBRQ54CQAJBUgDoHhARI
KkCdA0ICJBWgzgEhAZIKUOeAkACQVIA6B4QESCpAnQNCAiQVoM4BIQGSClDngJAAkFSAOgeEBEgq
QJ0DQgIkFaDOASEBkgq0Z51/+/bNeo93d3dbz3V5r584cYILhpAA5AdS+IHOFpJdu3aZa9eumd+/
f9vvP3/+NAMDA/YDCAkAQgJJIVEvJKuX0tXVVfWbeikLFiww8+bNM4cOHZq0TWo5ICTQpmICCMny
5cvNqVOnbE8kj4sXL5orV67YXsuvX7/MjRs37DZFlwNCAggJtLGQjIyM2HER9Uz6+vrMpUuXzJMn
T6rWWb16deXRl0PbFF0OCAkgJNDGQuJ49uyZOXv2rNm2bZsVldOnT1eW6Xv4SHTWrFmFlwNCAggJ
dICQ+Lx69aqqR5ESBUQDIQGSCnRwnWtQPXwsJTRo7li5cqX5+vVr7r5TywEhAYQE2rjO9ZrvmTNn
zNjYmP3+48cPc+7cOXPw4MHKOlp+8uRJKzj66PvGjRsLLweEpO0vLJ/O+ZBEstGru0uXLrWPqPSH
iRKX8C2uo0ePmvnz55s5c+bYcZSPHz+WWg4ICXflQJ1z7oCQAI0KOrnuiXlASGhQQAxwzoCQ0KCA
GOCcASGhQQExwDkDQgI0KEBIACEBGhQQA5wzICQ0KCAGOGdASGhQM4bmQmqm/Uz1PokBznlynLXn
sRCSNmhQ+ote/XXu3LlzzY4dO8ynT5+qlstn4c8//7R/vbt27Vrz8uXL3H3dv3/fzoqqKbZLV3Ki
0ev4jaBR+4nts2gCm85Eh5BUMz5ujLyoFi7UTL7GrFihWA+3b67zaUToFj2n8FgzcS0m0omtm4Lp
BCGZqQalabPPnz9fmS9ocHCwar6g58+fm3Xr1pn379/b5devX7emQHlIRB48eFBbJScitVGJcCoS
aq37REhm5py/fTNmzRpjrlyRza6LdTNxw2TM1avNKyTTWZ5mOHeJSIl0gpDMVIPStNnfv3+fJAYO
eVv7Hg2pY4RzPGUdN088Yokub/6oPKvTnTt3mqGhoaqe0tatWwvNQ/Xu3Ts7b5J6aLoWy5YtM3fu
3Kkqi3wsFk7cyq6ZyEap89b8TXv27LH7076Gh4dzzzlm3ep6e5obSjPPPn78GCGp8ZyPHdOki5N/
l5hIYPxkeu6cMYsXa9r4yYltIlQmYsVM1O1/l01Ur/FCxW4/ESq21+P2m9pGwjYRLna5lrlw0b78
zz8xYyZiRjMX/7eHFYpBeHx/W3fHr3ObCCnjQirrWP52eWWM7TP/ich/y6596R72w4f4+SIkTdrF
d2hKbCUyiYdj8UQLKvP8PzxOo4Qka3nM6lST5+kxnJZpZlcJ5ujoaKHjrFq1yva8XC9NPTaJhl8O
zRKrZW6Svth5H5vIWrdu3bL/v3fvXlWPzl8vZd3q9/YePnxY2o0PIfkHVcH/Jv5N3pX39f2T3HT5
fbv3iVCZiBVjNCO9PhOhYrxQsdtrQmEtc/M5praRyP0vXCbi5b9lzeslTISM7VVpPxMhYx/N+W6/
Wcf39+EL40RIGT+kwmP532NljO0zRGKu83fXQucjgWpkrwghmUYh0R287oL1efHiRVXyUtLSnbQb
Q/ny5UtTCEnK6lSJWe53Ssb9/f11JVTfxEjbf3CZpcB5SziyvC/C9VLnIzFzgsSjrfrO2ReDlJAE
VZ1Mbr7fVdb2qW2UlHPCZdKxNXYQrhuKQaz8ErC8kIoJSayMsX2GaFzKn3BZ/+/uRkhaukfy327m
gH1s4m+3f/9+21tRklNy9nssMykkRaxOlZw1Rfi4RlZLXAs9ulJPQue6YiLaU+WMnffsSNYK14ud
jwRdv+mcjh8/jpDUcc56jFJUSFK/6dGR7tDVLJQY/eV5lzy2TUzkwv1p3fARUChksX2ox6DvEqQw
pGJCEitjbJ8xAc3aN0LSokKiRyp+4tPbXL5Hg8Qk9tZTI4Qkbxwj3FcRq9O+vj7bIygjJFevXrXb
XL582Tx69Mg+vpoOISlyPhI4PR7bsmWLOXLkCEJS4znr8dLnz1nxP3mMI5aINTCvu/OJUJmIlf8+
PkoJSWqbMkKSCpmiQqjHUxMhZfyQqlVIYvss0jMsIsQISZM1KD0u+ey1KIlGt9e31AC1j4RkbuR2
LiUkevurUT2SlNXphQsX7JiDBKHMoy2Jp7/fWJmLnLfMk4o82ipj3apXsMsKA0LyD7pT1thCyLVr
xqxfXzwRT4SK8atsIlSSiTC1zUS4FH60pYcHsZApIiT/xFS87EXLGNtniMofPtry71MRkhZpUHqU
pcckbmD577//th+Hnsnr45bLjlSD2GUeP7kBYtma6m2oWoVEAqaxCddDilmdqhex3ssIStJv3rzJ
3E+IXjBwb2m9fv3anm+qnOE+w8F2PZYSepMsb7A9Zd2q7fTmltA1nV30QT9CMgkN8+mR0sS9htFL
i0qKt2/Ly92YJ0+KJ2K9zeV6MBOhYtQ0UkKS2kaPvP4XLkYvHvoD2bqH05iHC10NVk+ETGWwWt99
t99U+bXv/4XUpBcJwmMVLWNsnyEqr96Kc+VXfUikEJIWa1B6lKU3kPS4SgPtEpYQiYd6Ls5O1CXk
IsdxCU+PbXRnrkRYq5Bo0Fxl8B+t5Vmd6qUA//Vf/V/L8/bj82Qik2iQW+VW8paQpsoZ7tNfR2+N
qTzan8ZbRkZGcvcVs27VYy1tr2upfTlRQUhqO2e9tbV7939fPdUjIr0e64VMoUQs0dHgtpKlEqgG
mVNCktpmIlwm4uWfP5L0wsW+kaUQ80N3ImRsL0e/KcR9t99U+fUISsdwrzb7IRUeq2gZY/vMvpn9
bx3ooze23r5FSFqyQQExwDlDJ8QA0UCDAmKgIeccvuXEp3U+CAlJBIgBzhnokdCggBjgnAEh4WIC
McA5A0ICNCggBjhnQEhoUEAMcM6AkNCggBjgnAEhoUEBMcA5dzjtYqmLkNCgZuzcy1oDEwOcc/6x
WnP7Rtv3Np+rJEJCEpnicy9rDUwMcM7tJiSNmYaEHklHN6iUrWzM3jVl/VqrbWw9+9VkhwcOHLDz
VfX09FiXwbxzz5uuXvONad+6Jpo00TexCm12Saqte855FrU7d1bPuaW5otwk2DGL2dRduf+bJiic
CFM7R9ZEmFpnw3CbmIVuke2r21ttlrq1lL3MeZS15UVImrRBpWxlY/ausWX12MbWs185IroZdDU9
fm9vb9IL3kcz7uoauOuh4+3xvD+zbHYRktY755hFrapVM/JqmSYnVPj9z6W5sA1uKhlPhGll1l65
OEyEadXylIVuavvJPe/aLHVrKXuZ8yhjy4uQtFgS8Q2WYvausWX12MbWs1/1Evzp4TXTbhkh0ey6
/vahP0uWzS5C0nrnnLKoVQJUwlTS86xsCtvgppKxOrO+i4Fmz/WXp8qX2n5ym6rNUreWspc5jzK2
vAhJkyeRmK1szN41tqwe29h69ht6dEh0yghJlkuhv89WTsYISfWdcMyi1iVB3UN45pqF3QtTyTjc
j5JtuDxWvtT2IbVa6tZS9jLnUcaWFyFp4gaVspV1QpNn75q3rF7b2Fr3m2X2VEZIUtsjJO1xzgXC
0/T1/bcHMh1CEi5PlS+1fXZ7K2+pW0vZy5xHrFwISQs1qJStrE/M3jVc1ijb2LL7XbduXdWjKTkc
lhES7T98tOUbYCEkzXdOZer3n3qOW9TKqU/P9uWr7j/aKmqDGx42tNOdCNOqx0NySvSXp8qX2j7e
3opb6tZS9jLnESsXQtJCSSRlKxuzd40tq8c2tp796sWBwcHBymD7pk2bSg+2yxHS7V++70s970+E
pDmFJO8NvLxzjlnUarDd921XMnSmoDGL2fCu3Q0iy4lRzoX+8okwnYjTfwasJ8K0annKQje1fUgZ
S916y17mPMrY8iIkTZxEUrayMXvXlPVrrbax9exXnD592g6Q6xVhvXVV9o7Vvf6rj97Yeut5f7aD
kOQl33b95JFnUSsLWf/1X/3/fy7NUYtZ/1AuKerRju5DFMJhUSbC1I7B6NVYDe6Hy2MWukW2Dx8f
FbXUrbfsZc6jrC0vQsLdKBADTdMjgc6Me6KBJALEQK6QlDlnLGvb11YXISGJADHAOQM9EhoUEAOc
MyAkNCggBjhnQEiABgXEAHEPCAkNCogBzhkQEhoUEAOcMyAkNKim4VW7+4ESA9N6zsQTQgLTmERq
/eOuMtvlrev/f04j/ECJAc65xngqE8OAkJBEpqCB1CpANFSEZKrOuey1QEgQEjApy9F869pYz0Lb
ac6rrq4u6yoY61nIDErzVsm+duvWrdZwqmiPJJz+Qq6OIXJLXLRokfn27RuVTbKLnnPWdCopy+ky
MZxqU4CQtF0SSVnX5iV5bSOfEDfL7vr166OCoOndP336ZNe/ffu22bt3b2EhCf+vGX1DH3eVZ9++
fVQ0QlJTjyRlOV0mhlNtChCStmtQKevavGTuGpUjtLQN/+/fvel4Om6tQuIMr3xksfvixQsqGiGp
SUiy8E3UysRwqk0BQtJ2DSplXVt08Du0tE0NtufZ1xbdh3xURkdHKyImIQGEpB4hiVlOl4nhVJsC
hKTtGlQqwPMaU8obPdUI81wHi+5D5lX79++3/9dz60uXLlHJCEnNQpKynC4Tw4gGQtJxDSplXZvX
mOSkqLERhx4rxUTA9R6E7Gs1MF6PkOjYGvTU4zUNav6Q4xAgJDUKScpyukwMl7GZBoSkLRpUyrq2
6GC7tomJwObNm834+LhdX8crO9gu0dBbM76funoif/31lzl48CAVjJCUOucwnlKW02ViONWmACFp
yyQSs65NPV5Sb6Cnp8e+qRJ7XKXlWlfrqEGqEZcREr31om39YwwPD9t1+CtlhKTsOYfxlLKcLhPD
qTYFCAlJJAc9WvK7+tOBGqfuJAEh4ZwBIWnBBtXd3W1fw3Xvyg8MDNhHXdOFjqu7vuPHj1O5JFXO
GRCSVmxQerNFr9yq666/bD98+LAVlOlCz7j1eIFBdpIq5wwICQ0KiAHOGRASGhQQA5wzICQ0KCAG
OGdASIAGBcQA5wwICQ0KiAHOGRASGhQQA5wzICQ0KCAGOGdASIAGBcQAcQ8ICQ0KiAHOGRASGhQQ
A5wzICQ0KCAGOGdASIAGBQgJICRAgwJigHMGhIRGBdQ95w4zVfdEAo0KqHOuAdRV50RBgy8wn875
AHFP3CMkwF0pADQiB3AJACEBAIQEEBIAQEgAIQEAhAQQEgBASAAQEgBASAAhAQCEBBASAEBIACEB
AIQEACEBAIQEEBIAQEgAIQEAhAQQEgBASAAQEgBASAAhAQCEBBASAEBIACEBAIQEACEBAIQEEBIA
QEgAIQEAhAQQEgBASAAhAQCEBAAhAQCEBBASAEBIACEBAIQEEBIAQEgAEBIAQEgAIQEAhAQQEgBA
SAAhAQCEBAAhAQCEBBASAEBIoOkEJPwAAEICgJAAAEICMyMmAICQACAkAICQAEICAAgJICQAgJBA
p4kJACAkAAgJACAkzZBQ+XTOBwAQEu7KgToHQEhIKEDdAyAkJBIgBgAQEpIIEAMACAmQRIAYAEBI
SCJADAAgJCQRIAYAEBKSCBADAAgJNFUSefXqFRcaIQFASDotiXz//t3s37/fzJs3z8yZM8fs2LHD
fPnypaZjaPtGlnOqEl+j9lvvfqZ7e4QEEBKYkqTT399vLly4YH7//m0/AwMDVkxmKkG3UrJDSAAQ
EoRkgq6uLisgjl+/fkV7Fvfv3zezZ882s2bNMitXrjSPHz+u7D+c3ynrmP5vOu6BAwfM/PnzTU9P
j7lx40a0R3LixAmzYMEC23s6dOhQoXIV6fVcuXLFLF682G6rfTx48KCy/OfPn2bPnj1m7ty5Ztmy
ZWZ4eLhw76nMuabOr8j2CAkAQtIUd89KnAsXLsxd7ifahw8fmiVLluQeI5Vcz549a06ePGmT5OfP
n01vb29ucr548aJN+FpXYqdEeurUqULlSgnJtm3bzIcPH+x37UP7chw7dszcunXL/v/evXtm+fLl
NQlJ6lxT55faHiEBQEiaRkiuXbtmk2ceEhmXWFPHSCXXNWvWWOFyjIyM5Cbn1atXV/WchC8WsXKl
hMSJSNZyCUd43FqEJHWuqfNLbY+QACAkTSEk4+PjZufOnfaOOA/d7WtfSnzHjx+vS0j8O3/3+CYv
OWvd8PGZHkUVKVc9AhCWsVH7Cc81dX6p7RESAIRkxoVE4rF792772CTFs2fP7GOeLVu2mCNHjjRM
SGLJ2U+qZcvVjEJS9vxS2yMkAAjJjAqJeiJ6Bfj9+/el9vny5ctoMg2/a//+b+vWrat6XPP69evc
/WkA/evXrzWVqx4BWLp0aU2Ptsqea+r8UtsjJAAIyYwJydOnT82GDRvMp0+fCu1HYwZ6Q0qEA9N6
s0njDS7h+QPgY2NjdlDbL8f169fN4OBgZQB506ZNucn5zJkzlcFmffR948aNhcpVj5BovEiPzcTQ
0FDuYHu955o6v9T2CAkAQjJjQrJo0aJS9qx6fLRixYrKq7IueQu9ZaRXh93rwy6ha13d2WvdcN+n
T5823d3d9rVXvbkUS/JHjx61r79q/0rUHz9+LFSueoTkx48f9u9qtE/tX4PcWevVe66p8yuyPUIC
gJDM2KMtIAYAEBIgiQAxAICQkESAGABASEgiQAwAICQkESAGABASIIkAMQCAkJBEgBgAQEhIIkAM
ACAkJJFmpKylLxbACAkAQjKFSaSZk0veX6CXtfQN1+/UhIqQAEICHZdEGiV+JFCuAwBCMk1JOWU7
m4U83jU/lIylrl69Wmoeq3fv3tk5pTTZo44lK9s7d+5EeyRZc4LF9pNnAfzt2zc7z5jm0vLRhJOa
idcRs79FSAAQEoTElLOdDZH9q5uRVhMMysWvjJCsWrXKzmrrZrw9f/58lc1v3r7C/ZbZj/9dU+dr
lt3wnCQeImV/i5AAICQIiSlnOxsiN0L/jn54eLiUkGThGzwVFZIy+/G/j46O2l6J8xvRv3/++Wfl
GqTsbxESAIQEITGmrsRfxio37zdN/y7Pj127dtlp2ouIR9Z+i+4n/C4vFvU6hHo16pH55xezv0VI
ABAShKTBQlJ2fxpTkVHU5cuXzaNHj+zjsVqEpMx+wu+y5tWYitDYiLbP6tW0cwwAICQwY0Kyfv16
8+XLl8r3mFWuCO1nNUjv28uGy4sKSZn9ZH3XywUaG9FjLZ8y9r4ICQBCgpDUICS3b9+2b23l2b+m
7GeVwN3bVRKhtWvXFhKP0NI3tZ9w/fCcNIDe09MzaSA9ZX+LkAAgJAhJnUIi9GaT3pD6448/bDIv
Yz/75MkTO3itdfRo6tatW4WEJLT0Te0nXD88p/HxcbtMYhiSsr9FSAAQko4XEpIVMQCAkABCAtQN
AELSPkmk7DxYgJAAICQkESAGABASkggQAwAICZBEgBgAQEhIIkAMACAkJBEgBgAQEpJII8DelhgA
QEhIInUxnfa29ez74cOHpq+vr/Jdf32vv5DXFPIzTfgX+ggJAELSUUKSmiixWZBgyJfEUcQVcjrQ
3GSa1wshAUBIml5I3B245sPSbLePHz82b9++ta6DIXIJlBGUbGpjtrx59rbnzp2L2vjGbG2zypl1
brH1Qp4+fWo2b95ctZ+scsvrRPOJyQHSockqVU5NCKmE7xuCaRtNad/d3W26urrMzZs37YSPmrOr
qFBt2bLFvHnzBiEBQEiaX0j8xKbHPM4BUDP5hklYwrFv377K/mK2vFk9Ej1Cyls/ZWubV87wWLH1
Qvr7+62XSaondfDgwYqdsJAoyM7XzQqssu/Zs6dqm71799rzuHv3rhUQXTd9T9kXC9kXa/+NTv4I
CSAkMCVJRHfaehYfIsMn3RX76I78xYsXlf3FbHmzEnJs/ZStbV45w/3E1gvRdPOadj4lJGG55cDo
pqQX+r96H3nb6LvvaxJL6M+fP5/US0JIABCSphYS3bVrmRL58ePHq5bpMZQbPxgZGal6tJOacr7I
GEnYk4jZ2sbK6e8ntl6IHkuF4lWk3FnOianeWJG60CNDXeNPnz4hJAAISesIidAYgOuBHDlypOoR
y/79++3/9ejm0qVLUyYkRWxt88qZ5QOftV4RQShS7rIWw0WFRI/DZBY2VckfIQGEBKY8ibx8+bJq
PRk96a5dd8gaBP/x48eUCUkZW9uwnHnnFq7XqB6Jyho+2vJfd65VSMIeWTjwj5AAICRNKSRyFNSb
TiJrIFg9kb/++ssOOJcRhpS9bfhbytY2Vk5/P6nz8dEYiR7ZlU36KpveQHNlvXDhgnWArFdIpjr5
IySAkMCUJBE9BtLgsXsl1yVhx/DwsN02/Ev1lDCk7G2zfovZ2sbK6e8ndT4+emtLb1zVkvTd67/6
SGz1yjRCAoCQdKSQpFAy16B7OyKR9Hs9xAAAQgINTiJ6bKNeQurtp1ZGb3d1yrxgCAkgJDDtSUTj
HPqbBn+Qvd3QOIrGgIgBAIQESCJADAAgJCQRIAYAEBKSCBADAAgJSQSIAQCEBEgiQAwAICSdlUSw
5iUGABASkkhdhNa8MfRX70NDQ1QqQgKAkJBEaiufprb3p7QHhAQAIZnBJJJnJRuzvdU2chaUmZOW
a0LH8I8WU1a0/jGzZrpNWebqDyVllQsICQBC0gRCElrJpmxvnXGUxEHrSHQ0AaKjiBVteMywfCnL
XHmi+8cEhAQAIZlBIQmtZFO2t9pGEx46vn//bhYtWlT5XtaKNqt8KctcWeRqGnhASAAQkiYQkpCU
7a2+h0Lj+36UtaLN+i1lmavj69EZICQACEkTCknK9jZlP1vWijbvt5Rlbsy0ChASAIRkBoUkZXur
bWRj6/jy5Ys1pPK3L2NFm0pyWZa5GruhR4KQACAkTSokKdtbbaPv8nTX8r///tts3769avsyVrQi
tOZNWea+ePGCMRKEBAAhaVYhETHbW21z584d88cff9hB8cOHD9teiU8ZK1oRWvOmLHMvXbrEW1sI
CQBC0qpJpBkSUm9vrxUbQEgAEBKEpDR69VdvcwFCAoCQtGgSKTMv1lQga1zm2kJIABASkggQAwAI
CUkEiAEAhIQkAsQAAEICJBEgBgAQEpIIEAMACAlJBIgBAISEJALEAABCAiQRIAYAEBKSCBADAAgJ
SQSIAQCEhCQCxAAAQgIkESAGABASkggQAwAICYkEqHsAhISEAtQ5AEIC/yQWPp3zAYD/8v+M/vJB
ODjPqgAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2015-12-22 10:28:29 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAADnCAMAAAD4paggAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2015-12-22 10:28:29 +0000" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAQgAAAGRCAIAAAAW/bojAAAOTklEQVR42u3dPY4kxxGG4TnAGjR4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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2015-12-15 13:37:59 +0000" MODIFIED_BY="Anne Lawson">
<APPENDIX ID="APP-01" MODIFIED="2015-12-15 13:37:59 +0000" MODIFIED_BY="Anne Lawson" NO="1">
<TITLE MODIFIED="2015-11-11 15:49:21 +0000" MODIFIED_BY="[Empty name]">Sources searched and search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2015-12-15 13:37:59 +0000" MODIFIED_BY="Anne Lawson">
<TABLE COLS="3" ROWS="13">
<TR>
<TH VALIGN="TOP">
<P>Source</P>
<P/>
</TH>
<TH VALIGN="TOP">
<P>Search strategy</P>
</TH>
<TH VALIGN="TOP">
<P>Hits retrieved</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>1. ALOIS (www.medicine.ox.ac.uk/alois)</P>
</TD>
<TD VALIGN="TOP">
<P>statins OR statin OR simvastatin OR lovastatin OR pravastatin OR fluvastatin OR atorvastatin OR rosuvastatin</P>
</TD>
<TD VALIGN="TOP">
<P>Dec 2014: 60</P>
<P>Nov 2015: 3</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>2. MEDLINE In-process and other non-indexed citations and MEDLINE 1950-present (Ovid SP)</P>
</TD>
<TD VALIGN="TOP">
<P>1. exp Dementia/</P>
<P>2. Delirium/</P>
<P>3. Wernicke Encephalopathy/</P>
<P>4. Delirium, Dementia, Amnestic, Cognitive Disorders/</P>
<P>5. dement*.mp.</P>
<P>6. alzheimer*.mp.</P>
<P>7. (lewy* adj2 bod*).mp.</P>
<P>8. deliri*.mp.</P>
<P>9. (chronic adj2 cerebrovascular).mp.</P>
<P>10. ("organic brain disease" or "organic brain syndrome").mp.</P>
<P>11. ("normal pressure hydrocephalus" and "shunt*").mp.</P>
<P>12. "benign senescent forgetfulness".mp.</P>
<P>13. (cerebr* adj2 deteriorat*).mp.</P>
<P>14. (cerebral* adj2 insufficient*).mp.</P>
<P>15. (pick* adj2 disease).mp.</P>
<P>16. (creutzfeldt or jcd or cjd).mp.</P>
<P>17. huntington*.mp.</P>
<P>18. binswanger*.mp.</P>
<P>19. korsako*.mp.</P>
<P>20. or/1-19</P>
<P>21. (statin or statins).ti,ab.</P>
<P>22. atorvastatin.ti,ab.</P>
<P>23. cerivastatin.ti,ab.</P>
<P>24. fluvastatin.ti,ab.</P>
<P>25. lovastatin.ti,ab.</P>
<P>26. pravastatin.ti,ab.</P>
<P>27. simvastatin.ti,ab.</P>
<P>28. lipitor.ti,ab.</P>
<P>29. baycol.ti,ab.</P>
<P>30. lescol.ti,ab.</P>
<P>31. mevacor.ti,ab.</P>
<P>32. altocor.ti,ab.</P>
<P>33. pravachol.ti,ab.</P>
<P>34. lipostat.ti,ab.</P>
<P>35. zocor.ti,ab.</P>
<P>36. mevinolin.ti,ab.</P>
<P>37. compactin.ti,ab.</P>
<P>38. fluindostatin.ti,ab.</P>
<P>39. rosuvastatin.ti,ab.</P>
<P>40. Hydroxymethylglutaryl-CoA Reductase Inhibitors/ or Lovastatin/</P>
<P>41. Simvastatin/</P>
<P>42. or/21-41</P>
<P>43. 20 and 42</P>
<P>44. randomized controlled trial.pt.</P>
<P>45. controlled clinical trial.pt.</P>
<P>46. controlled clinical trial.pt.</P>
<P>47. randomized.ab.</P>
<P>48. placebo.ab.</P>
<P>49. drug therapy.fs.</P>
<P>50. randomly.ab.</P>
<P>51. trial.ab.</P>
<P>52. groups.ab.</P>
<P>53. or/44-52</P>
<P>54. (animals not (humans and animals)).sh.</P>
<P>55. 53 not 54</P>
<P>56. 43 and 55</P>
<P>57. exp *Secondary Prevention/ or exp *Primary Prevention/</P>
<P>58. (prevent or prevention).ti,ab.</P>
<P>59. "delay onset".ti,ab.</P>
<P>60. exp *Cognition/</P>
<P>61. ((cognit* or cognition or memory or mental or brain) adj3 (impair* or decline* or deficit* or los* or stop* or reduc*)).ti,ab.</P>
<P>62. (dementia or alzheimer*).ti,ab.</P>
<P>63. Dementia/</P>
<P>64. or/57-63</P>
<P>65. 42 and 64</P>
<P>66. 55 and 65</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Dec 2014: 2001</P>
<P>Nov 2015: 310</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>3. EMBASE</P>
<P>1974-2012 September 05 (Ovid SP)</P>
</TD>
<TD VALIGN="TOP">
<P>1. (statin or statins).ti,ab.</P>
<P>2. atorvastatin.ti,ab.</P>
<P>3. cerivastatin.ti,ab.</P>
<P>4. fluvastatin.ti,ab.</P>
<P>5. lovastatin.ti,ab.</P>
<P>6. pravastatin.ti,ab.</P>
<P>7. simvastatin.ti,ab.</P>
<P>8. lipitor.ti,ab.</P>
<P>9. baycol.ti,ab.</P>
<P>10. lescol.ti,ab.</P>
<P>11. mevacor.ti,ab.</P>
<P>12. altocor.ti,ab.</P>
<P>13. altocor.ti,ab.</P>
<P>14. pravachol.ti,ab.</P>
<P>15. lipostat.ti,ab.</P>
<P>16. zocor.ti,ab.</P>
<P>17. mevinolin.ti,ab.</P>
<P>18. compactin.ti,ab.</P>
<P>19. fluindostatin.ti,ab.</P>
<P>20. rosuvastatin.ti,ab.</P>
<P>21. hydroxymethylglutaryl coenzyme A reductase inhibitor/</P>
<P>22. simvastatin/</P>
<P>23. mevinolin/</P>
<P>24. fluindostatin/</P>
<P>25. rosuvastatin/</P>
<P>26. pravastatin/</P>
<P>27. atorvastatin/ or cerivastatin/</P>
<P>28. or/1-27</P>
<P>29. randomized controlled trial/</P>
<P>30. controlled clinical trial/</P>
<P>31. (RCT or CCT).ti,ab.</P>
<P>32. randomly.ab.</P>
<P>33. placebo.ab.</P>
<P>34. trial.ab.</P>
<P>35. randomized.ab.</P>
<P>36. or/29-35</P>
<P>37. 28 and 36</P>
<P>38. primary prevention/ or prevention/ or secondary prevention/ or prevention study/</P>
<P>39. dementia/</P>
<P>40. ((prevent* or delay*) adj3 (dement* or alzheimer* or cognit*)).ti,ab.</P>
<P>41. or/48-40</P>
<P>42. 41 and 37</P>
</TD>
<TD VALIGN="TOP">
<P>Dec 2014: 2872</P>
<P>Nov 2015: 397</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>4. PsycINFO</P>
<P>1806-July week 1 2015 (Ovid SP)</P>
</TD>
<TD VALIGN="TOP">
<P>1. (statin or statins).ti,ab.</P>
<P>2. atorvastatin.ti,ab.</P>
<P>3. cerivastatin.ti,ab.</P>
<P>4. fluvastatin.ti,ab.</P>
<P>5. lovastatin.ti,ab.</P>
<P>6. pravastatin.ti,ab.</P>
<P>7. simvastatin.ti,ab.</P>
<P>8. lipitor.ti,ab.</P>
<P>9. baycol.ti,ab.</P>
<P>10. lescol.ti,ab.</P>
<P>11. mevacor.ti,ab.</P>
<P>12. altocor.ti,ab.</P>
<P>13. altocor.ti,ab.</P>
<P>14. pravachol.ti,ab.</P>
<P>15. lipostat.ti,ab.</P>
<P>16. zocor.ti,ab.</P>
<P>17. mevinolin.ti,ab.</P>
<P>18. compactin.ti,ab.</P>
<P>19. fluindostatin.ti,ab.</P>
<P>20. rosuvastatin.ti,ab.</P>
<P>21. hydroxymethylglutaryl coenzyme A reductase inhibitor/</P>
<P>22. simvastatin/</P>
<P>23. mevinolin/</P>
<P>24. fluindostatin/</P>
<P>25. rosuvastatin/</P>
<P>26. pravastatin/</P>
<P>27. atorvastatin/ or cerivastatin/</P>
<P>28. or/1-27</P>
<P>29. randomized controlled trial/</P>
<P>30. controlled clinical trial/</P>
<P>31. (RCT or CCT).ti,ab.</P>
<P>32. randomly.ab.</P>
<P>33. placebo.ab.</P>
<P>34. trial.ab.</P>
<P>35. randomized.ab.</P>
<P>36. or/29-35</P>
<P>37. 28 and 36</P>
<P>38. primary prevention/ or prevention/ or secondary prevention/ or prevention study/</P>
<P>39. dementia/</P>
</TD>
<TD VALIGN="TOP">
<P>Dec 2014: 253</P>
<P>Nov 2015: 14</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>5. CINAHL (EBSCOhost)</P>
</TD>
<TD VALIGN="TOP">
<P>S1 (MH "Dementia+")</P>
<P>S2 (MH "Delirium") or (MH "Delirium, Dementia, Amnestic, Cognitive Disorders")</P>
<P>S3 (MH "Wernicke's Encephalopathy")</P>
<P>S4 TX dement*</P>
<P>S5 TX alzheimer*</P>
<P>S6 TX lewy* N2 bod*</P>
<P>S7 TX deliri*</P>
<P>S8 TX chronic N2 cerebrovascular</P>
<P>S9 TX "organic brain disease" or "organic brain syndrome"</P>
<P>S10 TX "normal pressure hydrocephalus" and "shunt*"</P>
<P>S11 TX "benign senescent forgetfulness"</P>
<P>S12 TX cerebr* N2 deteriorat*</P>
<P>S13 TX cerebral* N2 insufficient*</P>
<P>S14 TX pick* N2 disease</P>
<P>S15 TX creutzfeldt or jcd or cjd</P>
<P>S16 TX huntington*</P>
<P>S17 TX binswanger*</P>
<P>S18 TX korsako*</P>
<P>S19 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18</P>
<P>S20 TX statin OR statins</P>
<P>S21 TX atorvastatin</P>
<P>S22 TX cerivastatin</P>
<P>S23 TX fluvastatin</P>
<P>S24 TX lovastatin</P>
<P>S25 TX pravastatin</P>
<P>S26 TX simvastatin</P>
<P>S27 TX Lipitor</P>
<P>S28 TX baycol</P>
<P>S29 TX lescol</P>
<P>S30 TX mevacor</P>
<P>S31 TX altocor</P>
<P>S32 TX pravachol</P>
<P>S33 TX lipostat</P>
<P>S34 TX Zocor</P>
<P>S35 TX mevinolin</P>
<P>S36 TX compactin</P>
<P>S37 TX fluindostatin</P>
<P>S38 TX rosuvastatin</P>
<P>S39 (MH "Statins") OR (MH "Rosuvastatin")</P>
<P>S40 (MH "Simvastatin")</P>
<P>S41 (MH "Atorvastatin")</P>
<P>S42 (MH "Fluvastatin")</P>
<P>S43 (MH "Pravastatin")</P>
<P>S44 S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR S28 OR S29 OR S30 OR S31 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR S43</P>
<P>S45 S19 AND S44</P>
<P>S46 (MH "Preventive Trials") OR (MH "Preventive Health Care")</P>
<P>S47 TX prevention</P>
<P>S48 TX prevent or preventing or delay or delaying</P>
<P>S49 S46 or S47 or S48</P>
<P>S50 S49 and S45</P>
</TD>
<TD VALIGN="TOP">
<P>Dec 2014: 286</P>
<P>Nov 2015: 72</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>6. Web of Science and conference proceedings</P>
</TD>
<TD VALIGN="TOP">
<P>(dement* OR alzheimer* OR AD OR VCI OR VaD OR "vascular cognitive impairment" OR "lew* bod*" OR CADASIL OR cognit*) <I>AND</I> <B>TOPIC:</B> (prevent* OR delay* OR stop*) <I>AND</I> <B>TOPIC:</B> (statin* OR atorvastatin OR cerivastatin OR fluvastatin OR lovastatin OR pravastatin OR simvastatin OR lipitor OR baycol OR lescol OR mevacor OR altocor OR pravachol OR lipostat OR zocor OR mevinolin OR compactin OR fluindostatin OR rosuvastatin) <I>AND</I> <B>TOPIC:</B> (random* OR trial OR placebo OR "double-blind*" OR "single-blind*" OR RCT OR "control group*")</P>
<P/>
<P>
<B>Timespan:</B> 2014-2015.</P>
<P>Search language=Auto</P>
</TD>
<TD VALIGN="TOP">
<P>Dec 2014: 410</P>
<P>Nov 2015: 59</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>7. LILACS (BIREME)</P>
</TD>
<TD VALIGN="TOP">
<P>statins OR statin OR simvastatin OR lovastatin OR pravastatin OR fluvastatin OR atorvastatin OR rosuvastatin [Words] and elderly OR cognition OR cognitive OR dementia OR alzheimer OR alzheimers [Words] and randomly OR randomised OR randomized OR RCT OR "controlled trial" OR "double blind$" OR placebo [Words]</P>
</TD>
<TD VALIGN="TOP">
<P>Nov 2015: 19 (all dates)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>8. CENTRAL (<I>The Cochrane Library</I>) (Issue 10, 2015)</P>
</TD>
<TD VALIGN="TOP">
<P>#1 MeSH descriptor: [Dementia] explode all trees</P>
<P>#2 MeSH descriptor: [Delirium] this term only</P>
<P>#3 MeSH descriptor: [Wernicke Encephalopathy] this term only</P>
<P>#4 MeSH descriptor: [Delirium, Dementia, Amnestic, Cognitive Disorders] this term only</P>
<P>#5 dement*</P>
<P>#6 alzheimer*</P>
<P>#7 "lewy* bod*"</P>
<P>#8 deliri*</P>
<P>#9 "chronic cerebrovascular"</P>
<P>#10 "organic brain disease" or "organic brain syndrome"</P>
<P>#11 "normal pressure hydrocephalus" and "shunt*"</P>
<P>#12 "benign senescent forgetfulness"</P>
<P>#13 "cerebr* deteriorat*"</P>
<P>#14 "cerebral* insufficient*"</P>
<P>#15 "pick* disease"</P>
<P>#16 creutzfeldt or jcd or cjd</P>
<P>#17 huntington*</P>
<P>#18 binswanger*</P>
<P>#19 korsako*</P>
<P>#20 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19</P>
<P>#21 statin or statins</P>
<P>#22 atorvastatin or cerivastatin or fluvastatin or lovastatin or pravastatin or simvastatin or lipitor or baycol or lescol or mevacor or altocor or pravachol or lipostat or zocor or mevinolin or compactin or fluindostatin or rosuvastatin</P>
<P>#23 #21 or #22</P>
<P>#24 MeSH descriptor: [Hydroxymethylglutaryl-CoA Reductase Inhibitors] explode all trees</P>
<P>#25 #23 or #24</P>
<P>#26 #25 and #20</P>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Dec 2014: 62</P>
<P>Nov 2015: 2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>9. Clinicaltrials.gov (<A HREF="http://www.clinicaltrials.gov/">www.clinicaltrials.gov</A>)</P>
</TD>
<TD VALIGN="TOP">
<P>(statins OR statin OR simvastatin OR lovastatin OR pravastatin OR fluvastatin OR atorvastatin OR rosuvastatin) AND (elderly OR cognition OR cognitive OR dementia OR alzheimer OR alzheimers) AND Interventional trials</P>
</TD>
<TD VALIGN="TOP">
<P>Dec 2014: 14</P>
<P>Nov 2015: 2</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>10. ICTRP Search Portal (<A HREF="http://apps.who.int/trialsearch">apps.who.int/trialsearch</A>) [includes: Australian New Zealand Clinical Trials Registry; ClinicalTrilas.gov; ISRCTN; Chinese Clinical Trial Registry; Clinical Trials Registry &#8211; India; Clinical Research Information Service &#8211; Republic of Korea; German Clinical Trials Register; Iranian Registry of Clinical Trials; Japan Primary Registries Network; Pan African Clinical Trial Registry; Sri Lanka Clinical Trials Registry; The Netherlands National Trial Register]</P>
</TD>
<TD VALIGN="TOP">
<P>(statins OR statin OR simvastatin OR lovastatin OR pravastatin OR fluvastatin OR atorvastatin OR rosuvastatin) AND (elderly OR cognition OR cognitive OR dementia OR alzheimer OR alzheimers)</P>
<P>Recruitment status: ALL</P>
</TD>
<TD VALIGN="TOP">
<P>Dec 2014: 24</P>
<P>Nov 2015: 1</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>TOTAL before de-duplication and first assessment</P>
</TD>
<TD VALIGN="TOP">
<P>Dec 2014: 5982</P>
<P>Nov 2015: 879</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" VALIGN="TOP">
<P>TOTAL after de-dupe and first assessment</P>
</TD>
<TD VALIGN="TOP">
<P>Dec 2014: 310</P>
<P>Nov 2015: 36</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;2 studies included in qualitative synthesis (from 4 reports)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;36 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;288 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;288 records after manual de-duplication&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;346 records identified through database searching left in after software de-duplication and first assessment&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;2 additional records identified through other sources&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;252 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;32 full-text articles excluded:&lt;/p&gt;&lt;p&gt;Not randomised trials (26)&lt;/p&gt;&lt;p&gt;Elective use of statins within a randomised controlled trial (1)&lt;/p&gt;&lt;p&gt;&amp;lt; 12 months (4) &lt;/p&gt;&lt;p&gt;Ineligible treatment (1)&lt;/p&gt;&lt;p&gt;See &lt;a link_type=&quot;SECTION&quot; href=&quot;CHARACTERISTICS_OF_EXCLUDED_STUDIES&quot; protected=&quot;true&quot;&gt;Characteristics of excluded studies&lt;/a&gt; table&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>